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Abstract 
 
Neuronavigation-Guided Transcranial Ultrasound: Development towards a 





Brain diseases including neurological disorders and tumors remain undertreated due to the 
challenge in accessing the brain, and blood-brain barrier (BBB) restricting drug delivery, which 
also profoundly limits the development of pharmacological treatment. Focused ultrasound (FUS) 
with acoustic agents including microbubbles and nanodroplets remains as the only method to open 
the BBB noninvasively, locally, and transiently to assist drug delivery. For an ideal medical system 
to serve a broad patient population, it requires precise and flexible targeting with simulation to 
personalize treatment, real-time monitoring to ensure safety and effectiveness, and rapid 
application, as repetitive pharmacological treatment is often required. Since none of current 
systems fulfills all the requirements, here we designed a neuronavigation-guided FUS system with 
protocol assessed in in vivo mice, in vivo non-human primates, and human skulls from in silico 
preplanning, online FUS treatment and real-time acoustic monitoring and mapping, to post-
treatment assessment using MRI. Both sedate and awake non-human primates were evaluated with 
total treatment time averaging 30 min and 3-mm targeting accuracy in cerebral cortex and 
subcortical structures. The FUS system developed would enable transcranial FUS in patients with 
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Figure 1.1.  Anatomy of human skull and meninges structures. (A) Superior view of the human 
skull bone. (B) Schematic cross section of the meninges and the scalp. Modified from Netter [2], 
and NIH training materials [3].  
 
Figure 1.2. Human brain structure. Source: (A) Sagittal view of the head cutting from mid-
sagittal plane. (B) Horizontal view of the human brain showed subcortical structures including 
basal ganglia and thalamus. Modified from Netter [2]. 
 
Figure. 1.3. The blood-brain barrier. (A) The neurovascular unit interacting with the BBB. It 
consists of endothelium with tight junctions lining the cerebral vessels, pericytes, and astrocyte 
end-feet. Nerve terminals and microglia surround and interaction with the neurovascular unit and 
BBB. (B) Various mechanisms across the BBB, including both transcellular and paracellular 
passages. Modified from Abbot et al [7] and Leinenga et al [8].  
 
Figure. 1.4. The heating threshold for desired thermal effects in the tissue. Heat treatment is 
dependent on both the temperature and the exposure time. Modified from FUS foundation [16]. 
 
Figure. 1.5. The acoustic cavitation. (A) Stable cavitation occurs at low pressures, and bubbles 
oscillates periodically in the volume and shape. (B) Stable cavitation by the wall generates 
microstreaming and induced shear stress. (C) Inertial cavitation at higher pressures lead to bubble 
collapse that generates shock waves and sometimes along with smaller bubbles. (D) Inertial 
cavitation may form microjets generating high force against the wall. Modified from Stride [19]. 
 
Figure 1.6. FUS-induced BBB opening disrupt the tight junction and increase the BBB 
permeability to allow drug molecules delivered to the brain. Modified from FUS foundation 
[16]. 
 
Figure 1.7. Schematic of the transcranial MRgFUS system. Modified from Leinenga et al [8]. 
 
Figure 1.8. Neuronavigation system (Brainsight).  (A) Computer to store and process brain 
images. (B) Position sensor camera.  
 
Figure 1.9. Frequency spectrum of PCD signals during sonication with microbubbles. 
Fundamental frequency corresponded to the excitation frequency (f). Harmonic frequency (n*f) 
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occurred when bubbles oscillated stably and periodically (stable cavitation). Ultraharmonic 
frequency (n*f+f/2) refers to as bubble shell oscillation or asymmetric oscillation during stable 
cavitation. Broadband respond occurs when bubbles undergoing inertial cavitation and release 
shock waves.  
 
Figure 1.10. Schematic of microbubble structure. Modified from Wu et al. [77] and Chen et al 
[100].  
 
Figure 1.11. Schematic of phase-shift nanodroplets vaporized to microbubbles. Modified 
from Chen et al [78].  
 
Figure 2.1. Design of acoustic source for simulation. (A) 3D image of the ring-shaped, 
spherically focused ultrasound transducer for simulation, and the central space was reserved of 
passive cavitation detector (PCD). This design is to mimic the FUS transducer used in experiments 
(B). The generated acoustic pressure field in silico (C) showed an ellipsoidal focus in water.  
 
Figure 2.2. Calibration of simulation with the FUS pressure field in water (used for primate 
experiments). (A) The in silico acoustic profile in the focal region was calibrated to be the same 
as the profile from the FUS transducer measured in water using a hydrophone, including the focal 
width and the side-lobes in lateral (B) and axial (C) direction. 
 
Figure 2.3. In vivo mice experimental setup. The animals were positioned in a stereotaxic frame 
during the sonication. Microbubbles were injected through the tail immediately prior to the 
sonication. Water containers coupled the animal’s head to the ultrasonic transducers using 
coupling gel. A therapeutic transducer was driven by an arbitrary waveform generator (AWG). A 
10 MHz transducer was used for targeting and passive cavitation detection (PCD). 
 
Figure 2.4. Customized chirp and random signal used for sonication. The varied magnitude in 
the temporal domain was due to the adjustment of FUS transducer sensitivity in order to reach the 
same pressure. Both the chirp and the random signals composed of a frequency range from 1.4-
1.9 MHz as shown in the frequency spectra.  
 
Figure 2.5. In vivo NHP experimental setup. (A) A focused ultrasound (FUS) transducer was 
used for sonication and a hydrophone coaxially and confocally aligned with the FUS transducer 
served for passive cavitation detection (PCD). (B) Targeting was performed using stereotaxis with 
pre-planning for focusing at the caudate nucleus (left) or putamen (right) based on the preoperative 




Figure 2.6. Simulation of acoustic pressure field through the mice skull using customized 
pulses. (A) The mice skull was imaged in microCT. The peak negative pressure fields for different 
coded pulses using (B) regular sonication (1.5 MHz); (C) Chirp: 1.5-1.9 MHz, 10 kHz, 3 cycles; 
(D) Chirp: 1.5-1.9 MHz, 10 kHz, 2 cycles; (E) Chirp: 1.23-2.29 MHz, 10 kHz, 3 cycles; (F) 
Random: 1.5-1.9 MHz, 10 kHz, 3 cycles; (G) Random: 1.5-1.9 MHz, 1 kHz, 2 cycles; and (H) 
Random:1.23-2.29 MHz,1kHz,3 cycles. The lateral (H) and axial (I) beam profiles were plotted 
comparing the regular pulses to the coded pulses with best focusing quality and less standing wave 
in (E) and (H). 
 
Figure 2.7. BBB opening in mice using customized pulses. (A) The spectrograms of the 
cavitation signals demonstrated varied harmonic frequencies using chirp or random coded pulses 
compared to consistent frequencies in the regular pulses. (B) Contrast enhanced T1- weighted MRI 
images showed the BBB opening for chirp, random and regular sonication methods, respectively. 
(C) Using coded pulses resulted in a more localized BBB opening. (D) The quantified stable 
cavitation dose showed a lower cavitation activity with coded excitation. 
 
Figure 2.8. Simulation of acoustic pressure field through the NHP skull using customized 
pulses. (A) The peak negative pressure fields for different coded pulses using regular sonication 
(frequency: 0.5 MHz, pulse length: 10 ms), short logarithmic chirp (sweeping frequency: 0.5-2.0 
MHz, pulse length: 0.5 ms), and long logarithmic chirp (sweeping frequency: 0.5-2.0 MHz, pulse 
length: 0.05 ms). Pressure profiles for the corresponding pulses in the (B) axial and (C) lateral 
direction.  
 
Figure 2.9. Simulation of the acoustic pressure field to estimate the BBB opening in NHP. 
(A) The CT scan of a monkey used to calculate the acoustic properties of the skull including 
density and the speed of sound. (B) The simulated transcranial peak-negative pressure (PNP) field 
(unit normalized to the pressure without the skull) corresponded to the BBB opening in the caudate 
and putamen (arbitrary unit, A.U.). 
 
Figure 2.10. Estimated skull attenuation and focal shift in silico. (A) The in situ PNP was 
negatively correlated with the thickness and density of the skull in the acoustic beam path as shown 
in the plane-fitting result with a R2 of 0.6. (B) The in silico focal shift due to the skull in the lateral 
and axial direction of the acoustic wave propagation was estimated to be 0.8 mm laterally and 1 
mm axially. 
 
Figure 2.11. BBB opening in two NHPs showing inter-animal variation. (A-B) Two 
representative cases of BBB opening at the putamen were visualized by overlaying the contrast 
enhancement onto the post-Gd T1w image (A: NHP 1 at 300 kPa; B: NHP 2 at 600 kPa). (C) The 
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opening volume was quantified at various pressures, and the error bar represents standard deviation. 
It was found that NHP 1 had larger opening volume than NHP 2 using the same pressure. 
 
Figure 2.12. Targeted BBB opening in NHP in both the caudate and the putamen. (A) 
Visualization of targeting in the caudate nucleus (dashed contour in the left column) and the 
putamen (dashed contour in the right column) and the BBB opening by overlaying the contrast 
enhancement onto the post-Gd T1w image, where * denotes the centroid of BBB opening. (B) 
Targeting trajectory and the opening trajectory showed in the stacked horizontal slices. (C) 3D 
images with the trajectory of acoustic beam (light blue) and BBB opening (dark blue) relative to 
the skull. 
 
Figure 2.13. Targeting accuracy for in vivo BBB opening in NHP. (A) Schematic of the angle 
definition to the skull. Target shift in BBB opening was quantified in distance (B) and in angle (C), 
where lPut represents left putamen, rPut for right putamen, lCd for left caudate, and rCd for right 
caudate. The error bar represents standard deviation. 
 
Figure 2.14. The transducer was targeted the human brain at various orientation through 
the skull.  
 
Figure 2.15. Simulation of acoustic pressure field through the human skull at various angle 
of incidence. The pressure distribution for placing the FUS transducer toward the brain through 
the occipital area of the human skull at (A) 0⁰ and (B) 20⁰ angle of incidence. The focal properties 
were quantified for the parietal (blue), occipital (red), and temporal (black) bone. (C) The FWHM 
focal size. (Solid line: axial direction. Dotted line: lateral direction.) (D) The focal shift or deviation. 
(Solid line: axial direction. Dotted line: lateral direction.) (E) The skull attenuation.  
 
Figure 2.16. Simulation of acoustic pressure field through the human skull at various 
separation distance between the transducer and the skull. The pressure distribution for placing 
the FUS transducer toward the brain through the occipital area of the human skull at (A) 20 mm 
and (B) 60 mm separation distance. The focal properties through the occipital bone were quantified. 
(C) The FWHM focal size. (Blue line: axial direction. Red line: lateral direction.) (D) The focal 
shift or deviation. (Blue line: axial direction. Red line: lateral direction.) (E) The skull attenuation. 
 
Figure 3.1. Experimental setup (A) and timeline (B) for FUS-induced BBB opening in mice 
in vivo. A focused ultrasound (FUS) transducer was used for sonication, while a pulse-echo 
transducer at the center of the FUS transducer was used for both targeting and passive cavitation 
detection (PCD) purposes. After the targeting procedure, a 30 s of sonication before microbubble 
injection was performed as a baseline control for PCD. The freshly diluted microbubble solution 
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was then co-administered with dextran intravenously, and the sonication (1 min for microbubbles 
and 5 min for nanodroplets) for BBB opening started 5 s after injection. 1 hr after the end of 
sonication the mice was sacrificed using transcardial perfusion, and its brain was extracted and 
preserved for future processing. 
 
Figure 3.2. Schematic of the lipid-shelled microbubble used in this study (A) and their 
representative size distribution in number (B) and volume (C). Three different lipid acyl chain 
lengths (C16, C18, C24) were used to generate microbubbles of different physicochemical 
properties, while the emulsifier (DSPE-PEG2000), the molar ratio between the main lipid and the 
emulsifier (9:1), the gas core (PFB), and the size of the microbubbles (4-5 µm) were kept the same 
in order to focus on the effects of lipid hydrophobic chain length. The size of the different-shelled 
microbubbles was statistically the same. All microbubble suspensions were diluted to the same 
concentration (8×108 particle/mL) immediately prior to injection. 
 
Figure 3.3. Fluorescently-tagged microbubble structure. (A) Molecular structure of 5-
dodecanoylaminofluorescein (C-12). (B) Cartoon showing how the C-12 alkyl tail protrudes into 
the microbubble lipid shell converting the microbubble into a fluorescent drug carrier. (C) Epi-
fluorescence image of a fluorescent microbubble sample. C-12 did not enter the core of the 
microbubbles; all the fluorescence is located at the lipid shell. The scale bar corresponds to 10 µm. 
 
Figure 3.4. Nanodroplet characteristics. (A) Schematics of phase-shift nanodroplets through 
condensation process using microbubbles. The average size distribution of (B) the nanodroplets 
and (C) their precursor microbubbles. The average concentration and the median size for DFP 
droplets were 2.8×1011 particles/mL and 171 nm, respectively; those for DFP droplets were  
1.3×1011 particles/mL and 183 nm, respectively. 
 
Figure 3.5.   Effects of lipid hydrophobic chain length on delivery efficiency for 3-kDa 
dextran after FUS-induced BBB opening using 100-cycle (67 µs) pulses. (A-L) Representative 
fluorescence images comparing the targeted and the control (insets) hippocampi when C16, C18 
or C24 microbubbles were used to mediate BBB opening at various pressures. The scale bar in A 
depicts 1 mm. (M) The quantified fluorescence enhancement between the sonicated and the control 
ROIs showed no significant shell effect on the 3-kDa dextran delivery across the BBB.  
 
Figure 3.6.  Effects of lipid hydrophobic chain length on delivery efficiency of 40-kDa dextran 
after FUS-induced BBB opening using 100-cycle (67 µs) pulses. (A-L) Representative 
fluorescence images compare the targeted and the control (insets) hippocampi when C16, C18 or 
C24 microbubbles were used to mediate BBB opening at various pressures. The scale bar in A 
depicts 1 mm. (M) The quantified fluorescence enhancement between the sonicated and the control 
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ROIs showed significant shell effects on the 40-kDa dextran delivery across the BBB at higher 
pressures. 
 
Figure 3.7.  Effects of lipid hydrophobic chain length on delivery efficiency of 40-kDa dextran 
after FUS-induced BBB opening using 1000-cycle (670 µs) pulses. (A-L) Representative 
fluorescence images compare the targeted and the control (insets) hippocampi when C16, C18 or 
C24 microbubbles were used to mediate BBB opening at various pressures. The scale bar in A 
depicts 1 mm. (M) The quantified fluorescence enhancement between the sonicated and the control 
ROIs showed significant shell effects with C24 microbubbles on the 40-kDa dextran delivery 
across the BBB at higher pressures. 
 
Figure 3.8.  Quantified acoustic emission detected during BBB opening at various pressures 
and pulse lengths. For 100-cycle pulses, stable cavitation dose with harmonics (SCDh) (A), 
inertial cavitation dose (B), and stable cavitation dose with ultraharmonics (SCDu) (C) was 
calculated. The three types of cavitation dose for 1000-cycle pulses were also quantified (D-F).  
 
Figure 3.9.  Representative histological images of the targeted (left) and control (right) 
hippocampi using 100-cycle (A-F) and 1000-cycle pulses (G-L) at 600 kPa. No erythrocyte 
extravasation, dark neurons, gross hemorrhage or microvacuolations were observed when C16 
microbubbles were used to mediate BBB opening using either 100-cycle (A-B) or 1000-cycle (G-
H) pulses. Small clusters of dark neurons (indicated with stars) were identified when C18 
microbubbles were used with 100-cycle pulses (C-D), while a few petechial hemorrhages 
(indicated with triangles) were observed with 1000-cycle pulses (I-J). Larger degree of 
perivascular hemorrhages was seen with C24 microbubbles regardless of the pulse length (E-F, K-
L). The scale bar in A depicts 1 mm. 
 
Figure 3.10.  Using stable cavitation dose (SCDh+u = SCDh + SCDu) to evaluate the opening 
outcomes qualitatively for classification (A) and quantitatively for delivery efficiency assessment 
(B). In the qualitative analysis (A), the SCDh+u was separated into groups of no opening and 
opening (fluorescence enhancement was higher than the mean plus 2 times of standard deviation 
of the sham cohort), while based on the histological results it was separated into groups of no 
damage and damage (erythrocyte extravasation or dark neurons appeared). In the quantitative 
analysis (B), the fluorescence enhancement was positively correlated with the SCDh+u, with a R
2 
of 0.63 and 0.61 using linear fitting for 100-cycle pulses and 1000-cyle pulses, respectively.  
 
Figure 3.11. Fluorescence enhancement in the sonicated region showed successful drug 




Figure 3.12. PCD monitoring of the cavitation doses in the cases of (A) significant and (B) 
insignificant fluorescence delivery. 
 
Figure 3.13.  Still-frame images showing nanodroplet activation within the first two cycles of 
the pulse as a function of sonication pressure.  Frames A-D and G-J were taken in the first 
rarefactional half-cycle, while E-F and K-L were taken in the following compressional cycle.  No 
nanodroplet vaporization was detected at 0.35 MPa (left) while micron-scale acoustically-
responsive bubbles were seen expanding in the rarefactional cycle at 0.45 MPa (G-J).  When 
transitioned to the next positive pressure cycle (K, L), the newly formed bubbles were observed to 
respond to the acoustic pressure by compressing until no longer visible in the field of view.  Times 
shown are relative to the start of the pulse, and the scale bars indicate 5 µm. 
 
Figure 3.14. Normalized fluorescence enhancement between the targeted and the control 
hippocampi using either nanodroplets (A) or microbubbles (B) to mediate BBB opening at 
distinct sonication pressures.  The normalized fluorescence enhancement with pressure followed 
a linear relationship with correlation coefficient R2 being 0.76 and 0.94 for nanodroplets and 
microbubbles, respectively.  Significant dextran delivery was observed at pressures higher than 
0.45 MPa using nanodroplets while the BBB opening threshold was decreased down to 0.30 MPa 
when microbubbles were administered.  All numbers are reported as mean ± standard deviation.  
(ns: not significant; *: P<0.05; **: P<0.01; ***: P<0.001) 
 
Figure 3.15. Representative fluorescence images comparing the targeted and the control 
(insets) hippocampi when nanodroplets (top) or microbubbles (bottom) were used to mediate 
BBB opening at various sonication pressures.  The left hippocampus was sonicated in the 
presence of either nanodroplets or microbubbles and fluorescently-labeled 3-kDa dextran.  
Sonications were achieved at distinct peak-rarefactional pressures: 0.15 MPa (A&F), 0.225 MPa 
(B&G), 0.30 MPa (C&H), 0.45 MPa (D&I) and 0.60 MPa (E&J).  The scale bar in A depicts 1 
mm. 
 
Figure 3.16. Quantified acoustic emission detected during BBB opening at various sonication 
pressures.  Stable cavitation implied that vaporized nanodroplets or microbubbles underwent 
stable nonlinear oscillation during sonication, while inertial cavitation signified particle 
fragmentation.  Significant SCD increase was detected after nanodroplet injection at the highest 
pressure level (A), but no significant ICD increase was measured (B). On the other hand, 
significant increase of SCD was detected for all pressures after microbubble administration (C), 
and ICD increase was detected at the highest acoustic exposure level (D).  All numbers are reported 




Figure 3.17. Correlation between differential stable cavitation dose (SCD) and fluorescence 
enhancement.  The SCD was normalized based on the background emission signal measured prior 
to contrast agent injection.  Linear correlations were obtained for both (A) nanodroplets (R2=0.74) 
and (B) microbubbles (R2=0.67). 
 
Figure 3.18. Stable cavitation dose (SCD)-indicated BBB opening threshold.  The SCD was 
grouped based on whether significant dextran delivery was detected.  Each individual brain was 
concluded to have significant BBB opening when the difference in fluorescence intensity between 
the sonicated and the control hippocampi was two standard deviations greater than the average 
value obtained for the corresponding sham group.  Sonication using microbubbles as the contrast 
agents produced a much wider range of SCD values comparing to when nanodroplets were used.  
The SCD threshold for predicting BBB opening appeared to be contrast agent dependent.  7 out of 
10 mice showed significant dextran delivery with SCD values greater than 74 V·s using 
nanodroplets while 92.3% of the animals showed significant dextran delivery at SCD above 1.4 
kV·s using microbubbles.  The slightly weaker threshold for the nanodroplet group indicated 
secondary mechanism other than cavitation could induce the BBB opening.  (*: P<0.05; ***: 
P<0.001) 
 
Figure 3.19. Representative histological images of the targeted and control hippocampi.  The 
animals were sacrificed 1 h after sonication.  (Left) No erythrocyte extravasations, dark neurons, 
gross hemorrhage or microvacuolations were observed when nanodroplets were used to mediate 
BBB opening at either 0.45 MPa or 0.60 MPa.  (Right) When microbubbles were used, erythrocyte 
extravasations or dark neurons were not seen at 0.45 MPa.  However, small clusters of erythrocyte 
extravasations and a few dark neurons were observed (arrow heads in O), indicating minor damage, 
after sonication at 0.60 MPa. The boxed regions in all 4x images are further zoomed into 10x.  The 
scale bars in A and C depict 1 mm and 100 µm, respectively. 
 
Figure 3.20.  Detection of acoustic droplet vaporization using high-speed optical microscopy. 
(A) OFP-filled droplets were found to vaporize at pressures at and above 300 kPa, but not at 150 
kPa. (B) DFB droplets were found to vaporize inconsistently at 600 kPa (vaporization did not 
occur with every activation pulse). Vaporization was consistently observed at 750 kPa and 900 kPa 
for DFB droplets. On average, more bubbles were generated from OFP droplets at low pressures 
(300-450 kPa) compared to those generated from DFB droplets at higher pressures (750-900 kPa). 
Scale bar represents 10 μm. (C) The vaporization efficiency defined as the number of bubbles 
formed in the field of view after normalized by the nanodroplets concentration was calculated. The 




Figure 3.21.  Delivery efficiency (40 kDa dextran) using fluorescence microscopy after BBB 
opening. Fluorescence images of sonicated vs. non-sonicated hippocampi (insets) using (A) OFP 
droplets at 300 kPa, (B) OFP droplets at 450 kPa, (C) microbubbles at 450 kPa, and (D) DFB 
droplets at 900 kPa. The stacked slices showed localized delivery across the entire sonicated 
hippocampi for (E) OFP droplets at 450 kPa, (F) microbubbles at 450 kPa, and (G) DFB droplets 
at 900 kPa. (H) The mean BBB opening area (normalized to the entire hippocampus) and (I) mean 
fluorescence intensity increase for all cohorts, with a dash line representing the threshold of 
successful delivery defined by the sham group (mean plus 2 time of the standard deviation). 
Successful delivery was found to be at and above 300 kPa for OFP droplets, and 900 kPa for DFB 
droplets.  
 
Figure 3.22.  Passive cavitation detection during the sonication for BBB opening, with the 
cavitation evolution within a pulse (spectrograms) and within the whole sonication duration 
(cavitation level for stable cavitation dose SCDh, SCDu, and inertial cavitation dose ICD) shown 
on the left panel and the right panel, respectively. (A) OFB droplets at 150 kPa without delivery. 
(B) OFP droplets at 300 kPa with delivery. (C) OFP droplets at 450 kPa with delivery. (D) 
Microbubbles at 450 kPa with delivery. (E) DFB droplets at 750 kPa without delivery. (F) DFB 
droplets at 900 kPa with successful delivery. Strong and abundant cavitation events including both 
stable and inertial cavitation were observed in cases with successful delivery (B, C, D, F). 
 
Figure 3.23.  Cavitation dose of the entire sonication. (A) SCDh or stable cavitation dose with 
harmonic emissions. (B) SCDu or stable cavitation dose with ultraharmonic emissions. (C) ICD or 
inertial cavitation dose with broadband emissions. (D) The area of BBB opening and (E) the 
fluorescence intensity increase using OFP droplets was linearly correlated with the total stable 
cavitation dose (SCDu+h = SCDh + SCDu) for the cases with successful delivery. The dash line 
represents the threshold of successful delivery defined by the sham group (mean plus 2 times of 
the standard deviation). 
 
Figure 3.24.  Safety assessment using histological staining (H&E). Sonicated (A, C, E) and 
nonsonicated (B, D, F) hippocampi using OFB at 300 kPa (A, B), 450 kPa (C, D), and DFB at 900 
kPa (E, F).  The results showed no damage (erythrocyte extravasations or dark neurons) using OFP 
droplets. For DFB droplets at 900 kPa, only 1 out of 3 animals showed an increased amount of 
dark neurons on the hippocampi. The scalebar in (A) represents 1 mm. 
 
Figure 3.25.  Extravascular delivery using fluorescently tagged nanodroplets. OFP droplets 
were used at 450 kPa. (A) Fluorescent microscopy showed low or no delivery on the sonicated 
side compared to the control. (B) The quantified fluorescence intensity showed no statistical 




Figure 4.1. In vitro experimental setup. A focused ultrasound (FUS) transducer was used for 
sonication, while a flat-band hydrophone at the center of the FUS transducer was used for passive 
cavitation detection (PCD). The cranial part of the macaque skull (including frontal bone, parietal 
bones, and occipital bone) was 3.09-mm thick in average of the beam-path region, and the human 
skull (including the frontal and the parietal bones) was 4.65-mm thick. 
 
Figure 4.2. In vivo NHP experimental setup. (A) A focused ultrasound (FUS) transducer was 
used for sonication and a hydrophone coaxially and confocally aligned with the FUS transducer 
served for passive cavitation detection (PCD). (B) Targeting was performed using stereotaxis with 
pre-planning for focusing at the caudate nucleus (left) or putamen (right) based on the preoperative 
MRI scan with a stereotax. 
 
Figure 4.3. Pipeline for BBB opening volume quantification and drug delivery analysis based 
on MRI processing. (A) To quantify BBB opening volume, the contrast enhancement map (upper: 
horizontal slice, lower: coronal slice) were used after dividing the post-Gd T1 images by the pre-
Gd images. Then, after applying the brain mask and the vessel mask in order to filter out the 
contrast enhancement outside of the BBB opening area (B), the opening volume was calculated by 
subtracting the VOI in the contralateral area (dashed rectangle) from the targeted area (solid 
rectangle) (C). On the other hand, the pre- Gd T1,0  (D) and post-Gd T1 maps (E) were used to 
quantify the amount of Gd delivered and its delivery efficiency since the Gd shorted the T1 time 
after diffused the BBB opening region (arrowhead). The Gd concentration map (F)(upper: 
horizontal slice, lower: coronal slice) was acquired by calculating the change of T1 time between 
pre- and post-Gd T1 maps. After applying the brain mask and excluding the Gd retention in the 
vessels by thresholding (G), the amount of Gd delivered was calculated by subtracting the VOI in 
the contralateral area (dashed rectangle) from the targeting area (solid rectangle) (H). 
 
Fig. 4.4. In vitro cavitation monitoring: spectrograms. (A) Sonicating water without the skull 
in place. (B) Sonicating microbubbles without the skull in place. (C) Sonicating microbubbles with 
the macaque skull in place. (D) Sonicating microbubbles with the human skull in place. (i), (ii), 
(iii), and (iv) represents 50 kPa, 150 kPa, 200 kPa, and 450 kPa, respectively. The colorbar shows 
the intensity of the spectra, with a dynamic range of 25 dB and 15 dB for the macaque and human 
skull experiments, respectively, based on the preamplification (macaque: 20 dB, human: 10 dB). 
 
Figure 4.5. In vitro cavitation monitoring: B-mode images in transverse plane after the 
sonication. (A) Without the skull in place using 100 cycles. (B) With the macaque skull in place 
using 100 cycles. (C) With the human skull in place using 100 cycles. (D) Without the skull in 
place using 5000 cycles. (i), (ii), (iii), and (iv) represents 50 kPa, 150 kPa, 200 kPa, and 450 kPa, 
respectively. The arrows indicate the spot losing echogenicity at the pressure threshold (200 kPa). 
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The images showed good focal alignment to the channel and the bubbles lost the property of 
contrast enhancement at or above 200 kPa. The shape to the hypoechogenitic area was roughly a 
circle with an averaged diameter of 1.3 mm at 200 kPa and 4 mm at 450 kPa.  
 
Figure 4.6. In vitro cavitation doses. (A) SCDh, (B) SCDu, and (C) ICD for the macaque skull 
experiments using 100-cycle pulses. (D) SCDh, (E) SCDu, and (F) ICD for the human skull 
experiments using 100-cycle pulses. (G) SCDh, (H) SCDu, and (I) ICD without the skull in place 
using 100- and 5000-cycle pulses. The error bar shows the standard deviation. *: p<0.05. Green *: 
comparison made in the cases without the skull in place. Red *: comparison made in the cases with 
the skull in place. All of the comparisons in (G)-(I) showed statistical significance. All of the 
cavitation doses became detectable at 50 kPa, while this detectable pressure threshold may change 
after placing the skull. The nonlinear effect of the skull was seen after placing the human skull at 
high pressures as the SCDh increased significantly. Applying long pulses (5000 cycles) was 
effective in generating high cavitation doses at low pressures when compared with applying short 
pulses (100 cycles).  
 
Figure 4.7. In vitro cavitation SNR (a) without the skull in place using 100-cycle pulses, (b) 
without the skull in place using 5000-cycle pulses, (c) with the macaque skull in place using 100 
cycles, and (d) with the human skull in place using 100 cycles. The error bar shows the standard 
deviation. The dash lines in (a) represent the SNR threshold for surpassing the skull attenuation 
(macaque: 15.2 dB, human: 34.1 dB). For SNR higher than 1 dB, the detected cavitation doses were 
significantly higher than that of control. This 1 dB was deemed as the detection threshold with and 
without the skull. 
 
Figure 4.8. In vivo cavitation doses using 100- and 5000-cycle pulses. (A) SCDh. (B) SCDu. (C) 
ICD. *: p<0.05. The error bar shows the standard deviation. When using 5000-cycle pulses, the 
SCDh became detectable transcranially at 100 kPa; for the ICD, 250 kPa; while the SCDu was 
unrealiable and could be detected at high pressures. When using 100-cycle pulses, the pressure 
threshold in detecion increased.  
 
Figure 4.9. In vivo cavitation SNR using (A) 100-cycle and (B) 5000-cycle pulses. The error 
bar shows the standard deviation. The cavitation SNR using 100-cycle pulses increased with 
pressure. When using 5000-cycle pulses, the SNR of the SCDu and ICD increased with pressure, 
while it for the SCDh reached plateau due to the nonlinear effect of the skull at high pressures.  
 
Figure 4.10. Real-time cavitation monitoring during in vivo BBB opening at (a) 275 kPa, (b) 
350 kPa, (c) 450 kPa, and (d) 600 kPa in the thalamus (orange arrow) or the putamen (green arrow). 
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The upper and middle rows show the post-contrast T1 weighted images with calculated 
enhancement (with colorbar) in axial and coronal view, respectively. The opening volume of (a) 
to (d) was 494.7, 230.9, 112.9, and 299.2 mm3, respectively. The bottom row shows the real-time 
monitoring of the SCDh, SCDu, and ICD for sonicating the thalamus. Note that in (d) the 
microbubbles were injected before the sonication was started. Case (b)-(d) were performed in the 
same macaque.  
 
Figure 4.11. Safety assessment using MRI at (a) 275 kPa, (b) 350 kPa, (c) 450 kPa, and (d) 600 
kPa. The upper row shows the T2-weighted images (coronal view) for detecting the edema, which 
is lighter if occurred. The lower row shows the SWI (coronal view) for detecting the hemorrhage, 
which is darker if occurred. In all cases, no hemorrhage and edema was detected. 
 
Figure 4.12. BBB opening with real-time acoustic cavitation monitoring in two NHPs. FUS-
induced BBB opening in NHPs was visualized in T1w images after overlaying the contrast 
enhancement onto the post-Gd T1w image (A-B) (A: NHP 2 at 300 kPa; B: NHP 3 at 600 kPa). 
The corresponded Gd concentration map ([Gd]c) (C-D) showed the variation of Gd delivered in 
gray and white matter according to the tissue segmentation map based on the pre-Gd T1 map (E-
F)(dark gray: gray matter, light gray: white matter, black: blood, white: CSF). The acoustic 
cavitation emission were recorded and calculated in real time. (G-H). The BBB opening of NHP 
2 and 3 showed an inter-animal variation and may be due to the skull.  
 
Figure 4.13. Cavitation monitoring in assessing the BBB opening and drug delivery. (A) In 
order to study the intra-animal variation, NHP 1 was sonicated with the same targeting (putamen) 
and acoustic parameters (275 kPa) in a bi-weekly basis five times. FUS-induced BBB opening was 
performed in three NHPs with the opening volume (B), and the drug delivery analysis was 
performed in two NHPs for the amount of Gd delivered and the delivery efficiency (C). NHP 1 to 
NHP 3 were sonicated 7, 12, and 24 times, respectively, and the error bar represents standard 
deviation. Both (B) and (C) showed an inter-animal variation as the BBB opening threshold for 
NHP 1 and 2 were lower than that for NHP 3. Quantified cavitation doses (SCDh: stable cavitation 
dose with harmonics, SCDu: stable cavitation dose with ultraharmonics, ICD: inertial cavitation 
dose) were correlated with the BBB opening outcomes. The SCDh can be used to detect the 
effectiveness of BBB opening (D). For a quantitative assessment, the opening volume (E), the 
amount of delivered Gd and delivery efficiency (F) was positively correlated with the total 
cavitation dose (SCDh + SCDu + ICD). (The R
2 of the linear fitting in (E) for NHP 1 to 3 and all 
experiments across animals was 0.81, 0.63, 0.50, and 0.47, respectively; that in (F) for NHP 2, 3, 
and all experiments across animals was 0.52, 0.71, and 0.61, respectively.)  
 
Figure 4.14. Effect of gray and white matter. FUS was applied in the caudate and putamen in 
three animals causing a BBB opening volume close to 400 mm3 (300 kPa for NHP 2, 450 kPa for 
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NHP 3 and 4). The opening volume was shown in (A), and the total cavitation dose in (B). Based 
on the tissue segmentation, the gray-and-white matter composition in the sonicated area (C) and 
in the BBB opening area (D) were calculated. The correlation of total cavitation dose to the BBB 
opening volume was calculated in (E), in which it was better correlated with the total opening 
volume than with the volume in gray matter. 
 
Figure 4.15. Vasculature effect. MR angiography (MRA) in NHP in (A) coronal, (B) sagittal, 
and (C) horizontal view, and the middle cerebral artery (MCA) was indicated by an arrowhead. 
(D) Four BBB opening cases targeting regions proximal to the MCA (arrowhead) at 450 kPa in 
NHP 4, where the upper row showed the opening volume overlaying onto the post-Gd T1w images 
and the lower row was the cavitation response along the sonication time. PCD calibration (E-G) 
after BBB opening in cases i-iii was performed in order to assess the cavitation level at different 
pressures (10 pulses per pressure) with targeted regions near or include the MCA (E: SCDh, F: 
SCDu, G: ICD), and the errorbar represented the standard deviation of the 10 sonications. Note 
that the opening volume for case i to iv was 309, 469, 443, and 758 mm3 and angle of incidence to 
the skull: 24°, 18°, 35°, 41°, respectively. The cavitation level varied as the targeted region 
approached the MCA that was correlated with the opening volume but was found to be independent 
of the incidence angle.  
 
Figure 4.16. Safety assessments in the MRI. (A) NHP 1 targeting putamen at 275 kPa. (B) NHP 
2 targeting caudate nucleus and putamen at 400 kPa. (C) NHP 3 targeting putamen at 450 kPa. (D) 
NHP 4 targeting caudate nucleus and putamen at 600 kPa. No edema or hemorrhage was detected 
in any of the cases. 1st row: contrast enhancement of the BBB opening overlaying onto the post-
Gd T1w imaging; 2
nd row: T2w imaging for edema; 3
rd row: susceptibility-weighted imaging (SWI) 
for hemorrhage. 
 
Figure 5.1 Schematic of passive cavitation mapping algorithm based on time exposure 
acoustics. The passive cavitation signal was acquired in a PCD array, stored as channel data for 
each sonicated pulse. Several passive frames were reconstructed in one single FUS pulse with 
different time windows representing the cavitation map in each time segment. They were summed 
together as integration over the exposure time (Te) to enhance the cavitation signals in a spatial 
domain. 
 
Figure 5.2. Matrix calculation for reconstructing a cavitation map. (A) Delay-and-sum (DAS) 
beamforming to reconstruct a series of radiofrequency (RF) frames using sparse matrix calculation. 
(B) The cavitation map of a single pulse is the sum of squared RF frames at each time window, 
i.e., the time integration of TEA. (C) The channel dataset in (A) is extracted from a series of time 




Figure 5.3. Experimental setups for (A) the in vitro skull and phantom and (B) the in vivo 
BBB opening in NHP. In the in vitro experiment, the FUS transducer was place on top of the 
channel phantom orthogonal to the PCD array, and the skull was placed in between the phantom 
and the PCD array for assessing the skull effects on the cavitation mapping. In the in vivo 
experiment, the FUS transducer was targeted to the region of interest based on the stereotaxis while 
the PCD array was placed against the temporal bone toward the FUS focus. 
 
Figure 5.4. The impact of exposure time on computational time and mapping characteristics. 
(A) The exposure time (Te) was linearly correlated with the computational time (Tc) since it 
determined the number of RF frames required to be reconstructed for one single cavitation map. 
(B) This exposure time also affected the mapping quality in terms of denoising and homogeneity 
of cavitation distribution. The maximal intensity of the map increased until reached to a plateau as 
more RF frames were added. This cavitation distribution also formed in a localized region at a 
very short exposure time (1.44 µs) as shown in the cavitation region (-6 dB area) until reaching a 
steady state at 62.5 µs. This representative case was performed at 450 kPa, while all other cases at 
various pressure showed the same trend. 
 
Figure 5.5. Detection threshold of cavitation mapping through the primate skulls. Cavitation 
maps at various pressures (A) without the skull in place, (B) with the NHP skull, (C) with the 
human skull in place were acquired. The cavitation distribution was successfully reconstructed at 
all pressures from 150 kPa to 600 kPa. It can be detected at and above 300 kPa and 450 kPa through 
the monkey skull and human skull, respectively.   
 
Figure 5.6. Cavitation mapping during BBB opening in NHP 1. (A) BBB opening (colored) 
revealed after post processing in the horizontal slice of the contrast-enhanced T1w MRI. BBB 
opening was induced at 450 kPa while the PCD array (placed against the temporal bone toward 
the FUS focus) acquired cavitation signals for reconstruction of cavitation maps. (B) Both the 
single-element PCD and the PCD array acquired cavitation signal for real-time monitoring. The 
calculated cavitation doses from the single-element PCD is shown on the left, and the total intensity 
of cavitation signals (sum of the squared channel data) from the PCD array on the right. (C) The 
reconstructed cavitation maps at each time point revealed the location cavitation events in the brain 
(using the -6 dB scale relative to the maxima).    
 
Figure 5.7. Stable cavitation mapping during BBB opening in NHP 2. (A) BBB opening 
(colored) revealed after post processing in the horizontal slice of the contrast-enhanced T1w MRI. 
BBB opening was induced at 450 kPa while the PCD array (placed against the temporal bone 
toward the FUS focus) acquired cavitation signals for reconstruction of cavitation maps. (B) Both 
the single-element PCD and the PCD array acquired cavitation signal for real-time monitoring. 
The calculated cavitation doses from the single-element PCD is shown on the left, and the total 
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intensity of cavitation signals from the PCD array on the right. (C) The reconstructed cavitation 
maps at each time point revealed the location and intensity increase of cavitation events in the 
brain (using the intensity as the color scale).    
 
Figure 6.1. Acquiring preoperative anatomical images with fiducials for registration. (A) A 
NHP skull with a bite bar connecting unique teeth impression to the fiducial plates. (C) NHP brain 
images with donut-shape fiducials (D) in T1w MRI. The fiducial landmarks (center of the fiducials) 
were identified in the neuronavigation system for registration. 
 
Figure 6.2. Experimental setup with neuronavigation for (A) the sedate and (B) the awake 
animal. Infrared (IR) camera was the position tracking device connected to the computer to 
process image registration in real time in the neuronavigation system. The trackers bared three 
reflective spheres for the IR camera to detect transducers (tool trackers) relative to the animal 
subject in the physical space (subject tracker). At the beginning of the treatment session, the 
fiducials were attached to the invariant traits (bite bars or head post) of the animal for registering 
the animal subject to the neuronavigation system. After the registration, the fiducials were removed 
and the FUS transducer was aligned to the preplanned targeting and secured with the free-guide 
arm or stereotactic arm for sonication. 
 
Figure 6.3. Preplanning procedure for FUS targeting. (A) Flowchart for preplanning and FUS 
treatment procedure of neuronavigation-guided ultrasound. (B) Screenshots of the preplanning on 
the neuronavigation system. Preplanning for the FUS target and trajectory through the 3D 
segmented and reconstructed skull (1), basal ganglia (2), and the scalp with the donut-shaped 
fiducials (3), and the focus was at the crosshair of the MRI slices (4-6) acquired preoperatively.  
 
Figure 6.4. Neuronavigation-guided FUS treatment procedure. (A) Flowchart for 
implementing FUS targeting to the preplanning. (B) Screenshots of the online session showing the 
FUS trajectory in the reconstructed 3D brain (1) targeted the putamen in two orthogonal MRI slices, 
in which the vertical arrows represent the FUS trajectory pointing at the focus (2-3). (4) The 
implementation accuracy of the FUS transducer to the preplanning was displayed as a feedback 
for the distance (visualized as the distance between the red dot and the center of the larger circle) 
and the angle deviation (visualized as the distance between the red dot and the center of the smaller 
circle) during the guiding process. (5) The PCD array for cavitation mapping was aligned to the 
FUS focus before the sonication with neuronavigation guidance. 
 
Figure 6.5. Neuronavigation-guided FUS for BBB opening in the sedate animal.  Accurate 
BBB disruption were achieved with neuronavigation in the caudate nucleus (NHP 2 at 450 kPa) 
and in the putamen (NHP 3 at 600 kPa). The coronal slices in (A) and (E), the sagittal slices in (B) 
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and (F), the horizontal slices in (C) and (G), and the stacked horizontal slices with the BBB opening 
trajectory (red line) and the planned trajectory (blue line) in (D) and (H). The cross represents the 
centroid of BBB opening and the circle the FUS focus in the neuronavigation system. 
 
Figure 6.6. Neuronavigation-guided FUS for BBB opening in the awake animal trained to sit 
in the customized chair.  Accurate BBB disruption were achieved with neuronavigation in the 
central sulcus and in caudate nucleus (NHP 4 at 300 kPa). The coronal slices in (A) and (E), the 
sagittal slices in (B) and (F), the horizontal slices in (C) and (G), and the stacked horizontal slices 
with the BBB opening trajectory (red line) and the planned trajectory (blue line) in (D) and (H). 
The cross represents the centroid of BBB opening and the circle the FUS focus in the 
neuronavigation system. 
 
Figure 6.7. Accuracy for the neuronavigation-guided ultrasound system compared with 
frame-based method. (A) The total focal shift with the neuronavigation was slightly smaller than 
with the stereotaxis although it showed no statistical significance. (B) After breaking into the 
lateral (lat), the axial (ax) direction and the angle, the neuronavigation showed a significant 
improvement on the lateral direction.  
 
Figure 6.8. Neuronavigation-guided cavitation mapping during sonication for BBB opening. 
(A) The averaged frequency spectra in the channel data of the PCD array. (B) The total intensity 
of the channel data during the 2-min sonication showed significant cavitation response after 
microbubbles perfused the brain. The reconstructed cavitation maps showed the exact location of 
the BBB opening in the caudate at 450 kPa (C) and the putamen at 450 kPa (D).  (E) The cavitation 
mapping showed an accurate monitoring at the location of BBB opening. 
 








Aβ   Amyloid plaques made up of beta-amyloid peptides 
AD   Alzheimer’s disease 
AFM   Atomic force microscopy 
BBB   Blood-brain barrier 
Cau   Caudate nucleus 
CNS   Central nervous system 
CSF   Cerebral spinal fluid 
CT   Computerized tomography 
DBS   Deep brain stimulation 
DFB   Decafluorobutane 
DLiPC (C24)  1,2-dilignoceroyl-sn-glycero-3-phosphocholine 
DPPC (C16)  1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DSPC (C18)  1,2-distearoyl-sn-glycero-3-phosphocholine 
DSPE-PEG2000 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N- 
[methoxy(polyethylene glycol)2000] 
H&E   Hematoxylin and eosin staining 
IACUC  Institutional Animal Care and Use Committee 
ICD   Inertial cavitation dose 
IV   Intravenous 
IP   Intraperitoneal 
IR   Infrared 
IRB   Institutional Review Boards 
FDA   U.S. Food and Drug Administration 
FUS   Focused ultrasound 
FWHM  Full-width at half maximum 
GBM   Glioblastoma multiform 
Gd   Gadolinium 
GDNF   Glia-derived neurotrophic factor 
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GPU   Graphic processing unit 
HIFU   High-intensity focused ultrasound 
MRgFUS  Magnetic resonance imaging guided focused ultrasound 
MRI   Magnetic resonance imaging 
NIH   National institutes of health 
NINDS  National institute of neurological disorders and stroke 
NHP   Non-human primates 
ns   Not statistically significant  
OFP   Octafluoropropane 
PBS   Phosphate-buffered saline 
PCD   Passive cavitation detection 
PD   Parkinson’s disease 
PFC   Perfluorocarbon 
PL   Pulse length 
PNP   Peak-negative pressure 
PRF   Pulse repetition frequency 
Put   Putamen 
RF   Radiofrequency 
RMS   Root mean square 
SCDh   Stable cavitation dose with harmonics 
SCDu   Stable cavitation dose with ultraharmonics 
SWI   Susceptibility-weighted imaging 
T1w   T1 weighted MRI 
T2w   T2 weighted MRI 
TEA   Time exposure acoustics 
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Chapter 1   
Background & Thesis Overview 
 
1.1 THE BRAIN & DISEASES 
1.1.1   The brain in the central nervous system 
The brain (encephalon) is the information processing center of central nervous system (CNS) that 
interprets sensation and controls movement through the sensory and motor nerves in spinal cord 
and the functional circuits [1, 2]. It is protected by the skull (Fig. 1.1A). Under the skull, it is 
covered by meninges that enclose a cavity filled with cerebral spinal fluid (CSF) to provide 
cushioning effect (Fig. 1.1B). Inside the brain, it consists of ventricular system for CSF circulation, 
cerebrum, cerebellum, brain stem, with cerebral vascular system supports the nutrition and 
metabolism (Fig. 1.2A). The highest nervous organ lies in cerebral cortex and its subcortical 
structures (e.g. caudate nucleus, putamen, thalamus, hippocampus) (Fig. 1.2B) in the cerebrum 
that process consciousness, memory, thoughts, and voluntary activities. It is dark and light color 
of the tissue known as gray and white matter is due to different composition of the nerve cells. The 
gray matter represents concentrated neuronal cell bodies, and the white matter for fiber tracks or 





Figure 1.1.  Anatomy of human skull and meninges structures. (A) Superior view of the human 
skull bone. (B) Schematic cross section of the meninges and the scalp. Modified from Netter [2], 





Figure 1.2. Human brain structure. Source: (A) Sagittal view of the head cutting from mid-
sagittal plane. (B) Horizontal view of the human brain showed subcortical structures including 
basal ganglia and thalamus. Modified from Netter [2]. 
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1.1.2   The blood-brain barrier (BBB) 
Besides the outer protection of the skull and meninges, the brain tissue is sealed from the rest of 
the body by the blood-brain barrier (BBB), a highly selective barrier preventing most molecules 
entering the brain parenchyma from the bloodstream [4]. The BBB is formed by the endothelial 
cells lining the cerebral microvessels and interconnected with the tight junctions (Fig. 1.3A) 
forming a physical barrier to block paracellular passage. The specific transport systems on the 
luminal and abluminal membranes also strictly regulate the transcellular traffic, permitting the 
entry of few small hydrophilic molecules (Fig. 1.3B). Moreover, a combination of intracellular 
and extracellular enzymes in the BBB form another metabolic barrier by selectively metabolizing 
or inactivating many neuroactive and toxic compounds. These factors result in a much lower 
degree of cellular trafficking activity than other peripheral endothelium and shape the properties 
of the BBB.  
 
1.1.3   Neurological diseases and treatments 
Since the brain controls consciousness, memory, thoughts, and voluntary activities as described 
previously, its malfunction or alteration of any single component could result in a drastic disease 
ranging from epilepsy to Alzheimer’s disease. In fact, neurological diseases have affected up to 
one million people worldwide according to the report from World Health Organization [5]. They 
affect people in all countries irrespective of age, sex, education or income, which result in death 
of 6.8 billion people every year. What’s worse, the impact to the worldwide society is still 
increasing due to the aging of global population. Even so, the treatments are still limited due to the 
challenge in accessing the brain through the skull or the BBB and the risk of infection, damage of 
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health tissue, etc. The following described a few common neurological disorders [6] currently 
targeted by FUS treatment. 
 
Figure. 1.3. The blood-brain barrier. (A) The neurovascular unit interacting with the BBB. It 
consists of endothelium with tight junctions lining the cerebral vessels, pericytes, and astrocyte 
end-feets. Nerve terminals and microglia surround and interaction with the neurovascular unit and 
BBB. (B) Various mechanisms across the BBB, including both transcellular and paracellular 






Essential tremor is the most common movement disorder that causes unintentional muscle 
movement most often in hands, while sometimes in head, arms, voice, tongue, legs, and trunk [6]. 
It may be mild or progressive, starting on one side of the body to both sides in the end. There is no 
cure for essential tremor, but medication, deep brain stimulation (DBS), or thalamotomy 
(destroying a small volume of tissue in the thalamus that is known to cause the tremor) could relief 
symptoms in a short term. Thalamotomy could be performed with stereotactic radiosurgery or 
radiofrequency ablation. FUS is also FDA approved for noninvasive ablation in thalamotomy since 
2016 [9, 10].  
Alzheimer’s disease (AD) is a type of neurodegenerative diseases. It is also the most 
common cause of dementia, often age-related and developed over a period of time [6]. Patients 
initially experience memory loss and confusion, and gradually show behavior and personality 
changes, with declining cognitive abilities such as decision making and language skills, and 
inability to recognize family and friends. Major characteristics in the brain associated with AD 
include amyloid plaques made up of beta-amyloid peptides (Aβ) mixed with neuronal cells, and 
neurofibrillary tangles inside the neurons as abnormal aggregation of tau protein. As a result, 
neurons die and loss of connection in the functional circuits, leading to memory loss. It causes 
widespread damage of the brain tissue and significant shrinkage in the final stage of AD. There 
are no successful disease-modifying therapies, but only symptomatic treatment to improve 
personality and behavioral changes.  
Parkinson’s disease (PD) is a group of motor system disorders including tremor, rigidity 
(muscle stiffness), bradykinesia (slowness of movement), and postural instability (loss of 
coordination) resulted from the loss of dopamine-producing cells in the brain [6].  PD is a chronic 
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and progressive disease that will interfere with the patients’ daily activities. Other symptoms 
include depression; difficulty in swallowing, chewing, and speaking; urinary problems or 
constipation; skin problems; and sleep disruption. Currently, there is no treatment to cure PD, but 
only a few medication including levodopa combined with carbidopa and DBS to relief symptoms.  
Primary brain tumors have more than 688,000 patients in the U.S., with 68% of benign 
cases and 37% of malignant cases [11]. Besides, approximately 20-40% of all other cancers 
develop a brain metastases. Among them all, glioblastoma multiform (GBM) is the most common 
and aggressive malignant brain tumor in adults, representing 17% of all brain tumors and 52% of 
primary brain tumors [12] and causing approximately 15,000 deaths per year in the U.S. [13]. 
Standard treatment includes surgical removal, followed by radiation therapy and may accompany 
by chemotherapy [12]. Chemotherapy is less common to treat brain tumors because of BBB 
blocking the entry to cancerous cells.  
  Most of the diseases remain undertreated due to complicated or unknown pathogenesis, 
difficulties in accurate diagnosis on the early stage, and inaccessibility of the brain through the 
skull or BBB. Available treatments, though limited, include medication, surgery, radiotherapy, or 
DBS that may introduce risks such as infection, damage of healthy tissue, exposure of radiation, 






1.2 THERAPEUTIC ULTRASOUND 
1.2.1 Medical ultrasound and its biological effects 
Ultrasound are material waves that propagates through compressional particle movement in the 
medium, with frequencies higher than 20 kHz outside of the audible limit in humans. In medicine, 
it was first used for diagnostic imaging by sending short pulses (1 to 5 cycles in 2 to 12 MHz range 
at pressures of 2 MPa or lower) to see the internal tissue structure and elasticity. While with 
different settings of the acoustic parameters, ultrasound can induce certain biological effects to 
achieve therapeutic purposes, including heating, cavitation or gas body activation, compressional 
or shear stresses [14]. For example, increasing the frequency, nonlinear acoustic distortion, or 
pulse length can generate heating and enhance non-thermal mechanical effects such as radiation 
force. While decreasing the frequency with extended pulse lengths increases the likelihood of 
cavitation. In general, increasing the power and intensity of acoustic waves tends to increase the 
likelihood and magnitude of all biological effects.  
Heating can be induced by high-intensity ultrasound due to tissue absorption of the 
ultrasonic energy. It can be achieved with unfocused heating as used in physical therapy to enhance 
bone or tendon healing without injury [14]. Alternatively, the heat can be concentrated by focused 
ultrasound (FUS) to achieve thermal ablation (57-60 ⁰C causing coagulation necrosis) comparable 
to surgery, as show in Fig. 1.4 [15, 16]. Besides, elevating and maintaining tissue temperature to 
42 ⁰C can increase blood flow and drug absorption without causing permanent damage, a technique 




Figure. 1.4. The heating threshold for desired thermal effects in the tissue. Heat treatment is 
dependent on both the temperature and the exposure time. Modified from FUS foundation [16]. 
 
 Ultrasound can also induce mechanical effects such as cavitation and radiation force. 
Cavitation, the most prominent one, refers to as the bubble inception and dynamics including the 
formation of bubbles and bubble oscillation (Fig. 1.5), and is associated with the rarefactional 
pressure amplitude of ultrasonic waves [18, 19]. After bubble formation, it can oscillate stably 
with pressure changes at relatively low amplitude (stable cavitation), causing microstreaming and 
shear forces. While it can collapse at higher pressure (usually rarefactional pressure) known as 
inertial cavitation, generating shock waves, shear forces, heat, or free radicals. Therefore, 
cavitation is used in a variety of applications for tissue destruction and drug delivery, which will 
be described as follows. Other mechanical effects include radiation force or compressional, tensile, 
and shear stressed from the applied ultrasound waves, which causes displacement of the tissue and 





Figure. 1.5. The acoustic cavitation. (A) Stable cavitation occurs at low pressures, and bubbles 
oscillates periodically in the volume and shape. (B) Stable cavitation by the wall generates 
microstreaming and induced shear stress. (C) Inertial cavitation at higher pressures lead to bubble 
collapse that generates shock waves and sometimes along with smaller bubbles. (D) Inertial 
cavitation may form microjets generating high force against the wall. Modified from Stride [19]. 
 
The following lists a few therapeutic applications in the brain and other organs:  
 
1.2.2   Tissue destruction 
FUS serves as a surgical tool to noninvasively and locally destroy tissues such as tumors via 
thermal or mechanical ablation (histotripsy). High intensity focused ultrasound (HIFU) provides 
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highly focused acoustic energy deposition to induce protein denaturation, and the temperature is 
often monitored with thermocouple or MR thermometry [15] to ensure efficacy. It has been used 
to treat uterine fibroids [20], prostate cancer [21], and neurological disorders such as essential 
tremor [9]. Besides, mechanical ablation (histotripsy) can also be achieved via sending a short and 
extremely high intensity pulse to induce inertial cavitation that releases strong shock waves to 
destroy or liquefy cells [22].  Histotripsy is promising with a shorter treatment duration and more 
precise targeting compared with thermal ablation.  
 
1.2.3   Targeted drug delivery  
Using FUS in conjunction with microbubbles, targeted drug delivery can be achieved with FUS to 
enhance cell uptake of the pharmaceuticals and increase vascular permeability for delivery to 
tumors via sonoporation [23], or to the brain via BBB opening [24]. The mechanisms behind are 
mainly cavitation and radiation force, and the microbubbles can be engineered for loading drugs 
or ligands for cell specificity [25, 26]. Enhanced drug delivery enables treatments such as 
chemotherapy with less systemic toxicity as less circulating drugs are required than with traditional 
chemotherapy. It also increase the specificity to the targeted location in the FUS focus. The 
delivery efficacy and safety is associated with cavitation and should be closely monitored. 
 
1.2.4   Neuromodulation 
FUS, with specific acoustic parameters, can stimulate or suppress neuronal activity. While the 
mechanism is still under investigation, the majority tend to believe that mechanical effects 
dominate this mechanism [16]. It has been reported that low-intensity and low-frequency 
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ultrasound stimulated electrical activity in neurons in vitro and ex vivo through activating voltage-
gated sodium and calcium channels [27]. FUS also disrupted electrographic seizure activity in 
mice [28], and suppressed somatosensory response in human [29]. FUS induced neuromodulation 
therefore holds the potential to treat epilepsy, study brain function, and assist surgical ablation for 
functional area testing.  
 
1.3 TRANSCRANIAL ULTRASOUND THERAPY & CURRENT 
CLINICAL TRIALS 
While facing an increasing need of efficacious brain treatments due to the continuous growth of 
world population and average age increase [5], brain diseases including neurological disorders and 
tumors remain poorly treated due to the challenge of access through the skull and the blood-brain 
barrier (BBB) for drug delivery. Focused ultrasound (FUS) resides as the only way to treat the 
brain noninvasively and locally for ablation (thermal effects) and BBB opening for drug delivery 
(mechanical effects through cavitation)[8]. It is also a valuable tool to study brain functions 
through neuromodulation [29]. With the exciting announcement of FDA approval to treat essential 
tremor with surgical ablation using FUS [9], several clinical trials are underway worldwide 
including surgical ablation to treat Parkinson’s disease and BBB opening for chemotherapy of 
glioblastoma [8, 30].  
 
1.3.1   Essential tremor 
Essential tremor is the first and foremost milestone of transcranial ultrasound therapy been 
successful in clinical trials and approved by FDA [10]. Since for patients do not respond to 
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medication (about 30%), surgical treatment such as thalamotomy may be carried out. FUS remains 
the only noninvasive and non-ionizing way to heat and destroy target cells locally among all other 
surgical procedures including stereotactic radio surgery or radiofrequency ablation. It requires no 
anesthesia, no incisions in the scalp, and no burr holes through the skull. The targeting and ablation 
procedure can be closely monitored using MRI. There are currently two locations been targeted 
such as the ventralis intermedius, a small cluster of cells in the thalamus [9] and the 
cerebellothalamic tract below the thalamus [31]. 
 
1.3.2   Alzheimer’s diseases 
FUS with microbubbles could opening the BBB and facilitate drug delivery. BBB opening alone 
has been shown to treat AD in two different AD models via clearance of Aβ and improvement of 
memory loss [32, 33]. Its application with disease-modifying therapeutic drugs under development 
(anti-Aβ and anti-Tau antibodies, stem cells, gene therapy, etc.) may have potential to treat AD in 
different aspects [34]. An overview of pilot clinical trial for BBB opening to treat AD has been 
proposed in 2015 [34]. It will evaluate safety, reproducibility, and efficacy in patients with mild 
AD in Phase 1, targeting the cortex (gray matter with the presence of Aβ) in the right frontal lobe 
and/or the hippocampus (memory related structure). 
 
1.3.3   Parkinson’s disease 
Both ablation and BBB opening for drug delivery could help treat PD. Only symptomatic 
treatments are available currently. When patients face refractory period in levodopa therapy in the 
late stage, often surgical option is considered to improve their quality of life through lesioning 
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targeted cells interfering motor functions. FUS is undergoing clinical trials to treat Parkinsonian 
tremor (lesioning target in the thalamus) [35] and Parkinsonian dyskinesia (lesioning target in the 
globus pallidus or subthalamic nucleus)[36] via ablation. On the other hand, disease-modifying 
treatments are being investigated through BBB opening to delivery neurotrophic factors. FUS-
induced BBB opening to delivery therapeutic gene of glia-derived neurotrophic factor (GDNF) 
showed neuroprotective effects in a PD model [37]. Neurturin neurotrophic factor delivery after 
BBB opening also showed bioactivity that triggered nigrostriatal pathway [38]. Therefore, BBB 
opening with antibody delivery such as neurotrophic factors may have potential to restore 
neurodegeneration in PD. 
 
1.3.4   Brain tumors 
Current treatment options for brain tumors involve in surgical removal or radiofrequency ablation 
for partial or complete tumors with chemotherapy. FUS can improve the treatment via ablation 
and BBB opening to assist chemotherapy, which outlines the ongoing clinical trials as well. In the 
reported patient results, the tumor was successfully heated and monitored suing MR thermometry 
[39] and the tumor has been successfully ablated [40]. Successful BBB opening was reported with 





1.4 FUS-INDUCED BBB OPENING & DRUG DELIVERY 
1.4.1   Cavitation disrupts tight junctions and permeates endothelium 
As described in Section 1.1, the BBB inhibits most molecules including toxic substances from 
entering the brain parenchyma, while it also blocks therapeutic agents ≥ 400 Da for therapeutic 
delivery [42]. Many strategies have been used to overcome this limitation, such as intracranial 
injection [43], disruption by mannitol [44], and endogenous transport mechanisms [45]. However, 
there are either invasive or nonspecific, risking the brain in infection and systemic toxicity.  
Focused ultrasound (FUS) alone has been found to occasionally disrupt the BBB without 
neuronal damage [46]. With the intravenous circulation of microbubbles (1-10 µm), BBB opening 
could be achieved consistently and reversibly with low-intensity ultrasound. Cavitation has been 
regarded as the major reason increasing BBB permeability by bubble deformation to physically 
stretch the cerebral microvessels and induce vessel distention and invagination as seen under a 
high speed camera [47], and it was found to correlate with BBB opening [48]. Once the BBB is 
disrupted, molecules in the blood stream could pass via transcytosis, endothelial cell cytoplasmic 
openings, tight junction disintegration, or free passage through the injured cells if higher acoustic 




Figure 1.6. FUS-induced BBB opening disrupt the tight junction and increase the BBB 
permeability to allow drug molecules delivered to the brain. Modified from FUS foundation 
[16]. 
 
1.4.2   Molecules delivered and treatment applications 
Focused ultrasound (FUS) in conjunction with microbubbles (1-10 µm) is currently the only way 
to open the BBB noninvasively, locally, and transiently for drug delivery and treatment for central-
nervous-system (CNS) diseases. Various therapeutic agents have been successfully delivered with 
with FUS-induced BBB opening [51], including chemotherapeutic molecules [52], antibodies and 
neurotrophic factors [53] [54], siRNA [55], viral vectors [56], , nanoparticles [57, 58], neural stem 
cells [59], etc. The delivery efficiency can vary depending on the size of molecules been delivered, 
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the acoustic energy applied, and microbubbles used. In general, small molecules (< 70 kDa or 10.2 
nm) require less acoustic energy compared with large molecules (> 500 kDa or 30.6 nm) [60]. 
It has been shown to treat brain tumors [61, 62] and Alzheimer’s disease [32, 33], 
Parkinson’s disease [37], Huntington’s disease [63], and cerebral ischemia/reperfusion induced 
neuronal injury [64]. More applications are to be explored. This technique has been translated to 
large animals such as non-human primates (NHP) [65, 66], with short-term (hours to 9 weeks) and 
long-term (4 to 20 months) safety confirmed with MRI, histology, and behavioral assessment [67, 
68]. The recent findings in the ongoing clinical trial also proved safe for the repetitive BBB 
opening [41].  
 
1.5 TRANSCRANIAL ULTRASOUND SYSTEMS & ACOUSTIC 
AGENTS 
The key to FUS treatment success in clinics is a robust system with 1) precise and flexible targeting 
to personalize treatment planning, 2) in silico simulation, and 3) real-time monitoring to ensure 
safety and effectiveness. Besides the system, streamlining the procedure is crucial to allow 
minimal cost and repetitive treatment. For BBB opening, the properties of acoustic agents are 
crucial as the treatment effectiveness relies on cavitation.    
 
1.5.1    Targeting: MRgFUS vs. stereotaxis and neuronavigation 
Magnetic resonance-guided FUS (MRgFUS) system (Fig. 1.7) is been used in several clinical trials, 
especially for surgical ablation [8]. Its integration of MRI and FUS allows to target and monitor 
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the thermal ablation process through MR thermometry [15, 39]. At the beginning of the targeting 
procedure, FUS focus is visualized in the MRI by applying relatively low intensity FUS to the 
patient that increases temperature in the focal area. Then the position of the FUS transducer is 
adjusted with motorized positioner until the focus reaches the desired location. Since MRgFUS is 
time-consuming and costly, its utilization in non-thermal and transient treatment (BBB opening 
and neuromodulation) is suboptimal as they often require repetitive procedure. 
 
Figure 1.7. Schematic of the transcranial MRgFUS system. Modified from Leinenga et al [8]. 
 
 The stereotactic FUS system has the advantages of providing precise targeting and fast 
treatment procedure, and can be coupled with real-time acoustic monitoring for BBB opening as 
previously shown in non-human primates (discussed in Chapter 2 and Chapter 4) [69, 70]. This 
targeting method can be achieved by acquiring a pre-operative MRI scan with stereotaxis to serve 
as a personalized brain atlas [71]. Although it had achieved BBB opening consistently in monkeys 
19 
 
[65, 66], this frame-based method can only be used in the laboratory setting or operating room. 
Moreover, the preplanning process was tedious in stereotactic calculation to set the stereotactic 
manipulator, and the orientation of the transducer was restricted by the stereotactic manipulator as 
well. Its accuracy could also be affected by the way of fixing the subject’s head to the stereotactic 
frame and placing the transducer due to the lack of online feedback of the positioning. 
Utilizing image-guided neuronavigation technology could overcome the drawbacks of 
frame-based stereotaxis while maintaining the translational capability to human applications. 
Neuronavigation is a frameless, computer-aided, and interactive stereotaxis that localizes the 
instrument in real-time on the neuro-radiologic images acquired before the procedure, and thus 
allows real-time feedback for positioning and intraoperative changes [72, 73]. It requires an 
imaging system to acquire preoperative neuro-radiologic images (MRI, CT, etc.), a position-
tracking device to track the positioning of the patient and instruments such as surgical tools, and 
an image-processing system to reconstruct and store the images with the information of the 
instrument location relative to patients. During the treatment session, it provides registration 
between the preoperative images and the physical operating space after calibration based on 
common features (or fiducials) on the patient and the preoperative images. The registration 
transforms the images in real time and in different orientations interactively based on the 
instrument location detected by the position tracking device, and guides the operators to position 
the instruments. Incorporating neuronavigation with FUS sonication has been shown feasible in 
swine with BBB opening [74].  
Another system undergoing clinical trials is the implantable ultrasound device [41]. Since 
it requires invasive surgery and does not provide targeting flexibility, it is not listed here.   
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Figure 1.8. Neuronavigation system (Brainsight).  (A) Computer to store and process brain 
images. (B) Position sensor camera.  
 
1.5.2   Monitoring: MRI vs. passive cavitation detection 
Besides targeting, real-time monitoring is essential to provide control feedback in ensuring 
effectiveness and safety of the FUS treatment. MRI is used as an online monitoring tool for thermal 
ablation in the MRgFUS system. For BBB opening, however, it serves as a post-treatment 
assessment tool to evaluate the BBB opening through contrast-enhanced T1 weighted imaging as 
contrast agent does not cross intact BBB. Since BBB opening is associated with cavitation [48] 
that cannot be monitored with the MRI, the acoustic monitoring method passive cavitation 






Figure 1.9. Frequency spectrum of PCD signals during sonication with microbubbles. 
Fundamental frequency corresponded to the excitation frequency (f). Harmonic frequency (n*f) 
occurred when bubbles oscillated stably and periodically (stable cavitation). Ultraharmonic 
frequency (n*f+f/2) refers to as bubble shell oscillation or asymmetric oscillation during stable 
cavitation. Broadband respond occurs when bubbles undergoing inertial cavitation and release 
shock waves.  
 
This association of cavitation and BBB opening lies on the physical mechanism for BBB 
opening. Cavitation occurs in the vessels in the focal area during the FUS treatment, and the 
oscillating bubbles generated an acoustic signature reflecting both the strength and type of bubble 
activity [18, 19] (Fig. 1.9). If bubbles oscillate periodically without disruption, harmonic (bubble 
volumetric oscillation; n*f, where n = 1,2,3,… and f = excitation frequency) and/or ultraharmonic 
signals (bubble shell oscillation; n*f+f/2, where n = 1,2,3,… and f = excitation frequency) will be 
generated, a phenomenon known as stable cavitation. At higher pressures when bubbles oscillate 
violently and collapse rapidly, shock waves and microjets are generated with broadband emission 
known as inertial cavitation. Both stable and inertial cavitation applies mechanical stress onto the 
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vessel walls [47, 75] which could disrupt the tight junctions and other processes of BBB and 
increase the permeability of capillary endothelium[50].  
 PCD can achieve real-time transcranial monitoring during FUS, and could serve as an 
online treatment evaluation complement to the post-operative MRI-based methods (discussed in 
Chapter 3-5). Since its initial use during BBB opening in small animals [48], PCD has been 
expanded to various types of contrast agents such as microbubbles of various sizes [76], various 
shells [77], and nanodroplets [78] reporting a positive correlation between BBB opening and 
cavitation dose. A feedback control mechanism for BBB opening based on ultraharmonics and 
subharmonics was established in small animals [79, 80]. The permeability and reversibility of BBB 
opening could also be predicted based on cavitation in mice [81].  
Furthermore, PCD can be applied transcranially in large animals as well [71, 77], and has 
been shown feasible through the human skull [70] (discussed in Chapter 4). With the advent of 
passive acoustic mapping technique [82, 83] guided with neuronavigation (discussed in Chapter 5 
and Chapter 6), the acoustic monitoring could then visualize the acoustic events such as cavitation 
in the brain in order to assess and control the treatment more precisely in various locations, which 
is unachievable in any other imaging modalities including MRI.  
 
1.5.3    Microbubbles  
Microbubbles, gas-filled microspheres (1-10 µm) (Fig. 1.10) initially used merely as contrast 
agents for ultrasound imaging, have recently been shown critical in ultrasound-mediated 
therapeutic applications such as sonothrombolysis [84, 85], molecular delivery to the cell via 
sonoporation [23, 86] and/or endocytosis [87, 88], and to the brain parenchyma via blood-brain 
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barrier (BBB) opening [24, 89] paracellularly or transcellularly. For molecular delivery purposes, 
although the biological mechanisms may vary, sonoporation and/or endocytosis and BBB opening 
share the same physical mechanism that cavitation increases the permeability of the cell 
membranes. In all the cases, the microbubble properties play important roles in determining the 
delivery efficiency. For example, larger microbubbles (4-5 µm in diameter) induce larger BBB 
opening and delivery efficiency than smaller microbubbles (1-2 µm in diameter) [76, 90]; soft-
shelled (lipid or protein) microbubbles gave higher cell viability and transfection rate of gene 
delivery than hard-shelled (polymer) microbubbles [91].  
 Overall, the main goal of drug delivery is to achieve high efficiency without causing cell 
damage, and with the use of lipid-coated microbubbles it is achievable. In fact, with lipid-coated 
microbubbles the overall drug delivery efficiency could be influenced by changing the lipid 
hydrophobic chain length that modulates the overall physicochemical properties of the monolayer 
shell. Borden et al. have shown that increasing the lipid hydrophobic chain length increased the 
gas permeation resistance to the environment [92], decreased the acoustic dissolution rate while 
enhancing the lipid-shedding phenomenon during insonification [93]. Kwan et al. have reported 
that bubbles with longer lipid hydrophobic chains required longer re-stabilization following shell 
rupture, and longer to dissolve after the onset of collapse due to stronger attractive intermolecular 
forces [94, 95]. Longer acyl chains can also increase the lipid monolayer thickness [96] and 
microbubble mechanical properties such as in-plane rigidity [97], thereby modulating cavitation 
response and the shear stress applied on the cell membrane [98, 99]. Those results suggest that the 
physicochemical properties of the lipid-shelled microbubbles may play a role in affecting the drug 





Figure 1.10. Schematic of microbubble structure. Modified from Wu et al. [77] and Chen et al 
[100].  
 
1.5.4    Nanodroplets 
Shell-stabilized liquid perfluorocarbon (PFC) droplets (Fig. 1.11) [101-103] are new generation of 
acoustic contrast agents for imaging [104, 105] and therapeutic mediators to assist tumor occlusion, 
thermal ablation or drug delivery [106]. They retain the acoustic characteristics after vaporization 
while possessing several advantages over conventional gaseous microbubbles. First, refraining 
from the gas dissolution in the blood stream has granted better in vivo stability for droplets [107]. 
Second, the small size distribution of nanodroplets after microbubble condensation enables 
extravascular interrogation once entering the interstitial space before phase transition, including 
imaging in the extravascular space, cell-specific targeting, drug delivery, and tumor ablation [105, 
108]. Third, their capability of carrying high payloads demonstrates significant improvement on 
targeted treatment and imaging [109-111]. 
These characteristics of nanodroplets are promising to revolutionize the brain treatment 
with ultrasound as challenges are faced in human trials with prolonged procedure and requirement 
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of enhanced treatment in the sonicated region. For surgical ablation, prolonged sonication is often 
required to achieve the desired temperature at multiple locations with scalp and skull cooling taken 
exchangeably [39]. The use of droplets in the brain could shorten the treatment time since ablation 
with droplets has been achieved in a shorter time (decreased by a factor of 2.5 in tissue-mimicking 
phantoms) or with a larger lesion volume at equal exposure time (increased by a factor of 7 in 
tissue-mimicking phantoms or 15 in canine liver) [106, 112, 113]. On the other hand, drug delivery 
to the brain through blood-brain barrier opening with focused ultrasound (FUS) was found more 
difficult for large molecules [60, 114], and bubble shielding effects (clusters of bubbles in the pre-
focal area scattering acoustic waves) caused failure of BBB opening [65] or BBB opening in the 
undesired pre-focal area in large animals [71]. These problems can be solved by droplets vaporized 
only in the focal area generating highly concentrated mechanical stress during sonication. 
Moreover, both thermal ablation and drug delivery in the brain can be further improved with 
extravascular cavitation once nanodroplets enter into the brain parenchyma.  
 
 
Figure 1.11. Schematic of phase-shift nanodroplets vaporized to microbubbles. Modified 




1.5.5    Clinical use of acoustic agents 
Microbubbles after been developed for more than 50 years since 1968 [115] have been approved 
for imaging in Europe and for echocardiography in the U.S. [116]. They are often injected as a 
bolus through the peripheral vein in the arm with a dosage of 0.2-2 mL, a number similar to the 
number of red blood cells in 1 mL of blood. The contrast is increased in the blood and last for 5 
min, then it diminished gradually since the microbubbles are filtered out through the lung or 
metabolized in the body over time. With infusion through saline drip or an infusion pump, the 
contrast could then last up to 20 min. They are well-tolerated after injecting in the human body. 
The most severe adverse event is caused by anaphylactoid reaction with a probability of 0.014% 
(one in 7000)[117-119], while its usage is considered safe as the rate of the adverse event is 
comparable to other analgesics and antibiotics (0.005%-0.015%)[120, 121]. For therapeutic use, 
however, they are still under investigation as the bubble behavior or cavitation can be difficult to 
predict or control and thus may cause tissue damage. Currently the clinical trials including BBB 
opening for drug delivery are undergoing in France [41] and Canada [122], and sonothrombolysis 
to treat ischemic stroke has been recently completed in Spain with the results unpublished yet 
[123].  
 On the other hand, droplets are new generations of acoustic agents that have been 




1.6 MOTIVATION & AIMS 
Brain diseases including neurological disorders and tumors remain undertreated due to the 
challenge in accessing the brain, and blood-brain barrier (BBB) restricting drug delivery, which 
also profoundly limits the development of pharmacological treatment. Focused ultrasound (FUS) 
with microbubbles remains as the only method to open the BBB noninvasively, locally, and 
transiently to assist drug delivery. For an ideal medical system to serve a broad patient population, 
it requires precise and flexible targeting with simulation to personalize treatment, real-time 
monitoring to ensure safety and effectiveness, and rapid application, as repetitive pharmacological 
treatment is often required. Since none of current systems fulfills all the requirements, here we 
designed a neuronavigation-guided FUS system with protocol assessed in non-human primates 
from in silico preplanning, online FUS treatment and real-time acoustic mapping for monitoring, 
to post-treatment assessment. 
The objective of this thesis was to develop a seamless neuronavigation-guided transcranial 
ultrasound system with targeted sonication and acoustic monitoring for clinical use, and the 
protocol demonstrated from in silico preplanning, online treatment and monitoring, to post-
treatment assessment. The system and protocol were tested in both sedate and awake non-human 
primates (NHP) with BBB opening to evaluate the performance of simulation, targeting accuracy, 
and monitoring. In achieving the goal, three sub-aims were listed as follows. 
1) To develop a treatment preplanning tool (Chapter 2), numerical simulation of the 




2) To develop an online treatment monitoring tool (Chapter 3-5), real-time cavitation 
detection and mapping were built and evaluated in NHP with BBB opening.  
3) To facilitate efficient and precise FUS treatment procedure (Chapter 6), the 
neuronavigation system was customized with FUS system including targeting and 
cavitation mapping. The established system and protocol was evaluated in NHPs in 
both a sedate setting, where the animal was lying prone on the operating table under 
anesthesia, and an awake setting, while the animal was trained to sit in a customized 
chair. The accuracy of targeting as well as the cavitation mapping was evaluated 
comparing to the BBB opening based on contrast enhanced MRI. 
 
1.7 THESIS OVERVIEW & SIGNIFICANCE 
The world is facing the increasing need of efficacious brain treatments due to the continuous 
growth of world population and average age increase [5]. According to the report from World 
Health Organization (WHO), neurological disorders have affected more than 1 million people [5]. 
The burden not only lies in the health care, but also the caregiver in the whole society. Given the 
challenge in accessing the brain either through the skull or the BBB for drug delivery, focused 
ultrasound (FUS) remains the sole technique for treating the brain noninvasively and locally for 
surgical ablation (thermal effects) and BBB opening for drug delivery (mechanical effects through 
cavitation)[8]. With an efficient transcranial FUS system to assist pharmaceutical treatment, it can 
prevent the situation from going worse.  
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The key to FUS treatment’s success is a robust clinical system with 1) precise and flexible 
targeting to personalize treatment planning, 2) in silico simulation, and 3) real-time monitoring to 
ensure safety and effectiveness. Besides the system, fast application is crucial to allow minimal 
cost and re-application. Magnetic resonance-guided FUS (MRgFUS) system reliably ablates the 
brain tissue with temperature monitored by the MRI[15, 39]. Non-thermal treatment such as BBB 
opening and neuromodulation that are transient and may require re-application, a more suitable 
system is still yet to be established, as the MRgFUS system is time-consuming and costly, while 
implantable ultrasound devices require invasive surgery without targeting flexibility[41].  
Our developed neuronavigation-guided FUS system could provide a streamlined procedure 
with both efficacy and efficiency of the treatment. Since its evaluation in sedate and awake non-
human primates (NHP) with BBB opening, it is ready for approval for clinical use. This 
dissertation will thus be beneficial to both research and clinical applications for BBB opening and 
neuromodulation. 
This dissertation is structured to fulfill three sub-aims described in Section 1.6. Followed 
by the background of brain and diseases, and the state of art in FUS in this chapter (Chapter 1), 
numerical simulation will be described in Chapter 2. It includes three studies: the first one utilized 
pulse design in simulation to improve the focal quality, and validated with in vivo BBB opening 
in mice; the second one using 3D simulation to evaluate intra- and inter- animal variation in NHP, 
and validated with in vivo BBB opening in NHP; the last one exploring focal properties through 
the human skull with various targeting parameters. Real-time cavitation monitoring will be 
covered in Chapter 3 to Chapter 5. Starting from mice (Chapter 3) to investigate physical 
mechanisms with various customized acoustic agents, including microbubbles of different shells, 
microbubbles with model drug loaded on the shell and acoustically-activated nanodroplets with 
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different vaporization efficiency. This PCD method was then translated to large animals such as 
monkeys and humans (Chapter 4). The transcranial performance was evaluated through both the 
monkey and the human skull, and it correlation to the in vivo BBB opening findings were 
investigated in NHP, including BBB opening volume, amount of drug delivered and delivery 
efficiency, and the heterogeneous brain effects such as gray and white matter and vasculature. This 
lead to the development of cavitation mapping as the previous single-element PCD does not 
provide spatial information of cavitation. Therefore in Chapter 5, an efficient cavitation mapping 
algorithm was developed using sparse matrix multiplication in a GPU to achieve real-time 
monitoring. Again, its performance through both the monkey and the primate skull were 
investigated. Lastly in Chapter 6, the developed FUS system was integrated with the 
neuronavigation system, with a seamless protocol evaluated in both sedate NHP lying supine under 
anesthesia and the awake NHP sitting on the customized chair. Both the accuracy of targeted BBB 
opening and cavitation mapping were analyzed. A clinical protocol for neuronavigation-guided 
ultrasound was thus proposed in Chapter 7, with future work listed for getting approval for clinical 





Chapter 2   
Simulation of Transcranial FUS with In Vivo 
BBB Opening Validation 
  
2.1 INTRODUCTION 
As shown in Chapter 1, focused ultrasound (FUS) is the only non-ionizing, noninvasive, and 
targeted technique that can treat brain diseases through tissue ablation or blood-brain barrier (BBB) 
disruption for drug delivery. Tissue ablation utilizes the thermal effects of ultrasound requiring 
high intensity or pressure, while BBB disruption relies on nonthermal effect at low intensity with 
microbubbles such as cavitation generating mechanical stress onto the microvessel wall. In both 
types of brain therapy, it is of vital importance to estimate the transcranial focal quality and the 
pressure attenuation before FUS treatment, since the skull as hard tissue hinders the transmission 
of ultrasound waves. In this chapter, a simulation tool has been built and validated with in vivo 
BBB opening to assist transcranial FUS treatment planning for future clinics. With this aim to 
facilitate the preplanning process for BBB opening, three sub-objectives were listed as follows. 
 
1) To improve the focal quality of the therapeutic FUS, the excitation pulse design was 
investigated in simulation in mice and NHP and validated in the in vivo BBB opening in 
mice. The excitation pulse design was optimized in the simulation of the acoustic pressure 
distribution through the skull, including regular pulses (pulsed single-frequency sinusoidal 
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waves with a fixed pulse length), chirp-coded pulses (continuous sinusoidal waves with 
linearly-increased frequency in a small frequency range), and random-coded pulses 
(continuous sinusoidal waves with randomized frequency variation in a small frequency 
range). Chirp- and random-coded pulses were chosen as they have been reported to 
effectively reducing standing waves in the skull cavity [124, 125]. The evaluation of the 
focusing capability was quantified by the volume of BBB opening and the cavitation dose 
was evaluated for each technique. 
 
2) To investigate the inter- and intra-animal variation with various targeting in large animals, 
the acoustic pressure field through the skull has been simulated and compared with the 
BBB opening in non-human primates (NHP). Both the pressure loss and focal shift due to 
the skull were estimated in silico, and compared with the in vivo findings using the standard 
stereotactic targeting method. This study thus demonstrated the validity of using simulation 
to compensate the treatment variation in large animals.  
 
 
3) To investigate the targeting effects on focal properties in human, simulation with human 
skull through different bone regions (parietal, occipital, temporal) and with various 
targeting parameters including the angle of incidence and the transducer-skull distance 
were explored. The focal properties were evaluated in each targeting design, including the 
focal size, focal shift, and the skull attenuation. This study could provide crucial 





2.2.1 Preoperative acquisition of skull CT 
CT of the animal was acquired to extract skull properties (density and speed of sound) in order to 
construct the animal model in simulation to estimate the acoustic pressure decrease. For mice, ex 
vivo mice (C57BL/6) was imaged with a microCT (resolution = 80 ×80 × 80 mm3; RmCT2, Rigaku, 
Tokyo, Japan). For monkeys, in vivo rhesus macaques (Macaca mulatta) was imaged under 
anesthesia with a helical CT (resolution = 0.2 × 0.2 × 0.6 mm3; Siemens, Biograph 64, Malvern, 
PA, USA). For humans, the human cadavers were scanned (resolution = 1 × 1 × 1 mm3) as 
described in The Visible Human Project® (National Library of Medicine in National Institutes of 
Health, U.S.) [126] [126] [125] [124] [123] [122] [121] [120] [119] [119] [118] [117] [117] [117].  
 
2.2.2 Numerical simulation of acoustic wave propagation 
The numerical simulations were performed using k-Wave Matlab toolbox [127, 128] for the 
acoustic wave propagation. This toolbox provides the k-space pseudo spectral time domain 
solution for the coupled first-order acoustic equations in either homogeneous or heterogeneous 
media:   







Conservation of mass:                   
𝜕𝜌
𝜕𝑡
= −𝜌0∇𝒖 − 𝒖∇𝜌0, 
Pressure-density relation:               𝑝 = 𝑐0
2(𝜌 + 𝒅∇𝜌0 − 𝐿𝜌), 
where 𝒖 is the acoustic particle velocity, 𝑝 the acoustic pressure, 𝜌 the acoustic density, 𝜌0 the 
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equilibrium density, 𝑐0 the isentropic sound speed, 𝒅 the acoustic particle displacement, and 𝐿 the 
linear integro-differential operator that accounts for acoustic absorption (τ) and dispersion (η) that 


















). 𝛼0 is the power law perfactor in Np (rad/s)
-y/m, and y is the power law exponent.  
 
 
Figure 2.1. Design of acoustic source for simulation. (A) 3D image of the ring-shaped, 
spherically focused ultrasound transducer for simulation, and the central space was reserved of 
passive cavitation detector (PCD). This design is to mimic the FUS transducer used in experiments 
(B). The generated acoustic pressure field in silico (C) showed an ellipsoidal focus in water.  
 
The ring-shape focused transducer (Fig. 2.1) was created in silico with the focal size 
calibrated based on the FUS transducer calibration in water at room temperature (Fig. 2.2), with 
the same excitation frequency and pulse length used for the in vivo experiments. The acoustic 
properties of the skull including the speed of sound and density were converted from the 
Hounsfield units in CT [129], with an attenuation of 20 dB.cm−1 and the power law absorption 
exponent of 1.1 based on previous measurements in humans [130, 131], and 29 dB.cm−1 for mice 
based on calibration. The medium properties surrounding the skull were the same as water at the 
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body temperature (37⁰C, speed of sound = 1524 m/s, density = 1000 kg/m3, attenuation = 3.5×10-
4). 
 
Figure 2.2. Calibration of simulation with the FUS pressure field in water (used for primate 
experiments). (A) The in silico acoustic profile in the focal region was calibrated to be the same 
as the profile from the FUS transducer measured in water using a hydrophone, including the focal 
width and the side-lobes in lateral (B) and axial (C) direction. 
 
2.2.3 Ultrasound System  
Mice  
As shown in Fig. 2.3, a single-element FUS transducer (1.5 MHz; Imasonic SAS, Voray-sur-
lOgnon, France) was used for sonication, and a small pulse-echo transducer (center frequency: 10 
MHz, focal depth: 60 mm, radius 11.2 mm; Olympus NDT, Waltham, MA, USA) confocal to the 
FUS transducer was used for the targeting and passive cavitation detection (PCD) during the 
sonication. The transducer was attached to a 3-D positioning system (Velmex Inc., Lachine, QC, 
Canada) and controlled by a computer for targeting procedure developed previously [132]. The 
coded excitation signals were generated in Matlab, uploaded to the arbitrary waveform generator 
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(33220A, Agilent Technologies, Palo Alto, CA, USA), and transmitted to the FUS transducer 
through a 50 dB power amplifier (ENI Inc., Rochester, NY, USA).  
 
Figure 2.3. In vivo mice experimental setup. The animals were positioned in a stereotaxic frame 
during the sonication. Microbubbles were injected through the tail immediately prior to the 
sonication. Water containers coupled the animal’s head to the ultrasonic transducers using 
coupling gel. A therapeutic transducer was driven by an arbitrary waveform generator (AWG). A 
10 MHz transducer was used for targeting and passive cavitation detection (PCD). 
 
The regular pulses (1.5 MHz), chirp-coded pulses, and random-coded pulsed were generated 
separately for sonication in each experimental cohorts. Pulses coded with varying frequency 
component were designed to enhance the focal quality while minimizing standing waves. The 
signals were composed of sinusoidal waves with the carrier frequency 𝑓𝑐  varying linearly (chirp) 





Figure 2.4. Customized chirp and random signal used for sonication. The varied magnitude in 
the temporal domain was due to the adjustment of FUS transducer sensitivity in order to reach the 
same pressure. Both the chirp and the random signals composed of a frequency range from 1.4-
1.9 MHz as shown in the frequency spectra.  
 
Monkey  
The system setup is shown in Fig. 2.5A. For sonication with FUS, a spherically-focused single-
element transducer (H-107, Sonic Concepts, WA, USA) operating at 0.5 MHz (full-width-at-half-
maximum focal size: 5.85 mm in width and 34 mm in depth, geometric focal depth: 62.6 mm) was 
used. For real-time monitoring of the acoustic cavitation emission (passive cavitation detection, 
PCD), a spherically focused, flat-band, polyvinylidene fluoride (PVDF) hydrophone (Y-107, 
Sonic Concepts, WA, USA), coaxially and confocally aligned with the FUS transducer, served as 
the passive cavitation detector. A PC workstation (model T7600, Dell) with a customized program 
in MATLAB® (Mathworks, MA, USA) was developed to automatically control the sonication 
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through a programmable function generator (model 33220A, Agilent Technologies, CA, USA) 
and a 50-dB amplifier (A075, ENI, NY, USA). The PCD signal acquisition was performed with a 
14-bit analog-to-digital converter (Gage Applied Technologies, QC, Canada) (sampling rate: 50 
MHz) after 20-dB amplification.  
 
 
Figure 2.5. In vivo NHP experimental setup. (A) A focused ultrasound (FUS) transducer was 
used for sonication and a hydrophone coaxially and confocally aligned with the FUS transducer 
served for passive cavitation detection (PCD). (B) Targeting was performed using stereotaxis with 
pre-planning for focusing at the caudate nucleus (left) or putamen (right) based on the preoperative 
MRI scan with a stereotax. 
 



















30 s on-time 
Monkey 0.5 200-600 10 ms 2 2 min 




2.2.4 Experimental Procedures of in vivo BBB opening 
Mice 
All procedures with animals were approved and conducted in accordance with the Institutional 
Animal Care and Use Committee at Columbia University. A total of 17 C57BL/6 mice (mass: 20–
28 g, sex: male, Harlan, Indianapolis, IN, USA) were used in this study. During the experiment 
while the animal was under anesthesia with isoflurane (1-2%; SurgiVet, Smiths Medical PM Inc., 
Waukesha, WI, USA), its head was depilated and immobilized in the stereotaxic frame (David 
Kopf Instruments, Tujunga, CA, USA), and a small tank filled with degassed water was placed 
above the mice with the head coupled using coupling gel. After the targeting procedure aligning 
the FUS focus to the right caudate putamen region, a catheter was inserted to the tail vein for 
injection of polydisperse microbubbles (average size: 1.39 µm ± 0.99, 30 µL of 8×108 bubbles/mL) 
immediately before the sonication. During the sonication, cavitation signal was monitored through 
PCD. The mice were divided in 3 randomized groups with 5 animals each. The Chirp group was 
sonicated for 30 seconds using the chirp method sweeping between 1.5 MHz and 1.9 MHz with 
an increment of 10 kHz, PNP = 0.52 MPa, and 3 cycles per frequency. The random group was 
sonicated using the randomly ordered frequency pulses between 1.5 to 1.9 MHz with the same 
parameters. The regular group was sonicated with a pulsed wave with f = 1.5 MHz, 20 ms, 5 Hz 
of burst rate, 0.52 MPa for 5 min. 
Monkey 
In accordance with the National Institutes of Health Guidelines for animal research, all procedures 
were reviewed and approved by the Institutional Animal Care and Use Committee at Columbia 
University and the New York State Psychiatric Institute. Four male rhesus macaques (Macaca 
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mulatta, weight: 7-10 kg, age: 8-20 yo) were used in this study. Each animal was sedated with 
ketamine (5-15 mg/kg in conjunction with 0.04 mg/kg of atropine through intramuscular injection) 
for placement of an endotracheal tube and an intravenous catheter in the saphenous vein, and was 
under anesthesia using 1-2% isoflurane-oxygen mixture with vital signs (electrocardiography, 
heart rate, blood pressure, SpO2, breathing rate, end-tidal CO2) monitored during the entire 
experiments. No animals were euthanized in this study. 
A stereotaxis-based method developed previously [69] was used for targeting the dorsal 
striatum (caudate and putamen) (Fig. 2.5B), deep subcortical structures associated with 
neurodegenerative diseases such as Parkinson’s disease. For preplanning of the stereotactic 
sonication, the anatomical scan of the brain was acquired in T1-weighted MRI (3D turbo field 
echo sequence, TR/TE = 11.1/5.1 ms, FA=8⁰, resolution = 0.7 × 0.7 × 0.7 mm; Philips 3T). The 
pressures at the focus of the FUS transducer were calibrated using a bullet hydrophone through ex 
vivo rhesus macaque skulls, and 50% of pressure loss due to the skull was compensated in the in 
vivo experiments [133]. The in-house made, lipid-shelled, monodisperse microbubbles (4-5 µm in 
diameter)[134] were freshly diluted to 3 mL with a dosage of 2.5×108 bubbles/kg of body weight. 
Another 3 mL of saline was used to flush after microbubble injection. 
At the beginning of the FUS procedure, the control sonication (duration = 5 s) was 
performed before microbubble injection as a baseline for cavitation monitoring, and then the 
microbubbles were injected in a bolus intravenously (saphenous vein) followed by saline flush 
within 30 s while the sonication started at the same time (peak negative pressure = 200-600 kPa, 
pulse length = 10 ms, pulse-repetition frequency = 2 Hz, duration = 2 min). A second sonication 
was performed in 11 out of a total of 47 experiments at a second non-overlapping target 20 min 
after the microbubbles were eliminated from the first experiment.  
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After the FUS procedure, the animal was transferred to the MRI suite for assessing the 
BBB opening and safety within 1 h. Two sham cohorts were also performed by applying FUS 
without injecting microbubbles (FUS+/MB-, N = 4) or without FUS procedure (FUS-/MB-, N = 
3) for comparison to determine BBB opening in the experimental groups. 
 
Table 2.2. Number of experiments performed 
Animal Number of animals Number of sonications Targeting region 
Mice 17 17 Basal ganglia 
Monkey 4 70 Basal ganglia 
 
2.2.5 Postoperative MRI Acquisition 
Mice  
In order to confirm the BBB opening and calculate its volume, contrast enhanced T1-weighted 
MRI (spatial resolution of 80×80×400 µm3) were acquired for all mice using a 2-D FLASH 
sequence in a 9.4-T system (DRX400, Bruker BioSpin, Boston, MA, USA). MR contrast agent, 
gadodiamide (molecular weight = 573.66 Da; Omniscan®, GE Healthcare, NJ, USA) was injected 
intraperitoneally immediately after the sonication, and the animal was scanned after 30 min. 
 
Monkey  
A 3.0 T clinical system (Achieva, Philips Medical Systems, USA) with an eight-channel head coil 
was used for assessing BBB opening. Both pre- and post- contrast agent T1-weighted images were 
acquired before and 30 min after injection of gadodiamide (molecular weight = 573.66 Da; 
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Omniscan®, GE Healthcare, NJ, USA) with the same dosage suggested for patients (0.2 mL/kg or 
0.1 mmol/kg of body weight) using 3D spoiled gradient echo (SPGR) sequence (TR/TE = 8.5/4.8 
ms, FA = 8º, spatial resolution = 0.97×0.97×1 mm3).  
 
2.2.6 Quantification for BBB Opening 
Mice  
The acquired T1-weighted images were used to quantify the BBB opening volume firstly by 
thresholding based on the signals on non-sonicated region (mean+2.5 times of standard deviation) 
to exclude the voxels without opening [135]. Then an ellipsoid region-of-interest (5.5 mm of 
diameter in long axis, 4.0 mm of diameter in short axis, 0.4 mm of height, throughout 9 slices) was 
selected in the sonicated region of the horizontal slices.  
 
Monkey 
The BBB opening volume was quantified using pre- and post-Gd T1w images in Matlab with 
custom-built programs [70]. In brief, both pre- and post-Gd images were first registered to the 
individual stereotactically-aligned images (IST) with FSL’s FLIRT toolbox[136], computing the 
ratio of post- to pre-Gd images as a measurement of contrast enhancement, which was normalized 
by linear scaling with reference to the unsonicated thalamus and the anterior cerebral artery (ACA). 
In order to filter out the background contrast enhancement in the cerebral vessels and muscle tissue 
outside the brain for quantifying the BBB opening volume, the brain mask was applied (generated 
using pre-Gd T1w images from the no-FUS sham cohort with FSL’s Brain Extraction Toolbox 
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[137]) and the enhancement images of the FUS-/MB- sham cohort for each individual was 
subtracted from the enhancement images. Finally, the opening volume was calculated by applying 
a volume of interest (VOI, 10 × 10 × 32.5 mm3) on the targeted region subtracting the VOI on the 
contralateral side. The threshold of BBB opening (80 mm3) was defined by the average opening 
volume plus 3 times the standard deviation in the FUS+/MB- sham cohort.  
 
2.2.7 Analysis of targeting accuracy in NHP experiments 
The targeting accuracy was analyzed by comparing the planned targeting to the quantified BBB 
opening results using the T1w images as described in the previous section. The planned targeting 
was composed of a targeting vector with a focus and an approaching direction (trajectory) for an 
interested brain structure. The BBB opening vector was subsequently defined by the 3-D center of 
mass in the BBB opening in the VOI described previously and the vector from the 3D linear curve 
fitting of the 2-D center of mass in each of the horizontal slices, respectively. Finally, the target 
shift was defined as the distance between the center of focus in the targeting vector and the center 
of mass in the BBB opening, and the lateral and axial shift was the shift perpendicular and parallel 
to the targeting vector, respectively.  
 
2.3 RESULTS 
2.3.1 Simulation vs. BBB opening using customized pulses 
2.3.1.1 Simulated transcranial pressure field using customized pulses in mice 
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After acquiring the microCT of the mice skull (Fig. 2.6A), the transcranial peak negative pressure 
(PNP) fields were simulated using regular and frequency-coded pulses (chirp or random 
frequency) in mice. As shown in Fig. 2.6B, the regular sonication presented standing wave 
formation clearly in the focal region. In comparison, both the chirp-coded pulses (Fig. 2.6C-E) and 
the random-coded pulses (Fig. 2.6F-H) generated significantly less standing waves due to a range 
of frequencies transmitted. The chirp and random methods were then explored to optimize the 
pulse design by varying the frequency range, incremental frequency bandwidths, and the number 
of cycles. For the chirp method, the best parameters were found to be with a bandwidth of 1.23 to 
2.29 MHz, 10 kHz of incremental frequency and 2 cycles (Fig. 2.6E) because of the lowest 
standing waves and side lobes with the best focal quality. The other two cases (Fig. 2.6C-D) not 
only showed higher side lobes and standing waves were observed, but also points of maxima 
outside of the focus due to the interference pattern caused by the multiple scattering of the waves 
in the brain. Likewise, the random-based method showed better focusing for a bandwidth of 1.23 
to 2.29 MHz, 1 kHz of incremental frequency, and 3 cycles (Fig. 2.6H). 
For the three types of pulses (with optimized parameters), the axial and lateral beam profiles 
are shown in Fig. 2.6I-J. The axial profile shows the standing wave formation by the regular 
sonication which is not observed in the coded methods, and the lateral beam profiles shows the 
side lobes generated by the three techniques. The regular sonication presented higher oscillations 
on the pressure field with higher peak negative pressure, so it is more likely to enhance cavitation 
and drug diffusion. These parameters were thus used in the in vivo BBB opening experiments for 





Figure 2.6. Simulation of acoustic pressure field through the mice skull using customized 
pulses. (A) The mice skull was imaged in microCT. The peak negative pressure fields for different 
coded pulses using (B) regular sonication (1.5 MHz); (C) Chirp: 1.5-1.9 MHz, 10 kHz, 3 cycles; 
(D) Chirp: 1.5-1.9 MHz, 10 kHz, 2 cycles; (E) Chirp: 1.23-2.29 MHz, 10 kHz, 3 cycles; (F) 
Random: 1.5-1.9 MHz, 10 kHz, 3 cycles; (G) Random: 1.5-1.9 MHz, 1 kHz, 2 cycles; and (H) 
Random:1.23-2.29 MHz,1kHz,3 cycles. The lateral (H) and axial (I) beam profiles were plotted 
comparing the regular pulses to the coded pulses with best focusing quality and less standing wave 






2.3.1.2 BBB opening using customized pulses in mice 
As shown in Fig. 2.7A, the spectrograms of the received PCD signals demonstrated varying 
harmonic frequencies in the coded pulses while the regular method remained the same harmonic 
frequencies. The corresponded BBB opening results with the MRI were shown in Fig. 2.7B. The 
brighter regions in the brain show the extravasation of the contrast agent from the vascularity to 
the brain. The extravasation indicate where the ultrasound successfully opened the BBB. The chirp 
method and the random-based method presented smaller openings in comparison to that with the 
regular sonication method. The opening volumes showed the same trend for the three groups (Fig. 
2.7C), in which the mean opening volumes were 9.38 ± 5.71 mm3, 8.91 ± 3.91 mm3
 
and 35.47 ± 
5.10 mm3
 
for chirp, random and regular sonication, respectively. As predicted by the enhanced 
cavitation due to the varying pressure field using the regular pulses, the in vivo results also 
presented larger BBB opening volumes. While the coded excitation methods showed the about 
same opening volumes, which corresponded well with the simulation. Fig. 2.7D shows the 
ANOVA statistical analysis of the cavitation level (figure 5 middle). The cavitation level for the 
regular sonication was higher than the coded excitation methods. No significance difference was 





Figure 2.7. BBB opening in mice using customized pulses. (A) The spectrograms of the 
cavitation signals demonstrated varied harmonic frequencies using chirp or random coded pulses 
compared to consistent frequencies in the regular pulses. (B) Contrast enhanced T1- weighted MRI 
images showed the BBB opening for chirp, random and regular sonication methods, respectively. 
(C) Using coded pulses resulted in a more localized BBB opening. (D) The quantified stable 




2.3.1.3 Simulated transcranial pressure field using customized pulses in NHP 
The pulse design scheme was further studied in NHP to remove standing waves in the brain and 
improve the focal quality in large animals. After acquiring the CT of the NHP skull, the transcranial 
peak negative pressure (PNP) fields were simulated using regular (frequency: 0.5 MHz, pulse 
length: 10 ms) pulses that have shown to disrupt the BBB in NHP (Section 2.3.2) and chirp-coded 
pulses (sweeping frequency: 0.5-2 MHz, pulse length: 0.05 -0.5 ms). While the standing waves 
were clear in using regular pulses as shown in Fig. 2.8, the peak magnitudes relative to the baseline 
pressure (axial profile in Fig. 2.8B) were less significant compared with those in mice and may be 
due to the nature of lower-frequency waves in a larger brain. Using long logarithmic chirp pulses 
( 𝑓𝑖(𝑡) = 𝑓0 × 𝛽
𝑡 𝑤ℎ𝑒𝑟𝑒 𝛽 = 1.0210
5
𝑎𝑛𝑑 𝑓0 = 0.5 𝑀𝐻𝑧 , pulse length: 0.5 ms) eliminated a 
majority of standing waves, and increasing the sweeping rate of the pulses successfully enhanced 
the effect as shown with short logarithmic chirp pulses ( 𝑓𝑖(𝑡) = 𝑓0 × 𝛽
𝑡 𝑤ℎ𝑒𝑟𝑒 𝛽 =
1.0210
6
𝑎𝑛𝑑 𝑓0 = 0.5 𝑀𝐻𝑧, pulse length: 0.05 ms). Similar to the long logarithmic chirp pulses, 
using linear chirp pulses (increasing frequency in a linear rate) was less effective than using the 
short logarithmic chirp pulses. In all pulses used, the focal size remained the same as the regular 
pulses since the axial and lateral size was determined by the lowest frequency (0.5 MHz) in the 




Figure 2.8. Simulation of acoustic pressure field through the NHP skull using customized 
pulses. (A) The peak negative pressure fields for different coded pulses using regular sonication 
(frequency: 0.5 MHz, pulse length: 10 ms), short logarithmic chirp (sweeping frequency: 0.5-2.0 
MHz, pulse length: 0.5 ms), and long logarithmic chirp (sweeping frequency: 0.5-2.0 MHz, pulse 
length: 0.05 ms). Pressure profiles for the corresponding pulses in the (B) axial and (C) lateral 
direction.  
 
2.3.2 Simulation vs. BBB opening in NHP 
The skull effect on the acoustic pressure distribution was investigated with respect to the focal 
shift and the pressure in situ. Also, to validate the established 3D simulation of the transcranial 
acoustic pressure field through the primate skull, it was compared with the BBB opening in NHPs 
in vivo. The in silico acoustic focus was calibrated with the transducer focus in water in terms of 
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the focal length, width, and the side lobes (Fig. 2.2), and the acoustic properties of the skull such 
as the density and the speed of sound were converted from the CT images (Fig. 2.9A). 
 
2.3.2.1 Simulated transcranial pressure decrease and focal shift 
Through the NHP skull, the full-width at half maximum focal size decreased from 4 mm laterally 
and 35.3 mm axially without the skull to an average of 2.6 mm laterally and 16.7 mm axially Due 
to the skull lensing effect, which similar to the BBB opening size (Fig. 2.9B). 
 
Figure 2.9. Simulation of the acoustic pressure field to estimate the BBB opening in NHP. 
(A) The CT scan of a monkey used to calculate the acoustic properties of the skull including 
density and the speed of sound. (B) The simulated transcranial peak-negative pressure (PNP) field 
(unit normalized to the pressure without the skull) corresponded to the BBB opening in the caudate 




In order to investigate the pressure decrease and focal shift due to the skull, three NHP 
skull CT were acquired in vivo for simulation in the targeted basal ganglia. In the statistics from 
12 targeting in 3 NHPs, the average skull thickness was 2.6 mm, with an average density of 1532 
kg/m3 and a speed of sound of 2293 m/s. From the quantification of the peak-negative pressure 
(PNP) field distribution, an average focal shift of 2.1 mm (0.8 mm laterally, 1.8 mm axially)(Fig. 
2.10B) and a pressure decrease of 41% were found due to the skull. Furthermore, the transcranial 
pressure varied between animals and targeting was found to be highly correlated with the density 
and thickness of the skull in the beam path (R2=0.6) (Fig. 2.10A).  
 
Figure 2.10. Estimated skull attenuation and focal shift in silico. (A) The in situ PNP was 
negatively correlated with the thickness and density of the skull in the acoustic beam path as shown 
in the plane-fitting result with a R2 of 0.6. (B) The in silico focal shift due to the skull in the lateral 
and axial direction of the acoustic wave propagation was estimated to be 0.8 mm laterally and 1 
mm axially. 
 
2.3.2.2 Pressure threshold and target shift for BBB opening in NHP 
In the in vivo BBB opening experiments, an inter-animal variation was observed in the pressure 
threshold for BBB opening after applying an estimate of 50% pressure increase to compensate the 
skull attenuation. As shown in Fig. 2.11, the pressure threshold for NHP 1 was lower (200 kPa) 
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than that in NHP 2 (350 kPa). This inter-animal variation was found to be due the difference in 
skull in simulation. As based on the simulation results, an average of 67% and 46% of remnant 
pressure was found in NHP 1 and NHP 2, respectively. This then result in a similar BBB opening 
threshold of 268 kPa and 322 kPa for NHP 1 and 2, respectively after taking the in silico pressure 
decrease in to account instead of a general 50% decrease. Since the individual difference in the 
skull properties contributed to variation in skull attenuation and affects the in situ pressure, it is of 
vital importance to perform simulation for large animals and humans in order to account for 
pressure loss due to the skull and achieve safe and effective FUS treatment.  
 
Figure 2.11. BBB opening in two NHPs showing inter-animal variation. (A-B) Two 
representative cases of BBB opening at the putamen were visualized by overlaying the contrast 
enhancement onto the post-Gd T1w image (A: NHP 1 at 300 kPa; B: NHP 2 at 600 kPa). (C) The 
opening volume was quantified at various pressures, and the error bar represents standard deviation. 
It was found that NHP 1 had larger opening volume than NHP 2 using the same pressure. 
 
The in vivo target shift in BBB opening was also investigated. Following targeting planning 
in the caudate and putamen, the resulting BBB opening along the FUS beam trajectory was 
visualized in brain in the 2D coronal plane (Fig. 2.12A), the stacked 2D horizontal planes (Fig. 
2.12B), and the trajectory through the 3D skull piece (Fig. 2.12C). The targeting accuracy was 
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quantified in four animals based on the defined FUS orientation (axial and lateral distance shift 
relative to the planned FUS trajectory) and the angle relative to the skull (Fig. 2.13). The lateral 
and axial shift ranged between 0.9 mm to 6.4 mm and 1.0 mm to 7.6 mm. When targeting the 
caudate, the overall shift ranged between 2.4 mm to 6.5 mm with an average of 3.7 mm. When 
targeting the putamen, it ranged between 4.4 mm to 10.1 mm with an average of 7.5 mm. A larger 
shift in axial direction compared with the lateral direction was expected due to the simulation with 
NHP skulls.  
 
Figure 2.12. Targeted BBB opening in NHP in both the caudate and the putamen. (A) 
Visualization of targeting in the caudate nucleus (dashed contour in the left column) and the 
putamen (dashed contour in the right column) and the BBB opening by overlaying the contrast 
enhancement onto the post-Gd T1w image, where * denotes the centroid of BBB opening. (B) 
Targeting trajectory and the opening trajectory showed in the stacked horizontal slices. (C) 3D 





Figure 2.13. Targeting accuracy for in vivo BBB opening in NHP. (A) Schematic of the angle 
definition to the skull. Target shift in BBB opening was quantified in distance (B) and in angle (C), 
where lPut represents left putamen, rPut for right putamen, lCd for left caudate, and rCd for right 
caudate. The error bar represents standard deviation. 
 
2.3.3 Simulation of FUS targeting in human 
This 3D simulation has been validated with in vivo experiment using coded excitation in mice and 
regular pulses in NHP, it was then used with human skulls to investigate the targeting effects in 
clinically relevant settings. Various incidence angles (0-20⁰) and transducer-skull distance 
(separation distances between the transducer and the skull) (20-60 mm) were evaluated from three 
skull regions (parietal, occipital, and temporal bone). The focal qualities including the focal size 
in axial and lateral direction (FWHM or -6 dB size), the focal shift in axial and lateral direction 
(distance between the local maxima in the focal region and the ideal focal spot), and the skull 
attenuation were measured.   
 
Figure 2.14. The transducer was 
targeted the human brain at 





2.3.3.1    Effect of incidence angle to the skull 
 
Figure 2.15. Simulation of acoustic pressure field through the human skull at various angle 
of incidence. The pressure distribution for placing the FUS transducer toward the brain through 
the occipital area of the human skull at (A) 0⁰ and (B) 20⁰ angle of incidence. The focal properties 
were quantified for the parietal (blue), occipital (red), and temporal (black) bone. (C) The FWHM 
focal size. (Solid line: axial direction. Dotted line: lateral direction.) (D) The focal shift or deviation. 
(Solid line: axial direction. Dotted line: lateral direction.) (E) The skull attenuation.  
 
Both the pressure distribution and the quantified focal properties at various angles of 
incidence were shown in Fig. 2.15. A minimal change was shown in the lateral focal size and 
deviation, while the axial size decreased as the angle increased in most cases. Generally, the focal 
size through the skull fell at 7 mm laterally, and 30-50 mm axially. The deviation fell in 5 mm 
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laterally and 5-15 mm axially in most cases. On the other hand, the pressure loss increased with 
the angle, ranging between 8 to 14 dB.  
 
2.3.3.2    Effect of separation distance of the transducer to the skull 
 
Figure 2.16. Simulation of acoustic pressure field through the human skull at various 
separation distance between the transducer and the skull. The pressure distribution for placing 
the FUS transducer toward the brain through the occipital area of the human skull at (A) 20 mm 
and (B) 60 mm separation distance. The focal properties through the occipital bone were quantified. 
(C) The FWHM focal size. (Blue line: axial direction. Red line: lateral direction.) (D) The focal 
shift or deviation. (Blue line: axial direction. Red line: lateral direction.) (E) The skull attenuation. 
 
Both the pressure distribution and the quantified focal properties were shown in Fig. 2.16 
for the separation distance of transducer to the skull through the occipital bone. The focal size 
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remained the same, while the axial deviation decreased with the increase of separation distance. 
Furthermore, the pressure loss decreased with the increase of separation distance as well. Therefore, 
the further the transducer is to the skull, the better the focal quality it would be.  
2.4 DISCUSSION 
In this chapter, simulation of the acoustic pressure distribution was utilized for pulse design in 
mice and targeting design in monkeys and humans. To improve the focal quality, chirp pulses with 
a frequency range of 1.5-1.9 MHz were explored to eliminate standing waves and scattering from 
the skull cavity. To evaluate the validity of 3D simulation with the primate skull model, it was 
performed with the same targeting used for BBB opening in NHP. Both the focal quality and the 
skull attenuation in silico corresponded to the in vivo results. This 3D simulation was then 
performed with the human skull model to investigate the focal property change at various targeting 
factors including the skull bones, approaching angle of incidence to the skull, the separation 
distance of the transducer to the skull. These findings provide crucial information to plan for the 
FUS treatment. The developed simulation tool therefore will be valuable for in silico preplanning 
in clinics for pressure and targeting estimation.  
 
2.4.1 Pulse design using chirp to improve focal quality 
In this study, frequency-coded pulses were used for sonication in mice in silico and in vivo and 
NHP in silico. The coded excitation methods were driven continuously to facilitate the standing 
wave formation caused by the multiple scattered of the wave inside the brain. The coded methods 
were capable of avoiding the standing wave formation predicted by the simulations. The lower 
cavitation levels detected for the coded excitation methods indicate lower microbubble activity 
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which was confirmed with the more confined openings detected by the MRI images in mice. Those 
results corroborated other studies that demonstrated the cavitation reduction using random 
methods [125, 138]. Hence, the coded methods were capable to enhance the targeting of the BBB 
opening.  
The coded ultrasonic methods were capable of improving the targeting of the BBB opening. 
The larger bandwidth was concluded to achieve better focusing and lower standing wave formation 
for coded methods. Though, the choice of the frequency bandwidth needs to take into account the 
frequency response of the transducer, the skull attenuation and the microbubble optimum 
frequency range. The higher focusing capability found here improves the precision of the method 
allowing specific regions of the brain to be treat with drugs and other pharmacological substances. 
The coded methods can be easily implemented in different setups. The use of these methods 
together with large phased arrays may improve the focusing and reduce standing wave formation. 
Therefore, other techniques may benefit by this coded excitation method, for example, reducing 
hemorrhage found in sonothrombolysis trials. The improvement in targeting is an important 
advantage especially for HIFU which uses higher pressure levels and needs to be very precise to 
ablate the prescribed region and avoid damage to the healthy tissue. 
 
2.4.2 Simulation through the NHP skull predicted the BBB opening characteristics 
The 3D simulation predicted a varied skull attenuation between individuals and targeting 
parameters due to the difference in skull density and thickness. The inter-animal variation was also 
confirmed with the in vivo BBB opening threshold, implying that the variation is mainly associated 
with the skull attenuation while the pressure to induce BBB opening remained similar between 
animals (same threshold reported in mice [76] and rats [79]).  
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The simulation also predicted an average focal shift of 2 mm (0.8 mm laterally and 1 mm 
axially with higher variation in the axial direction). This also corresponded well to the in vivo 
findings (Fig. 2.13), while more factors may affect the targeting accuracy in vivo. For example, 
the targeting shift in the putamen was higher than in the caudate. Both the gyrencephalic brain and 
the incidence angle could play an important role as more layers of gyrus and sulcus were included 
in the beam path when targeting the putamen with larger incidence angles. Heterogeneous tissue 
in the acoustic beam path may affect the targeting accuracy due to the refraction between layers 
and the heterogeneous BBB opening in the gray and white matter affecting the analysis. Higher 
incidence angles could cause larger shifts due to the wave distortion in the skull [139] and 
refraction between the skull layer as well (refraction angle > incidence angle). Besides, the 
stereotactic arm holding the heavy FUS transducer may cause shift while targeting with a large 
angle deviating from the mid-sagittal plane. 
 
2.4.3 The focal quality through the human skull depended on the targeting design  
The targeting effects on the focal properties such as focal shift, focal size as well as skull 
attenuation were explored in human, providing crucial information for preplanning in the future. 
The skull attenuation was found to be related with both the skull thickness and density in monkeys, 
it was also found to be increased with the incidence angle that determines wave propagation mode 
and distortion [139]. It also increased when the transducer was placed closer to the skull, as the 
waves propagated through a higher volume of skull and may be distorted at a higher extent.  
The focal shift was affected by the angle of incidence as refraction of the ultrasonic waves 
in the skull determined the axial deviation. It can go from -2 to -15 mm depending on the area, 
angle and distance of incidence. However, it was not affected when the angle of incidence was 
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lower than 10⁰. Placing the transducer closer to the skull increased the axial shift as the skull 
volume in the beam path increased. On the other hand, lateral deviation of the focus provided the 
information about the non-axisymmetry of the skull. It ranged between 2 to 5 mm and remained 
stable with various angle of incidence and the separation distance. Besides, the focal size (axial 
and lateral FWHM size) showed different variations depending on the incidence zone. The 
occipital zone resulted in the shortest axial size of 30 mm, which was smaller than that in water 
(38.5 mm). This can be due to a focusing effect of the skull called skull lensing effect. On the other 
hand, lateral size remained stable in values between 5 and 9 mm, slightly higher than in water (4.4 
mm).  
Although several trends can be found in this study, local heterogeneities in the area where 
the ultrasound beam crosses the skull have shown to affect drastically the location and the quality 
of the focus. To validate most of the present conclusions, more simulations should be done in each 
area, as well as in different CTs. Future work will also incorporate both the skull volume as well 
as the distribution of skull density and incidence angle in the beam path for a more quantitative 
way to correlate with the focal characteristics. Once the correlation between the skull and the focal 
characteristics is established, an efficient estimation of focal quality can then be used for a quick 
preplanning before running a full simulation. This way, CT only can be used for an estimation of 
focal qualities by quantifying the skull characteristics such as thickness, density, and curvature in 
the beam path during preplanning. Lastly, ultrashort echo-time MRI utilizes the cortical bone 
nature of short T2* decay time to image the skull which may be able to replace the CT for 





In this chapter, a simulation tool was established and validated with in vivo BBB opening in small 
and large animals. It provided focal properties as well as in situ pressure with respect to various 
pulse design and targeting planning. To improve focal quality, chirp and random pulses with a 
small frequency range could eliminate standing waves. The skull-transducer distance and angle of 
incidence could also be optimized to improve the focal quality. Since the variation in the skull 
properties could dramatically change the in situ pressure and the focal characteristics, it is of vital 
importance to perform pre-operative simulation to ensure safety and effectiveness in the 
transcranial FUS treatment including BBB opening. The proposed in silico preplanning was thus 
summarized in chapter 7 followed by the neuronavigation-guided treatment procedure. 
 
2.6 SIGNIFICANCE & CONTRIBUTION 
The safety and effectiveness of transcranial FUS is directly determined by the applied pressure in 
the brain, but there exists no method to measure the pressure with unknown skull attenuation. 
Although several methods of numerical simulation have been developed to estimate the pressure, 
none of them was implemented and validated for BBB opening. In this chapter, the specific aim 
to develop a treatment preplanning tool for BBB opening has been achieved by modeling the 
acoustic wave propagation through the skull (mice, NHP, and human) and extensively validated 
with in vivo BBB opening (mice and NHP) for the first time. This simulation tool not only can be 
used to compensate for the animal variation, improve the focal quality, it also sheds lights on the 
clinical targeting design. In the first step of clinical trial in which safety is the utmost important 
issue, the developed simulation tool will provide the key information in the preplanning phase. 
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Chapter 3   
Acoustic Monitoring to Assess Drug 
Delivery with Customized Mediators 
 
3.1 INTRODUCTION 
In Chapter 2 it has been shown that ultrasound at 0.5 MHz can be applied through mice, monkey 
and human skull. While to achieve BBB opening and drug delivery, cavitation plays the key role. 
Proper acoustic agents and acoustic monitoring through passive cavitation detection (PCD) are 
thus crucial to ensure a safe and effective treatment outcome. Since the commercially available 
agents were designed for imaging purpose, their use in BBB opening and drug delivery often 
results in low delivery efficiency which is even more difficult for large molecules (> 1 kDa). In 
this chapter, acoustic agents with different properties including microbubbles and nanodroplets 
were designed and tested in mice, with PCD monitoring to assess their physical mechanisms for 
drug delivery. Three schemes were postulated with PCD monitoring of the efficacy and the safety 
to the cellular level evaluated.  
1) The microbubble shell physiochemical properties  
2) Fluorescently-tagged microbubbles as pseudo drug-loaded microbubbles 
3) Acoustically-activated nanodroplets 
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Lipid-shelled microbubbles have been used in ultrasound-mediated drug delivery. The 
physicochemical properties of the microbubble shell could affect the delivery efficiency since they 
determine the microbubble mechanical properties, circulation persistence, and dissolution 
behavior during cavitation. Therefore, the first objective was to investigate the shell effects on 
drug delivery efficiency in the brain via BBB opening in vivo using monodisperse microbubbles 
with different phospholipid shell components. The physicochemical properties of the monolayer 
were varied by using phospholipids with different hydrophobic chain lengths (C16, C18, and C24). 
The dependence on the molecular size (3 kDa and 40 kDa dextran been delivered) and acoustic 
energy (both pressure and pulse length) were investigated. The different shelled microbubble 
dynamics in vivo were also captured during insonification using passive acoustic cavitation 
detection (PCD) in order to potentially uncover the physical mechanisms affecting the delivery 
efficiency such as micro-streaming and micro-jetting. The signal recorded by PCD is the acoustic 
emission from the cavitating bubbles, which represents the cavitation intensity with the signature 
of stable and/or inertial cavitation. Stable cavitation (bubble oscillation) and inertial cavitation 
(violent bubble oscillation to bubble collapse) relates to micro-streaming and micro-jetting, 
respectively [18], and both are thought to contribute to ultrasound-mediated drug delivery. 
In the second scheme, microbubbles loaded with fluorophore 5-
dodecanoylaminfluorescein (C-12) on the lipid shell through covalent bond were used as vectors 
for localized drug delivery into the brain, with PCD monitored for all the experiments to investigate 
the physical mechanisms. Although drug-loaded microbubbles have been widely used for targeted 
drug delivery [141-143], their physical mechanisms of delivery during sonication have not been 
investigated. These mechanisms could provide important information for the design of drug-
loaded microbubbles.  
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Lastly, acoustically-activated nanodroplets were used as a new class of contrast agents to 
mediate FUS-induced BBB opening in order to study the feasibility of utilizing these nanoscale 
phase-shift particles for targeted drug delivery (3 kDa and 40 kDa dextran) in the brain. 
Customization of nanodroplets for the sensitivity to acoustic energy have been explored through 
modification on the boiling point of the perfluorocarbon liquid core. Again, PCD was used to 
monitor the vaporization and bubble activities and compared with the drug delivery results. Our 
findings offered a new means of developing the FUS-induced BBB opening technology for 
potential extravascular targeted drug delivery in the brain, extending the potential drug delivery 
region beyond the cerebral vasculature. 
 
3.2 METHODS 
3.2.1   Ultrasound System  
The experimental setup, as shown in Fig. 3.1A, was used as previously described [78]. A single-
element, ring-shaped focused ultrasound (FUS) transducer (center frequency: 1.5 MHz, focal 
depth: 60 mm; Imasonic, Besancon, France) was driven by a function generator (33220A; Agilent 
Technologies, Palo Alto, CA, USA) through a 50 dB power amplifier (325LA; E&I, Rochester, 
NY, USA). A pulse-echo transducer (center frequency: 10 MHz, focal length: 60 mm; Olympus 
NDT, Waltham, MA, USA) confocally and coaxially aligned with the FUS transducer was used 
for both targeting and passive cavitation detection (PCD) purposes. During the targeting procedure, 
the pulse-echo transducer was driven by a pulser receiver (Model 5800; Parametrics-NDT, MA, 
USA) in transmit-and-receive mode; while for PCD during sonication, it was switched in receive-
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only mode with 20 dB of amplification. The signal was digitized in 50 MHz of sampling rate 




Figure 3.1. Experimental setup (A) and timeline (B) for FUS-induced BBB opening in mice 
in vivo. A focused ultrasound (FUS) transducer was used for sonication, while a pulse-echo 
transducer at the center of the FUS transducer was used for both targeting and passive cavitation 
detection (PCD) purposes. After the targeting procedure, a 30 s of sonication before microbubble 
injection was performed as a baseline control for PCD. The freshly diluted microbubble solution 
was then co-administered with dextran intravenously, and the sonication (1 min for microbubbles 
and 5 min for nanodroplets) for BBB opening started 5 s after injection. 1 hr after the end of 
sonication the mice was sacrificed using transcardial perfusion, and its brain was extracted and 




The peak-rarefactional pressure profile used in the present study was estimated based on 
the calibration in degassed water with a bullet hydrophone (HGL-0400; Onda Corp., Sunnyvale, 
CA, USA), and the axial and lateral full-widths at half-maximum (FWHM) pressure of the focus 
were 10.6 mm and 1.3 mm, respectively. The pressure amplitudes were corrected to account for 
18.1% attenuation through the murine skull as measured previously [89], and the derated peak-
rarefactional pressure was reported in this study. 
 
3.2.2   Generation and characterization of acoustic agents 
3.2.2.1   Lipid-shelled microbubbles with various acyl chain lengths 
All the lipids were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA), including 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC or C16), 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC or C18), 1,2-dilignoceroyl-sn-glycero-3-phosphocholine (DLiPC or C24) 
and 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] 
(DSPE-PEG2000). The perfluorobutane gas (PFB, 99 wt% purity) used for microbubble 
generation was obtained from FluoroMed (Round Rock, TX, USA).   
The lipid-coated microbubbles as shown in Fig. 3.2A were prepared at a 9:1 molar ratio of 
lipids and lipopolymers (DSPE-PEG2000). They were generated using the probe sonication 
method and size selected to 4-5 µm in diameter using differential centrifugation, as described 
elsewhere [134]. A Multisizer III particle counter (Beckman Coulter Inc., Opa Locka, FL, USA) 
with a 30-µm aperture was used to measure the microbubble size distribution (Fig. 3.2B-C) and 
concentration. The final size-isolated (4-5 µm) microbubble suspension was stored at 4 ºC till the 
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time of injection. All the microbubble samples used for this study were freshly prepared within 24 
h to ensure experimental consistency. 
 
Figure 3.2. Schematic of the lipid-shelled microbubble used in this study (A) and their 
representative size distribution in number (B) and volume (C). Three different lipid acyl chain 
lengths (C16, C18, C24) were used to generate microbubbles of different physicochemical 
properties, while the emulsifier (DSPE-PEG2000), the molar ratio between the main lipid and the 
emulsifier (9:1), the gas core (PFB), and the size of the microbubbles (4-5 µm) were kept the same 
in order to focus on the effects of lipid hydrophobic chain length. The size of the different-shelled 
microbubbles was statistically the same. All microbubble suspensions were diluted to the same 
concentration (8×108 particle/mL) immediately prior to injection. 
 
3.2.2.2   Fluorescently-tagged microbubbles 
The fluorescent microbubbles were converted from the C18 microbubbles described previously 
with an addition of the lipophilic fluorescein probe, C-12 (Life technologies, Eugene, OR) 
(molecular weight 529.63 g/mol, maximum emission and excitation wavelengths 497±3 and 518±4 
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nm respectively) using a post-labeling technique. C-12 with a C12 alkyl chain (Fig. 3.3A) binds to 
the bubble shells with the fluorophore at the aqueous interface and the alkyl tail protruding into 
the lipid interior (Fig. 3.3B). C-12 was dissolved in pure ethanol at a concentration of 10 mM and 
put in direct contact with the microbubbles. Due to its amphiphilic nature, direct contact with the 
C-12 solution led to microbubbles binding to it. To allow the diffusion of C-12 to all the bubbles, 
the 1-mL syringe containing the suspension of microbubbles plus C-12 was incubated during two 
hours while it was rotated at 40 rpm. The size distribution and concentration of the fluorescent 
microbubbles were determined again with the Coulter Counter Multisizer III. Fig. 3.3C illustrates 
the appearance of the fluorescent microbubbles. It is clear that all the fluorescence is concentrated 
on the lipid shell. 
 
Figure 3.3. Fluorescently-tagged microbubble structure. (A) Molecular structure of 5-
dodecanoylaminofluorescein (C-12). (B) Cartoon showing how the C-12 alkyl tail protrudes into 
the microbubble lipid shell converting the microbubble into a fluorescent drug carrier. (C) Epi-
fluorescence image of a fluorescent microbubble sample. C-12 did not enter the core of the 




3.2.2.3   Nanodroplets 
Through the condensation process with microbubbles (Fig. 3.4A), perfluorocarbon droplets with 
two different boiling-point gases (octafluoropropane or OFP: −36.7 °C, decafluorobutane or DFB: 
−1.7 °C) (FluoroMed, Round Rock, TX, USA) were fabricated as previously described [108, 144]. 
Briefly, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (DSPE-PEG2000) (Avanti Polar 
Lipids, Alabaster, AL, USA) were combined in a 9:1 molar ratio and dissolved in a phosphate-
buffered saline (PBS)-based excipient solution containing 15% (v/v) propylene glycol and 5% 
(v/v) glycerol for a final lipid concentration of 1.0 mg/mL. The resultant lipid solution (1.5 mL) 
was added to 3 mL glass vials, and the headspace air was exchanged with OFP or DFB gas. 
Followed by vigorous shaking of the lipid-filled vials, precursor microbubbles were formed using 
a Vialmix mixer (Bristol-Myers-Squibb, New York, NY, USA). The nanodroplets were then 
generated via microbubble condensation under reduced temperature and increased ambient 
pressure. Vials of microbubbles were immersed in an isopropanol/CO2 bath maintained between -
8°C and -13°C for approximately 2 minutes. The vials were then attached to an adjustable pressure 
source, and the headspace pressure was increased until condensation was observed.  
The size distribution and concentration of nanodroplets (Fig. 3.4B) were measured using a 
Malvern NanoSight NS500 (Malvern, Worcestershire, UK) in comparison to their precursor 
microbubbles (Fig. 3.4C). This instrument measures nanoparticle size based on their Brownian 
motion and is able to detect particles between 30 and 2000 nm. Number weighted size distributions 




Figure 3.4. Nanodroplet characteristics. (A) Schematics of phase-shift nanodroplets through 
condensation process using microbubbles. The average size distribution of (B) the nanodroplets 
and (C) their precursor microbubbles. The average concentration and the median size for DFP 
droplets were 2.8×1011 particles/mL and 171 nm, respectively; those for DFP droplets were  
1.3×1011 particles/mL and 183 nm, respectively. 
 
3.2.3   In vitro experiments using high-speed camera 
Droplet vaporization characteristics including the pressure threshold and relative vaporization 
efficiency (i.e., number of bubbles generated with given acoustic parameters in the measurement 
field per nanodroplets) were investigated in vitro using a previously described high-speed optical 
microscopy setup [78]. Briefly, an inverted microscope with a 100X objective (Olympus IX71; 
Center Valley, PA, USA) was mounted with a water bath filled with degassed water at 37°C and 
interfaced with an ultra-high-speed framing camera (20 million fps with 24-frame buffer, SIMD24; 
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Specialised Imaging, Simi Valley, CA) to study the vaporization threshold or a high-speed camera 
(1000 fps, FastCam SA1.1; Photron Inc., San Diego, CA, USA) to study the vaporization 
efficiency. A spherically focused transducer (A305S; Panametrics, Inc., Waltham, MA, USA) with 
a focal size of 0.75 mm laterally and 2 mm axially was used to activate the droplets by sending 
1.5-MHz, 50-cycle sinusoidal pulses at 150-900 kPa driven by an arbitrary waveform generator 
(AWG 2021; Tektronix, Inc., Beaverton, OR, USA) through a RF amplifier (A500; ENI, Rochester, 
NY, USA).  
Before the experiment, the transducer focus was calibrated and aligned with the optical 
focus using a calibrated needle hydrophone (HNA-0400; ONDA Corp., Sunnyvale, CA, USA). 
The hydrophone at the center of focus was then replaced with a nearly optically and visually 
transparent microcellulose tube (200 µm in diameter, Spectrum Laboratories INC., Greensboro, 
NC, USA), which was aligned with the microscope field of view using a micropositioner (MMO-
203; Narishige Group, East Meadow, NY, USA). Nanodroplets (both OPF and DFB) were diluted 
by 50% in PBS and flowed through the microcellulose tube for visualization. At each sonication, 
a trigger pulse was transmitted from the waveform generator to the high-speed camera to allow 
synchronized video recording of the droplet vaporization events.  
After the experiments, the videos for the behavior of nanodroplets vaporization was 
analyzed offline to determine the pressure threshold for consistent vaporization, and to count the 
number of bubbles generated in the microscope field of view (an estimate of vaporization 
efficiency). Bubbles were counted using a custom image processing code in MATLAB 
(Mathworks Inc., Natick, MA, USA) based upon a Hough transform for circle pattern recognition 
(Supplementary Fig. 1) [145, 146]. The lighting in the setup allowed for good contrast between 
the background and the formed bubbles (shown as black shadows). Although the bubbles were 
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formed in and out of imaging plane due to the stochastic nature of vaporization process, the use of 
the Hough transform for circle recognitions allowed for accurate identification of bubbles since 
the principal radius component was chosen through an ordered voting process. Bubbles vaporized 
within a finite width slice around the plane of focus of the camera were counted, while those 
completely out of focus become part of the background and were therefore not counted. Since this 
plane remained the same between OFP and DFB experiments, our quantification gave a relative 
vaporization efficiency between OFP and DFB nanodroplets activated in vitro. 
 
3.2.4   In vivo mice experiments 
Pulsed FUS (parameters summarized in Table 3.1) was applied transcranially to the targeted left 
hippocampus of the mouse brain while the right hippocampus served as the control without FUS. 
After the FUS transducer was aligned with the targeted region following the procedure described 
previously [89], the sonication procedure as illustrated in Fig. 3.1B was then followed. A 30 s of 
sonication was performed before microbubble injection as a baseline control for PCD. While at 
the same time the microbubble and dextran solution was prepared for the sonication with 
microbubble injection. The microbubble samples were freshly diluted to a final concentration of 
8×108 bubbles/mL using sterile saline, and a 30 µL of the diluted microbubble suspension was co-
administered with 50 µL dextran solution (40 kDa, fluorescently tagged with Texas Red, 40 
mg/mL of weight concentration) via bolus injection through the tail vein 5 s prior to the start of 
sonication. Likewise, the nanodroplets (25 µL for OFP droplets and 100 µL for DFB droplets 
based on their concentration and vaporization efficiency difference) were co-injected with the 
same amount of dextran for the nanodroplets study. In addition, two sham cohorts without 
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sonication were injected with dextrans to serve as the basis for comparison of successful drug 
delivery in the fluorescence imaging analysis. 
A 1-h period was allowed after sonication to enable the dextran to circulate throughout the 
vasculature and to diffuse into the brain parenchyma.  At the end of the allotted time, the animal 
was sacrificed by transcardial perfusion using 30 mL phosphate buffer saline (PBS) for 5 min 
followed by 60 mL 4% paraformaldehyde for 8 min. The mouse brain was extracted from the skull, 
post-fixed in 4% paraformaldehyde overnight before sectioning for either fluorescence imaging or 
hematoxylin or eosin (H&E) staining in order to evaluate drug delivery efficiency and safety, 
respectively. 
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3.2.5   Quantification of Acoustic Cavitation Emission 
Three types of cavitation dose (SCDh, stable cavitation dose using harmonics; SCDu, stable 
cavitation dose using ultraharmonics; ICD, inertial cavitation dose) were quantified. First, each 
pulse of the PCD signal was calculated into the frequency spectrum in MATLAB (Mathworks Inc., 
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Natick, MA, USA). Second, after taking the root mean square (rms) of the voltage spectral 
amplitude, the harmonic signal (n*f; n = 3, 4, 5, 6; f = 1.5 MHz; maximum amplitude within a 
bandwidth of 20 kHz around the harmonic frequency), ultraharmonic signal (n*f+0.5*f; n = 2, 3, 
4, 5; f = 1.5 MHz; maximum amplitude within a bandwidth of 20 kHz around the ultraharmonic 
frequency), and the broadband signal in 3-9 MHz between them (applying a comb filter to suppress 
the harmonic and ultraharmonic signal with rejection bandwidths of 350 kHz and 100 kHz, 
respectively) were separately extracted. Third, the mean harmonic, ultraharmonic, and broadband 
signal were taken for each pulse and summed up over all pulses received during sonication to 
acquire SCDh, SCDu, and ICD, respectively. Lastly, the differential cavitation doses were 
computed by subtracting the normalized baseline cavitation doses (30s of sonication before 
microbubble injection). The cavitation doses reported in this study were the differential cavitation 
doses. 
 
3.2.6   Fluorescence imaging and analysis for BBB opening and drug delivery 
Followed by post-fixation process, the brains for delivery efficiency analysis were cryoprotected 
(30% of sucrose for 48 hr) and then sectioned horizontally using a cryostat (Leica RM2255; Leica 
Microsystems Inc., Buffalo, IL, USA) into 60-µm slices covering the hippocampi. The 60-µm frozen 
sections were used to quantify the relative fluorescence enhancement representing the ratio of 
dextran (in mass) been delivered to the targeted hippocampus through BBB opening relative to the 
contralateral hippocampus (unsonicated), since the dextran mass was kept constant for injection.  
The epi-fluorescence images of the brain sections were captured for quantifying the 
fluorescence enhancement using an Olympus DP30BW digital camera mounted on an up-right 
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Olympus BX61 microscope (Melville, NY, USA). Briefly, a section representing the ventral-
dorsal midline, as determined by anatomical landmarks, was first selected, and four adjacent 
sections were then selected on both the ventral and the dorsal side of the midline. The left 
(sonicated) and the right (unsonicated control) hippocampus were manually delineated using 
MATLAB (Mathworks Inc., Natick, MA, USA), and the fluorescence intensity increase as well as 
the BBB opening area in the region of interest (ROI) were calculated [147]. The relative 
fluorescence intensity increase was calculated by dividing the difference in fluorescence intensity 
between the left and the right ROIs (removing the auto-fluorescence) by the fluorescence intensity 
in the background (the spatial average of the background signal adding three times its standard 
deviation). For each brain, the reported fluorescence intensity increase was thus equal to the sum 
of all nine sections. The BBB opening area (intensity > background) was calculated as a percentage 
normalized to the sonicated ROI. A successful dextran delivery for an individual brain was 
concluded if both the fluorescence intensity increase and the BBB opening area were higher by 
two standard deviations relative to the average of the corresponding sham cohort. 
 
3.2.7   Histological evaluation for safety 
The histological examination for safety assessment of the entire hippocampi (both left and right) 
was performed via hematoxylin and eosin (H&E) staining, which can be used to identify damaged 
neurons (dark neurons showing shrunken and triangulated cell bodies) and red blood cell 
extravasations (hemorrhage) [148]. Followed by post-fixation process, the brains in the safety 
assessment study were paraffin-embedded and then sectioned horizontally into 6-µm slices with 
180-µm gaps covering the hippocampi. The bright field images of the stained slices were captured 
using the same microscope as mentioned previously. This histological examination was double-
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3.3.1 Microbubble shell effects on drug delivery 
Number of animals in each cohort is summarized in Table 3.2 







Number of mice per experimental condition 
Acoustic pressure (kPa) 




- 3 3 3 4a 
DSPC (C18) - 3 3 3 4a 




- 3 3 3 3 
DSPC (C18) - 3 3 4 3 




- 3 3 3 4a 
DSPC (C18) - 3 3 3 4a 
DLiPC (C24) - 3 3 3 4a 
4 - 3 - 5 - - - - 
5 - 40 - 3 - - - - 
a Number shown including 1 mouse per experimental condition used for histology examination. 
 
 
3.3.1.1    Drug delivery efficiency 
Using fluorescently-labeled dextrans as model drug molecules, the delivery efficiency due to FUS-
induced BBB opening could be quantified as the relative fluorescence enhancement in the 
sonicated hippocampus over the control. The two sham cohorts (Group 4 for 3-kDa dextran, Group 
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5 for 40-kDa dextran), for which no ultrasound was applied and no microbubbles were injected, 
did not show any change in fluorescence intensity between the two hemispheres (Suppl. Fig. 1). 
Quantified fluorescence enhancement results confirmed this observation as no detectable increase 
in fluorescence intensity between the two ROIs was acquired. For the rest of the 36 experimental 
conditions, the measured fluorescence enhancement was compared to their corresponding sham 
cohort in order to determine whether sufficient amount of dextran molecules were delivered to the 
targeted region. To study the shell effect on delivery efficiency with various drug molecule sizes, 
3-kDa (Group 1) and 40-kDa (Group 2) dextrans were used as model drugs after FUS-induced 
BBB opening using 100-cycle (67 µs) pulses. To study the shell effect with various sonication 
pulse lengths, results of 100-cycle pulses (Group 2) and 1000-cycle pulses with 40-kDa dextrans 
(group 3) were compared.  
Fig. 3.5 shows both the representative fluorescence images and the quantified enhancement 
results for Group 1 (3-kDa dextrans with 100-cycle pulses) after BBB opening. Due to the small 
molecular size, successful BBB opening was easily achieved at the lowest pressure level (225 
kPa): 100% BBB opening efficiency was obtained for all mice regardless of the microbubble shell 
composition, with the exception of 1 mouse from the C24 microubbble/225 kPa cohort. The 
representative fluorescence images showed homogeneous dextran diffusion within the sonicated 
locations with a fluorescence signal detected not only within or near large vessels, but also 
diffusely distributed across the entire hippocampi as the pressure increased (Fig. 3.5C-D, G-H, K-








Figure 3.5.   Effects of lipid hydrophobic chain 
length on delivery efficiency for 3-kDa dextran 
after FUS-induced BBB opening using 100-
cycle (67 µs) pulses. (A-L) Representative 
fluorescence images comparing the targeted and 
the control (insets) hippocampi when C16, C18 or 
C24 microbubbles were used to mediate BBB 
opening at various pressures. The scale bar in A 
depicts 1 mm. (M) The quantified fluorescence 
enhancement between the sonicated and the 
control ROIs showed no significant shell effect on 





Fig. 3.6 shows the representative fluorescence images for Group 2 (40-kDa dextrans with 
100-cycle pulses). Under the same acoustic exposures regardless of the microbubble shell type, 
BBB opening was obtained in 100% of the mice sonicated using pressures at or above 300 kPa. 
However, at the lowest pressure level (225 kPa), successful BBB opening was not consistently 
achieved: 1 out of 3 mice sonicated using C16 microbubbles and 2 out of 3 mice sonicated using 
C24 microbubbles did not show significant fluorescence enhancement. C16 microbubbles 
mediated the smallest dextran diffusion within the targeted hippocampi at all pressure levels. 
Moreover, the detectable dextran signal was predominantly contained within the blood vessels 
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even when some diffuse fluorescence enhancement within the targeted location was obtained as 
the pressure was increased above 300 kPa (Fig. 3.6C-D). On the other hand, significantly higher 
and more diffuse dextran distribution was induced using C18 and C24 microbubbles, especially at 
higher pressures (Fig. 3.6G-H, 3.6K-L). The quantified fluorescence analysis supported this 
finding (Fig. 3.6M). At 450 and 600 kPa, significantly higher 40-kDa dextran delivery was 
detected with both C18 and C24 microbubbles compared to C16 microbubbles. In addition, C24 






Figure 3.6.  Effects of lipid hydrophobic chain 
length on delivery efficiency of 40-kDa dextran 
after FUS-induced BBB opening using 100-cycle 
(67 µs) pulses. (A-L) Representative fluorescence 
images compare the targeted and the control (insets) 
hippocampi when C16, C18 or C24 microbubbles 
were used to mediate BBB opening at various 
pressures. The scale bar in A depicts 1 mm. (M) The 
quantified fluorescence enhancement between the 
sonicated and the control ROIs showed significant 
shell effects on the 40-kDa dextran delivery across 







Fig. 3.7 shows the representative fluorescence images for Group 3 (40-kDa dextrans with 
1000-cycle pulses). 100% BBB opening efficiency was obtained in all animals regardless of the 
microbubble lipid chain length. Based on the fluorescence images (Fig. 3.7A-L), in stark contrast 
with the 100-cycle BBB opening findings, the longer acoustic pulses produced significantly more 
homogeneous diffusion of the 40-kDa dextran, especially with the longer C18 and C24 acyl chain 
lengths. Punctate clusters of dextran were still visible within the vessels at all pressure levels. The 
quantified fluorescence enhancement results showed significantly more dextran accumulation 
within the targeted hippocampi after BBB opening using C24 microbubbles at 450 and 600 kPa 
(Fig. 3.7M). On the other hand, no statistical difference in dextran delivery was detected between 





Figure 3.7.  Effects of lipid hydrophobic chain length 
on delivery efficiency of 40-kDa dextran after FUS-
induced BBB opening using 1000-cycle (670 µs) 
pulses. (A-L) Representative fluorescence images 
compare the targeted and the control (insets) 
hippocampi when C16, C18 or C24 microbubbles were 
used to mediate BBB opening at various pressures. The 
scale bar in A depicts 1 mm. (M) The quantified 
fluorescence enhancement between the sonicated and 
the control ROIs showed significant shell effects with 
C24 microbubbles on the 40-kDa dextran delivery 





3.3.1.2   Acoustic cavitation emission 
Three different types of cavitation dose (SCDh, ICD, SCDu) were separately quantified 
representing different bubble activities. Stable cavitation dose with harmonics (SCDh) was for 
volumetric oscillation; inertial cavitation dose (ICD) identified drastic bubble oscillation and 
bubble collapse; stable cavitation dose with ultraharmonics (SCDu) was thought to identify 
asymmetric oscillation and shell waves [70]. Fig. 3.8 shows the quantified acoustic cavitation dose 
during BBB opening using 100-cycle pulses (Fig. 3.8A-C) and 1000-cycle pulses (Fig. 3.8D-F). 
Using 100-cycle pulses, the SCDh (Fig. 3.8A) for C18 and C24 was significantly higher than that 
of C16 at higher pressures, and the ICD and SCDu for C24 was the highest (Fig. 3.8B-C). These 
results indicated that both C18 and C24 had stronger volumetric oscillation, and C24 had the 
strongest asymmetric oscillation potentially and bubble collapse over the others, corresponding to 
the 40-kDa dextran delivery efficiency in Fig. 4. By increasing the pulse length to 1000 cycles 
(Fig. 3.8D-F), the cavitation difference among shells was compensated at lower pressures except 
at 600 kPa where the cavitation dose for C24 was still the highest, corresponding to the 40-kDa 




Figure 3.8.  Quantified acoustic emission detected during BBB opening at various pressures 
and pulse lengths. For 100-cycle pulses, stable cavitation dose with harmonics (SCDh) (A), 
inertial cavitation dose (B), and stable cavitation dose with ultraharmonics (SCDu) (C) was 
calculated. The three types of cavitation dose for 1000-cycle pulses were also quantified (D-F).  
 
3.3.1.3   Safety  
Histological evaluation was performed in order to assess for potential tissue damage 1 hr after 
insonification. Fig. 3.9B shows the representative images obtained from all brain samples 
sonicated at the highest pressure (600 kPa). This pressure was selected since it represented the 
highest amount of exposed acoustic energy among all three groups. Examination at higher 
magnification did not reveal any discrete damage sites, such as clusters of dark neurons, small 
erythrocyte extravasations, hemorrhage or microvacuolations for brains sonicated with C16 
84 
 
microbubbles. While a few petechial hemorrhages were observed within the brain parenchyma 
sonicated with C18 microbubbles. The most discernible abnormalities occurred in the C24 
microbubble cohorts, for which a larger degree of microscopic perivascular hemorrhages was 
detected. However, the damage to the brain parenchyma was negligible. The severity of all 
observed tissue damages was concluded to be Category 1 to 2 with Category 0 representing no 
damage based on the criteria provided by Hynynen et al. [149]. 
 
 
Figure 3.9.  Representative histological images of the targeted (left) and control (right) 
hippocampi using 100-cycle (A-F) and 1000-cycle pulses (G-L) at 600 kPa. No erythrocyte 
extravasation, dark neurons, gross hemorrhage or microvacuolations were observed when C16 
microbubbles were used to mediate BBB opening using either 100-cycle (A-B) or 1000-cycle (G-
H) pulses. Small clusters of dark neurons (indicated with stars) were identified when C18 
microbubbles were used with 100-cycle pulses (C-D), while a few petechial hemorrhages 
(indicated with triangles) were observed with 1000-cycle pulses (I-J). Larger degree of 
perivascular hemorrhages was seen with C24 microbubbles regardless of the pulse length (E-F, K-




3.3.1.4   Assessment of opening outcome using acoustic cavitation detection  
The acoustic cavitation emission has been used to assess the drug delivery efficiency with acoustic 
responsive agents. In order to investigate whether the cavitation dose for different shelled 
microbubbles followed the same trend for assessing the BBB opening outcomes and drug delivery 
efficiency, both qualitative classification and quantitative analysis were performed as shown in 
Fig. 3.10. The total stable cavitation dose (SCDh+u, sum of SCDh and SCDu) was adopted since it 
has been reported to correlate well with the drug delivery efficiency [78].  For the qualitative 
analysis (Fig. 3.10A), the SCDh+u was separated into groups of no opening and opening based on 
the fluorescence results, and into groups of no damage and damage based on the histological 
findings. Despite the overlap, the SCDh+u of the opening group was significantly higher than that 
of the no opening group for both 100-cycle and 1000-cycle pulses. The SCDh+u of the no damage 
group was lower than that of the damage group. For quantitative analysis (Fig. 3.10B), the 
fluorescence enhancement was positively correlated with SCDh+u for both 100-cycle and 1000-





Figure 3.10.  Using stable cavitation dose (SCDh+u = SCDh + SCDu) to evaluate the opening 
outcomes qualitatively for classification (A) and quantitatively for delivery efficiency assessment 
(B). In the qualitative analysis (A), the SCDh+u was separated into groups of no opening and 
opening (fluorescence enhancement was higher than the mean plus 2 times of standard deviation 
of the sham cohort), while based on the histological results it was separated into groups of no 
damage and damage (erythrocyte extravasation or dark neurons appeared). In the quantitative 
analysis (B), the fluorescence enhancement was positively correlated with the SCDh+u, with a R
2 
of 0.63 and 0.61 using linear fitting for 100-cycle pulses and 1000-cyle pulses, respectively.  
 
3.3.2   Fluorescently tagged microbubbles for drug delivery 
Table 3.3 summarizes the number of animals used in each experimental groups. BBB opening was 
validated with contrast-enhanced T1-weighted imaging (method described in Chapter 2.2), and all 
groups showed successful delivery. While the fluorescence enhancement was only successful at 
pressures of 600 and 750 kPa (Fig. 3.11), revealing a higher pressure threshold for drug delivery 
using drug-loaded microbubbles. The PCD monitoring showed that inertial cavitation was 
accompanied with cases of successful fluorescence delivery (Fig. 3.12). Therefore, disruption of 
microbubbles is crucial to for drug delivery using drug-loaded microbubbles. 
 









1 450 4/4 0/4 0 
2 600 15/15 3/9 4.63 ± 2.58 





Figure 3.11. Fluorescence enhancement in the sonicated region showed successful drug 




Figure 3.12. PCD monitoring of the cavitation doses in the cases of (A) significant and (B) 
insignificant fluorescence delivery. 
 
 
3.3.3    Feasibility of drug delivery using Nanodroplets 











Number of mice per experimental condition 1  
Sham 
Acoustic pressure (MPa)  




6 6 6 7 7 8 
 
2 Microbubble 5 7 7 7 7 7  
1 Number shown including up to 2 mice per experimental condition used for histology 
examination. 
 
3.3.3.1   Nanodroplet vaporization threshold 
In order to confirm the nanodroplets generated via microbubble condensation were acoustically 
vaporizable, high-speed optical microscopy was used to visually verify the vaporization of 
individual stationary droplets at pressures relevant to our in vivo experiment.  Fig. 3.13 shows that 
at peak-rarefactional pressure of approximately 0.35 MPa, no detectable number of vaporized 
bubbles appeared within the focal plane.  However, when the pressure amplitude was increased to 
0.45 MPa, vaporized bubbles were observed almost immediately upon exposure to the ultrasound 
beam.  These acoustically activated bubbles were within the micrometer size range and appeared 
to be acoustically responsive (i.e., they could expand and contract according to the pressure change 
during a single pulse).  The activation of sub-micron droplets was also repeatedly observed at 
higher pressures (up to 1.1 MPa tested in the current study) using the in vitro setup, complementing 







Figure 3.13.  Still-frame images showing nanodroplet activation within the first two cycles of 
the pulse as a function of sonication pressure.  Frames A-D and G-J were taken in the first 
rarefactional half-cycle, while E-F and K-L were taken in the following compressional cycle.  No 
nanodroplet vaporization was detected at 0.35 MPa (left) while micron-scale acoustically-
responsive bubbles were seen expanding in the rarefactional cycle at 0.45 MPa (G-J).  When 
transitioned to the next positive pressure cycle (K, L), the newly formed bubbles were observed to 
respond to the acoustic pressure by compressing until no longer visible in the field of view.  Times 
shown are relative to the start of the pulse, and the scale bars indicate 5 µm. 
 
3.3.3.2   Delivery of small molecules  
Using fluorescently-labeled 3 kDa dextran as a model drug molecule, the extent of the FUS-
induced BBB opening could be quantified as the relative fluorescence enhancement in the 
sonicated hippocampus over the control.  The two sham cohorts, for which no ultrasound was 
applied, did not show any change in fluorescence intensity between the two hemispheres.  
Quantified fluorescence enhancement results confirmed this observation as no detectable increase 
in fluorescence intensity between the two ROIs was calculated.  For the rest of the 12 experimental 
conditions, the measured fluorescence enhancement was compared to their corresponding sham 
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cohort in order to determine whether sufficient amount of dextran molecules were delivered into 
the targeted region. 
Following the systemic administration of nanodroplets and subsequent BBB opening, a 
significant increase in dextran delivery in the targeted ROI was observed at 0.45 and 0.60 MPa 
(60% opening efficiency with P=0.047 and 100% opening efficiency with P=0.0002, respectively) 
while only up to 33% of the animals evaluated showed a significant fluorescence enhancement 
when sonicated at pressures below 0.45 MPa.  Due to the inconsistency across animals, there was 
no statistically significant (P>0.56) increase in fluorescence enhancement to clearly indicate BBB 
opening with dextran delivery for sonication pressures ranging between 0.15 and 0.30 MPa (Fig. 
3.14A).  At pressures above 0.45 MPa, fluorescence was observed not only within or near large 
vessels, but also diffusely distributed across the hippocampi (Figs. 3.15D and 3.15E). 
Following the systemic administration of microbubbles and subsequent BBB opening, a 
significant fluorescence enhancement was detected for all mice when sonicated at pressures 
including and above 0.30 MPa (P<0.0050).  A similar inconsistency of dextran delivery across 
animals was seen at 0.225 MPa that only 3 out of 5 mice showed significant fluorescence 
enhancement in the targeted ROI.  Thus, no sufficient statistical difference (P>0.16) could be 
obtained to unequivocally show BBB opening at pressures below 0.30 MPa (Fig. 3.14B).  The 
detectable fluorescence signal was predominately contained within vessels at 0.30 MPa but more 
diffusely distributed throughout the targeted region at 0.45 MPa, indicating a more homogenous 
distribution of dextran molecules (Figs. 3.15H and 3.15I).  At 0.60 MPa, heterogeneous spots of 
particularly high levels of fluorescence in combination with diffusely distributed fluorescence was 




Figure 3.14. Normalized fluorescence enhancement between the targeted and the control 
hippocampi using either nanodroplets (A) or microbubbles (B) to mediate BBB opening at 
distinct sonication pressures.  The normalized fluorescence enhancement with pressure followed 
a linear relationship with correlation coefficient R2 being 0.76 and 0.94 for nanodroplets and 
microbubbles, respectively.  Significant dextran delivery was observed at pressures higher than 
0.45 MPa using nanodroplets while the BBB opening threshold was decreased down to 0.30 MPa 
when microbubbles were administered.  All numbers are reported as mean ± standard deviation.  
(ns: not significant; *: P<0.05; **: P<0.01; ***: P<0.001) 
 
 
Figure 3.15. Representative fluorescence images comparing the targeted and the control 
(insets) hippocampi when nanodroplets (top) or microbubbles (bottom) were used to mediate 
BBB opening at various sonication pressures.  The left hippocampus was sonicated in the 
presence of either nanodroplets or microbubbles and fluorescently-labeled 3-kDa dextran.  
Sonications were achieved at distinct peak-rarefactional pressures: 0.15 MPa (A&F), 0.225 MPa 




For each acoustic pressure, microbubbles produced greater fluorescence enhancement 
compared to nanodroplets.  The normalized fluorescence enhancement with pressure amplitude 
followed a linear relationship with correlation coefficients at 0.76 and 0.94 for nanodroplets and 
microbubbles, respectively.  The pressure threshold, at which significant fluorescence 
enhancement was detected in comparison to the sham animals, was higher for the nanodroplets 
(0.60 MPa) than that for the microbubbles (0.30 MPa), although the percent enhancement values 
at the threshold pressures were not statistically different (P=0.56). 
 
3.3.3.3   PCD monitoring to assess drug delivery 
Fig. 3.16 shows the quantitative acoustic emission results detected before and after the contrast 
agent administrations at various sonication pressures.  For nanodroplets, the quantified SCD 
showed significant increase (P<0.0001) at 0.60 MPa (Fig. 3.16A), corresponding to the significant 
dextran delivery detected based on fluorescence microscopy.  However, no statistical difference 
was determined at 0.45 MPa (P=0.21) despite a 90% mean signal increase after nanodroplet 
administration owing to the large variations among different mice.  The SCD increase followed a 
linear relationship with the sonication pressure (R2=0.99).  The quantified ICD, on the other hand, 
showed no detectable inertial cavitation dose across all pressures (Fig. 3.16B), implying that no 
significant vaporized nanodroplet fragmentation was detected during sonication. 
The acoustic emission results for the microbubble group are shown in Figs. 3.16C-D.  
Interestingly, the SCD showed significant increase (P<0.0005) for all pressure levels after 
microbubble injections regardless the outcome of the BBB opening (Fig. 3.16C).  Similar to the 
nanodroplet group, the SCD increase followed a linear correlation with the FUS pressure 
amplitude (R2=0.93).  The ICD measurement showed significant signal increase after microbubble 
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injection at 0.60 MPa (P=0.017) but not at other pressure levels, indicating microbubbles 
underwent inertial cavitation during sonication only at the highest acoustic energy exposure (Fig. 
3.16D). 
 
Figure 3.16. Quantified acoustic emission detected during BBB opening at various sonication 
pressures.  Stable cavitation implied that vaporized nanodroplets or microbubbles underwent 
stable nonlinear oscillation during sonication, while inertial cavitation signified particle 
fragmentation.  Significant SCD increase was detected after nanodroplet injection at the highest 
pressure level (A), but no significant ICD increase was measured (B). On the other hand, 
significant increase of SCD was detected for all pressures after microbubble administration (C), 
and ICD increase was detected at the highest acoustic exposure level (D).  All numbers are reported 
as mean ± standard deviation. (ns: not significant; *: P<0.05; ***: P<0.001) 
  
 In order to test whether acoustic emissions could be used to predict the magnitude of the 
BBB opening, the relative fluorescence enhancement was plotted against the SCD for all 
sonications using each contrast agent (Fig. 3.17).  Both agents showed relatively good linear 
correlations between these two parameters (R2=0.74 for nanodroplets and R2=0.67 for 
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microbubbles).  A cavitation dose opening threshold can also be derived when SCD was grouped 
based on whether significant dextran delivery was detected based on fluorescence enhancement 
[150] (Fig. 3.18).  For the mice sonicated in the presence of nanodroplets, a statistically higher 
(P<0.0001) stable cavitation emission was detected for cases where significant fluorescence 
enhancement was measured.  The highest SCD value, at which no evidence of dextran delivery 
was detected, was 74 V·s.  Out of the 10 animals that showed significant fluorescence increase, 3 
mice (30%) had their SCD lower than 74 V·s, suggesting that this level could be used as the 
threshold for predicting successful FUS-induced BBB opening using nanodroplets as the contrast 
agents. 
 
Figure 3.17. Correlation between differential stable cavitation dose (SCD) and fluorescence 
enhancement.  The SCD was normalized based on the background emission signal measured prior 
to contrast agent injection.  Linear correlations were obtained for both (A) nanodroplets (R2=0.74) 
and (B) microbubbles (R2=0.67). 
 
Interestingly, the acoustic threshold of BBB opening appeared to be contrast agent 
dependent.  For the microbubble group, the highest SCD value, for which no detectable dextran 
delivery was observed, was 1.4 kV·s, significantly higher (P<0.0001) than the SCD threshold 
found for the nanodroplet group.  A much more prominent threshold was held for group #2, for 1 
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out of 15 mice (6.7%) with significant fluorescence enhancement had a SCD lower than 1.4 kV·s.  
Despite the wider range of the calculated SCDs, in which successful BBB opening was detected, 
a statistical difference was obtained (P=0.04) between cases with or without significant dextran 
delivery.  The threshold for predicting FUS-induced BBB opening in the presence of microbubbles 
was therefore concluded to be 1.4 kV·s (Fig. 3.18). 
Figure 3.18. Stable cavitation dose 
(SCD)-indicated BBB opening 
threshold.  The SCD was grouped based 
on whether significant dextran delivery 
was detected.  Each individual brain was 
concluded to have significant BBB 
opening when the difference in 
fluorescence intensity between the 
sonicated and the control hippocampi was 
two standard deviations greater than the 
average value obtained for the 
corresponding sham group.  Sonication 
using microbubbles as the contrast agents 
produced a much wider range of SCD values comparing to when nanodroplets were used.  The 
SCD threshold for predicting BBB opening appeared to be contrast agent dependent.  7 out of 10 
mice showed significant dextran delivery with SCD values greater than 74 V·s using nanodroplets 
while 92.3% of the animals showed significant dextran delivery at SCD above 1.4 kV·s using 
microbubbles.  The slightly weaker threshold for the nanodroplet group indicated secondary 
mechanism other than cavitation could induce the BBB opening.  (*: P<0.05; ***: P<0.001) 
 
3.3.3.4 Safety 
Histological evaluation was performed in order to assess for potential tissue damage caused by the 
procedure.  Fig. 3.19 shows the bright-field microscopic images taken of representative brain 
samples at 0.45 and 0.60 MPa.  These two pressure amplitudes were chosen since relatively 
consistent BBB opening was detected only at these pressure levels for both nanodroplet and 
microbubble groups.  Close examinations did not reveal any discrete damage sites, such as clusters 
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of dark neurons, small erythrocyte extravasations, hemorrhage or microvacuolations at 0.45 MPa 
for either the nanodroplet or the microbubble group (Fig. 3.19 top).  A few (<10) dark neurons 
were identified from 3 nonadjacent sections of the representative brain sample that was sonicated 
at 0.30 MPa using nanodroplets.  No other tissue damage indicators were observed, indicating that 
this could be an artifact due to inadequate perfusion-fixation [151].  However, small clusters of 
extravasated erythrocytes in addition to a few dark neurons were observed for a sample from the 
microbubble/0.60 MPa cohort (Fig. 3.19O).  Less than 10 clusters were found throughout the 
sonicated region across all sections, indicating minor tissue damage.  The larger portion of the 




Figure 3.19. Representative histological images of the targeted and control hippocampi.  The 
animals were sacrificed 1 h after sonication.  (Left) No erythrocyte extravasations, dark neurons, 
gross hemorrhage or microvacuolations were observed when nanodroplets were used to mediate 
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BBB opening at either 0.45 MPa or 0.60 MPa.  (Right) When microbubbles were used, erythrocyte 
extravasations or dark neurons were not seen at 0.45 MPa.  However, small clusters of erythrocyte 
extravasations and a few dark neurons were observed (arrow heads in O), indicating minor damage, 
after sonication at 0.60 MPa. The boxed regions in all 4x images are further zoomed into 10x.  The 
scale bars in A and C depict 1 mm and 100 µm, respectively. 
 
3.3.4   Efficient drug delivery using highly-volatile nanodroplets 
The number of animals in each cohort is summarized in Table 3.5. 
Table 3.5. Summary of the experimental groups. 
Group Mediators 
Number of mice per experimental condition 
 
Sham 
Acoustic pressure (kPa) 
 
150 300 450 750 900 
 
1 OFP droplets 4 3 7* 8* - - 
 
2 DFB droplets - - - - 4 7* 
 
3 Microbubbles - - - 5 - -  
* Number shown including 3 mice per experimental condition used for histological examination. 
 
3.3.4.1   Nanodroplet vaporization efficiency 
Three different vials of each type of droplets were taken for measuring the size distribution and 
the concentration (Fig. 3.4B). The mean, median, and mode size of the OFP droplets were 171.2 
nm, 153.3 nm, and 109.1 nm, respectively; those for the DFB droplets were 182.5 nm, 145.1 nm, 
and 163.4 nm, respectively. The average concentration for OFP droplets was 2.8×1011 particles/mL, 
and 1.3×1011 particles/mL for DFB droplets. The droplet distributions were polydisperse since 
they were condensed from polydisperse microbubbles. 
In order to investigate the acoustic vaporization threshold and the relative vaporization 
efficiency for the droplets, the high speed camera with optical microscopy was used with a focused 
transducer exciting at the same excitation frequency and pressure as for the in vivo experiments. 
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As shown in the images before and after sonication (Fig. 3.20A-B), OFP droplets vaporized to 
microbubbles at pressures of 300 kPa and above, while DFB droplets required higher pressures for 
vaporization (600 kPa and above). On the other hand, the number of bubbles been vaporized were 
counted for estimating the nanodroplet vaporization efficiency. For OFP droplets, an average of 
11±7 (mean ± standard deviation) bubbles were generated in the microscope field of view at 300 
kPa. This was nearly doubled (25±7 bubbles) when the pressure was increased to 450 kPa. 
Qualitatively, we observed more bubbles being generated at even higher pressures (600-900 kPa) 
for OFP droplets. However, the number of bubbles formed from DFB droplets was lower, although 
the bubble size could be larger (>10 µm). On average, 0.4±0.7, 3±2, and 2±1 bubbles were 
generated at 600, 750, and 900 kPa, respectively. After normalizing with the nanodroplet 
concentration, the vaporization efficiency (number of bubbles formed in the microscope field of 
view divided by the concentration/1011) was found to be higher for OFP droplets than for DFB 
droplets as shown in Fig. 3.20C. 
Through in vitro experimentation, it was confirmed that more microbubbles were generated 
from OFP droplets compared to DFB droplets when using the relevant acoustic pressures for the 
same dilution factor. Therefore, OFP droplets were deemed as more efficient acoustic mediators. 
We hypothesized that a lower dose of OFP droplets (1/4 volume of the DFB droplets) would be 





Figure 3.20.  Detection of acoustic droplet vaporization using high-speed optical microscopy. 
(A) OFP-filled droplets were found to vaporize at pressures at and above 300 kPa, but not at 150 
kPa. (B) DFB droplets were found to vaporize inconsistently at 600 kPa (vaporization did not 
occur with every activation pulse). Vaporization was consistently observed at 750 kPa and 900 kPa 
for DFB droplets. On average, more bubbles were generated from OFP droplets at low pressures 
(300-450 kPa) compared to those generated from DFB droplets at higher pressures (750-900 kPa). 
Scale bar represents 10 μm. (C) The vaporization efficiency defined as the number of bubbles 
formed in the field of view after normalized by the nanodroplets concentration was calculated. The 
vaporization efficiency of OFP droplets was higher than that of DFB droplets.  
 
3.3.4.2   Delivery of large molecules 
The in vivo drug delivery outcomes (40 kDa dextran) after BBB opening were quantified with 
fluorescence microscopy comparing the fluorescence enhancement in the sonicated hippocampus 
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to the contralateral side (Fig. 3.21). With the OFP droplets, successful delivery was found to be at 
300 kPa (75%, 3 out of 4 mice)(Fig. 3.21A) and 450 kPa (100%, 5 out of 5 mice)(Fig. 3.21B), and 
no delivery for the 150 kPa group (0 out of 3 mice). Similar to OFP droplets at 450 kPa, 100% of 
successful delivery (5 out of 5 mice) was achieved using microbubbles at 450 kPa (Fig. 3.21C). 
For the DFB droplets, successful delivery was found to be at 900 kPa (100%, 4 out of 4 mice) (Fig. 
3.21D), whereas no delivery was detected at 750 kPa (0 out of 4 mice). As shown in the stacked 
images, the 40-kDa dextran was delivered locally over the entire sonicated hippocampi for both 
OFP droplets at 450 kPa (Fig. 3.21E), microbubbles at 450 kPa (Fig. 3.21F), and DFB droplets at 
900 kPa (Fig. 3.21G), with the opening area similar to the FUS focal size (1.3 mm laterally and 
10.6 mm axially).  
The quantitative results showed similar results for OFP droplets at 300 kPa to DFB droplets 
at 900 kPa (p>0.05), and for OFP droplets to microbubbles at 450 kPa (p>0.05) in both the area of 
BBB opening (Fig. 3.21H) and the fluorescence intensity increase (Fig. 3.21I). Thus, the pressure 
required for same amount of delivery using OFP droplets was 2-3 times lower than that using 
higher dosage of DFB droplets, which corresponded to the vaporization measurement detected in 
vitro. Furthermore, OFP droplets could achieve the same delivery outcomes as the microbubbles 




Figure 3.21.  Delivery efficiency (40 kDa dextran) using fluorescence microscopy after BBB 
opening. Fluorescence images of sonicated vs. non-sonicated hippocampi (insets) using (A) OFP 
droplets at 300 kPa, (B) OFP droplets at 450 kPa, (C) microbubbles at 450 kPa, and (D) DFB 
droplets at 900 kPa. The stacked slices showed localized delivery across the entire sonicated 
hippocampi for (E) OFP droplets at 450 kPa, (F) microbubbles at 450 kPa, and (G) DFB droplets 
at 900 kPa. (H) The mean BBB opening area (normalized to the entire hippocampus) and (I) mean 
fluorescence intensity increase for all cohorts, with a dash line representing the threshold of 
successful delivery defined by the sham group (mean plus 2 time of the standard deviation). 
Successful delivery was found to be at and above 300 kPa for OFP droplets, and 900 kPa for DFB 
droplets.  
 
3.3.4.3   PCD monitoring to assess drug delivery  
Transcranial cavitation monitoring was performed in all experiments in order to investigate the 
behavior of droplet vaporization and cavitation determining drug delivery and safety. 
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Representative monitoring findings from the six cohorts were shown in Fig. 4 after nanodroplets 
or microbubble injection. The left panel represented the temporal variation of frequency spectra in 
the beginning 0.3 ms of the first pulse, and the right panel showed the evolution of the stable (SCDh 
with harmonics and SCDu with ultraharmonics) and inertial (ICD) cavitation level during the entire 
sonication. In the cases with significant dextran delivery (Fig. 3.22B, C, D, F for OFP at 300 kPa, 
OFP at 450 kPa, microbubbles at 450 kPa, and DFB at 900 kPa, respectively), the cavitation events 
for SCDu, and ICD were significantly more frequent with higher intensity compared to the cases 
without delivery (Fig. 3.22A, E for OFP at 150 kPa and DFB at 750 kPa, respectively).  
 
Figure 3.22.  Passive cavitation detection during the sonication for BBB opening, with the 
cavitation evolution within a pulse (spectrograms) and within the whole sonication duration 
(cavitation level for stable cavitation dose SCDh, SCDu, and inertial cavitation dose ICD) shown 
on the left panel and the right panel, respectively. (A) OFB droplets at 150 kPa without delivery. 
(B) OFP droplets at 300 kPa with delivery. (C) OFP droplets at 450 kPa with delivery. (D) 
Microbubbles at 450 kPa with delivery. (E) DFB droplets at 750 kPa without delivery. (F) DFB 
droplets at 900 kPa with successful delivery. Strong and abundant cavitation events including both 
stable and inertial cavitation were observed in cases with successful delivery (B, C, D, F). 
 
The overall cavitation dose representing the accumulative cavitation intensity for each 
sonication was calculated and shown in Fig. 3.23. For the OFP droplets, the SCDh was significantly 
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higher at pressures with successful dextran delivery; the significantly higher SCDu appeared only 
at the pressure causing higher amount of delivery (450 kPa); whereas the ICD showed no 
significance. Similarly, microbubbles at 450 kPa showed significantly higher SCDh and SCDu with 
insignificant ICD. For DFB droplets, although the SCDh was insignificant due to the low 
volumetric bubble oscillation at high pressures, the SCDu and the ICD showed statistical 
significance at 900 kPa with successful delivery. Interestingly, although the SCDh for 
microbubbles was much higher than that for droplets, the SCDu was at the same level or even 
slightly lower. Since both types of the stable cavitation dose was detectable for OFP droplets, their 
sum (SCDh+u = SCDh + SCDu) was then plotted against the area of BBB opening (Fig. 3.23D) as 
well as the fluorescence intensity increase representing the delivery efficiency (Fig. 3.23E). In both 
of them, good agreement (R2 = 0.74, 0.92) was found in cases of successful delivery, similar to the 
DFB droplets [78]. 
 
Figure 3.23.  Cavitation dose of the entire sonication. (A) SCDh or stable cavitation dose with 
harmonic emissions. (B) SCDu or stable cavitation dose with ultraharmonic emissions. (C) ICD or 
inertial cavitation dose with broadband emissions. (D) The area of BBB opening and (E) the 
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fluorescence intensity increase using OFP droplets was linearly correlated with the total stable 
cavitation dose (SCDu+h = SCDh + SCDu) for the cases with successful delivery. The dash line 
represents the threshold of successful delivery defined by the sham group (mean plus 2 times of 
the standard deviation). 
 
3.3.4.4  Safety 
The histological (H&E) staining was performed in the cohorts with successful delivery (3 mice 
from each group: OFP at 300 kPa, OFP at 450 kPa, DFB at 900 kPa) in order to assess the potential 
tissue damage occurred 1 h after sonication (Fig. 3.24). The results showed no damage, i.e., no red 
blood cell extravasations or dark neurons, using OFP droplets at the pressures leading to successful 
delivery for all the animals (Fig. 3.24A-D). These results indicate a safe and effective drug delivery 
for relatively large molecules that could be achieved using OFP droplets. For DFB droplets at 900 
kPa, 2 out of 3 animals showed no damage while 1 had more dark neurons on the treated 
hippocampus (Fig. 3.24E-F), which was corresponded to the statistically significant inertial 





Figure 3.24.  Safety assessment using histological 
staining (H&E). Sonicated (A, C, E) and nonsonicated 
(B, D, F) hippocampi using OFB at 300 kPa (A, B), 450 
kPa (C, D), and DFB at 900 kPa (E, F).  The results 
showed no damage (erythrocyte extravasations or dark 
neurons) using OFP droplets. For DFB droplets at 900 
kPa, only 1 out of 3 animals showed an increased amount 
of dark neurons on the hippocampi. The scalebar in (A) 
represents 1 mm. 
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3.3.4.5  Extravascular delivery of fluorescently-tagged nanodroplets 
Fluorescently-tagged nanodroplets were used for BBB opening and delivery (Dil OFP, 4 mice), 
and for drug delivery after BBB opening with OFP droplets (OFP + Dil OFP, 4 mice) at 450 kPa. 
As shown in Fig. 3.25, there were slightly more fluorescence enhancement in the sonicated side in 
the OFP+Dil OFP group, while no statistical significance was found. It could be due to the size of 





Figure 3.25.  Extravascular delivery using 
fluorescently tagged nanodroplets. OFP droplets 
were used at 450 kPa. (A) Fluorescent microscopy 
showed low or no delivery on the sonicated side 
compared to the control. (B) The quantified fluorescence 
intensity showed no statistical significance. Therefore, 
higher pressures would be required to delivery 





In this chapter, different types of acoustic agents including lipid-shelled microbubbles and 
nanodroplets were customized for enhanced delivery through BBB opening in mice, and the 
amount of delivery was positively correlated with the cavitation dose given any types of mediators 
used. PCD served as a tool to monitor and to shed light on the physical mechanisms for drug 
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delivery during in vivo BBB opening. For example, C24 microbubbles had stronger stable and 
inertial cavitation intensity that also resulted in higher amount of delivery and the likelihood of 
damage. Drug-loaded microbubbles required bubble disruption for delivery. OFP droplets had 
more persistent stable cavitation at lower pressures that resulted in higher amount of delivery 
without damage. Therefore, PCD could be used with various acoustic agents to assess drug 
delivery and safety.  
 
3.4.1   Microbubble shell physicochemical properties determined the drug delivery efficiency  
Enhanced drug delivery with hydrophobic chain length in lipid-shelled microbubbles could be 
caused by the differences in (i) mechanical properties of the microbubbles, (ii) lipid buildup and 
shedding behavior, and (iii) microbubble persistence. Although the study was performed in FUS-
induced BBB opening, the same concept may be applied to focused ultrasound and microbubble 
mediated drug delivery applications in general.  
First, the difference in microbubble mechanical properties may affect the drug delivery 
efficiency by changing the force applied on the cell membrane through micro-streaming and 
micro-jetting during cavitation. For a lipid-shelled microbubble with longer hydrophobic chain 
length, the surface shear viscosity and surface yield shear were both higher, meaning that the shell 
became more rigid as the resistance to the shear deformation increased [97]. Besides, the 
microbubble stiffness may vary by adjusting the shell composition. As reported by Chen et al. 
using atomic force microscopy [100], the stiffness of C18 microbubbles in 4-5 µm was 15 mN/m, 
and adjustment of the shell composition could affect the overall stiffness [152]. Those differences 
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could result in different shear stress on the cell membrane during cavitation as reported in 
simulation [98, 99].  
Second, lipid buildup and shedding for microbubbles with longer hydrophobic chain length 
during cavitation could influence the process of drug delivery. Using high-speed microscopy, 
Borden et al. showed that microbubbles coated with longer hydrophobic chains had more cohesive 
shells and thus showed a higher probability of lipid buildup on their shells during sonication [93]. 
Therefore, it was possible that C18 and C24 microbubbles underwent a significant increase of the 
surface area through lipid buildup that has led to an increased contact area with the capillary 
endothelium during insonification. This induced higher shear stress along the vessel walls that may 
have led to more efficient drug delivery than with C16 microbubbles. In addition, the potentially 
increased shear stress could also explain the increased likelihood of minor petechial erythrocyte 
extravasation observed based on histological examination (Fig. 3B). On the other hand, although 
microbubbles with shorter hydrophobic chains had lower delivery efficiency, their lipid shedding 
mechanism may benefit the drug delivery applications using drug-loaded microbubbles [153-155]. 
C16 and C18 microbubbles with less cohesive shells could experience quasi-continuous to discrete 
phases of excessive lipid shedding and are capable of generating new micron-scale or smaller lipid 
vesicles [92, 93]. This mechanism has been used for multimodality imaging by converting 
microbubbles to nanoparticles after applying ultrasound [156]. Those small vesicles if carrying 
drugs could potentially be delivered to the cell as drug-loaded nanobubbles [157, 158]. 
Third, higher persistence for microbubbles with longer hydrophobic chain lengths during 
cavitation and circulation in vivo may enhance the drug delivery efficiency as well. It was reported 
that longer-acyl-chain (C18 or C24) microbubbles had higher resistance to natural gas permeation 
[92], acoustic dissolution and monolayer collapse due to the increased intermolecular cohesiveness 
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of the shell [93-95]. Therefore, it is plausible to assume that the increased monolayer stability for 
microbubbles coated with longer acyl chains could prolong the in vivo microbubble persistence 
during circulation and insonification, which could ultimately lead to increased dextran delivery. 
Even though Garg et al. showed that a hydrophobic mismatch could reduce the circulation time of 
DLiPC:DSPE-PEG5000 microbubbles [159], we did not observe any significant decrease in 
persistence of our C24 microbubbles based on the cavitation signal acquired during sonication 
when compared to C16 or C18 microbubbles. We attribute the discrepancies between these two 
studies to the differences in the experimental designs, including microbubble dosage, sonication 
and detection duration, signal detection methods including targeting organs (brain through the 
skull vs. kidney) as well as acoustic pulse sequences (different mechanical indexes, pulse lengths, 
pulse repetition frequencies). 
The observed microbubble shell effect appeared to be molecular size-dependent. Based on 
fluorescence analysis, there was no significantly different delivery amount detected for 3 kDa 
dextran among the various microbubble shells at each pressure (Fig. 3), while a difference was 
obtained at 40 kDa dextran delivery at pressures causing microbubble destruction or inertial 
cavitation (450 kPa and 600 kPa) (Fig. 4 and Fig. 5). This suggests that the microbubble shell 
effects were only dominant if the delivered agent has a size above that threshold, since a large 
amount of small molecules could easily permeate across the BBB in a short time until reaching 
saturation. Moreover, it also indicates that microbubbles of longer hydrophobic chain (C24) could 
be used to enhance the delivery efficiency of large molecules. This is promising since delivering 
large molecules has been shown challenging after BBB opening [60, 114]. 
 
3.4.2   Acoustic energy (by varying pressure and pulse length) modulated the shell effects  
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The shell effects occurred most significantly at pressures causing microbubble destruction or 
inertial cavitation (450 kPa and 600 kPa) (Fig. 4 and Fig. 5) may be due to more lipid buildup that 
cause higher shear stress generated on the cell membrane. The lipid buildup behavior during 
insonification may be dominant at intermediate or high pressures since the bubble oscillation 
amplitude is higher. This is consistent with the previous study using a pressure of 400 kPa or higher 
to observe lipid buildup in the microbubble shell with a high-speed camera [93].  
Increasing the pulse length did not alter the general trend of the microbubble shell effect 
although the difference in fluorescence enhancement between C16 and C18 microbubbles became 
statistically insignificant (Fig. 5). As shown in previous studies, the drug delivery efficiency 
increased with the pulse length until it reached to a plateau [160, 161]. This principle could also 
be applied to microbubbles of various hydrophobic chain lengths. The more significant pulse 
length effect for C24 microbubbles may be due to their higher persistence to dissolution in vivo as 
the delivery efficiency remained significantly higher than others. Our data suggests that the 
increased pulse length could be used to compensate for the microbubble shell effects when the 
hydrophobic chain lengths were close (e.g., C16 and C18). Furthermore, using microbubbles of 
longer hydrophobic chain length in combination with longer pulse length could maximize the 
delivery efficiency for large molecules.  
Overall, it is possible that the shell effects on drug delivery efficiency were dependent on 
the interactions between the acoustic energy and the drug properties, such as molecular size, 
molecular structure (linear vs. globular), and hydrophobicity (water-soluble vs. lipid-soluble). In 
the future, additional systematic and parametric studies could be performed to determine the 
optimal ultrasound and microbubble combination that achieves optimal delivery dose for various 




3.4.3    Acoustic cavitation detection revealed the microbubble shell effects 
Passive cavitation detection (PCD) revealed the possible physical mechanisms behind the 
in vivo microbubble shell effects. PCD offers an indirect way to record the microbubble dynamics 
in vivo both noninvasively and transcranially, in which other methods such as high-speed camera 
or B-mode imaging could hardly achieve. PCD records cavitation signatures including stable and 
inertial cavitation causing micro-streaming and micro-jetting [18]. The quantified SCDh could be 
related to microbubble circulation persistence which is usually measured with B-mode imaging, 
ICD to shock wave or force generated by microbubble collapse, and both SCDh and SCDu (SCDh+u) 
to the shear stress applied on the cell membrane, which were thus used to assess the BBB opening 
outcome (Fig. 8). In these scenarios, the circulation persistence and the strength from microbubble 
collapse for C24 may surpass other microbubbles, thereby delivering more 40kDa dextrans to the 
brain.  
 
3.4.4    Nanodroplets as new acoustic agents for drug delivery to the brain 
The current study utilized acoustically-activated nanodroplets as a new class of contrast agents to 
facilitate targeted drug delivery in the brain after FUS-induced BBB opening in mice.  Though 
similar agents have been used in other therapeutic applications, to the best of our knowledge, this 
is the first study that has explored the benefits of a nanodroplet-based approach to FUS-induced 
BBB opening.  Using fluorescent dextran as a model drug, the extent of the BBB opening was 
quantified and compared between nanodroplets and the conventional contrast agent, i.e., 
microbubbles.  The two agents were compositionally the same – having lipid-encapsulated 
perfluorobutane cores - but the nanodroplet approach afforded taking advantage of the benefits of 
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both the liquid and gaseous state of the cores.  The acoustic emission generated from the contrast 
agents during sonication was recorded and analyzed in order to gain insights to their cavitation 
characteristics.  A linear correlation between BBB permeabilization, as indicated by the relative 
fluorescence enhancement within the targeted hippocampus, and the acoustic emission, as 
characterized by the SCD, was found for both nanodroplets (R2 = 0.74) and microbubbles (R2 = 
0.67).  Interestingly, the acoustic threshold, at which significant dextran delivery was observed, 
appeared to be contrast agent dependent.  Our results suggested future contrast agent-specific 
monitoring during FUS-induced BBB opening might be needed. 
The high-speed microscopy results confirmed that the nanodroplet samples were 
acoustically vaporizable at exposure conditions similar to that used during BBB opening in vivo.  
The vaporization pressure threshold detected in vitro corresponded to our in vivo estimation 
remarkably well.  While it was possible that nanodroplet vaporization at pressures lower than 0.45 
MPa could still occur, it was more likely that the number of activated nanodroplets was too low to 
cause any detectable fluorescence enhancement.  Thus, nanodroplet-mediated dextran delivery to 
the targeted hippocampus could not be consistently achieved until the sonication pressure was 
higher than 0.45 MPa.  For the purpose of direct comparison, the droplets used in this study were 
formed from perfluorobutane.  While the pressures used were sufficient to cause some droplet 
vaporization, other studies have shown that highly efficient vaporization at frequencies near 1 
MHz required pressures on the order of 1 MPa or greater [108, 162].  Further studies are needed 
to develop different nanodroplet formulations in order to decrease the in vivo vaporization 
threshold by incorporating more volatile perfluorocarbons, such as perfluoropropane [144].  
Additionally, the not-yet-optimized droplet formulation could also explain the lower fluorescence 
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enhancement observed using nanodroplets than that of microbubbles even though the injection 
amount of the former was much greater. 
 
3.4.5    Improved drug delivery with highly volatile nanodroplets 
Nanodroplets are promising for highly targeted extravascular applications in the brain, while the 
delivery of small molecules to the brain was poor with DFB droplet in the first attempt. Here we 
showed that high amount of delivery for large molecules was achievable by modulating the 
droplet’s sensitivity to acoustic energy. OFP droplets hold high vaporization efficiency at low 
acoustic pressure, and could safely deliver large molecules to the brain with the amount of delivery 
comparable to conventional gaseous microbubbles. They were also safer compared to DFB 
droplets as they can be vaporized and cavitate stably at lower pressures. The excellent correlation 
of drug delivery to the cavitation monitoring also demonstrated high predictability of nanodroplets 
through acoustic cavitation monitoring for safe and effective FUS treatment.  
The droplet’s sensitivity to acoustic energy could be tailored through the PFC core [144] 
and the lipid chain length of the shell [103], that determined the number of bubbles been vaporized 
after applying ultrasound in the body temperature. After microbubble condensation at high 
pressures, the nanodroplets maintain metastable due to the pure superheated fluid to homogeneous 
nucleation [103]. Once experiencing temperature change or acoustic energy deposition, the 
droplets then vaporized to bubbles for contrast enhancement in imaging or cavitation for drug 
delivery or ablation. Due to extremely low boiling point of OFP, the droplets were highly efficient 
to form significantly more bubbles at and above 300 kPa than DFB droplets at 900 kPa. 
Furthermore, the formed OFP bubbles were more stable against dissolution than DFB bubbles, 
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although OFP droplets were more sensitive to the temperature (90% of them vaporized at 40°C 
compared to 75°C for DFB droplets) [103]. Because of these advantages, the OFP droplets could 
achieve tremendously higher amount of delivery for large molecules in vivo even with only one 
fourth dosage of the DFP droplets.  
The in vivo drug delivery outcomes (Fig. 3) were found to associate with the in vitro 
vaporization efficiency (Fig. 2). For OFP droplets, the pressure threshold for successful drug 
delivery was the same as the vaporization threshold (300 kPa), and the drug delivery outcomes 
correlated with the vaporization efficiency. For DFB droplets, low number of bubbles formed 
resulted in no or low delivery. The pressure threshold for successful drug delivery (900 kPa) was 
higher than the vaporization threshold (600 kPa) due to the difficulty in delivering large molecules 
with fewer bubbles. High vaporization efficiency of OFP droplets not only dramatically improved 
the drug delivery outcomes to be comparable to microbubbles. The use of nanodroplets also avoids 
the microbubble shielding effects which reduces spatial specificity of acoustic energy deposition. 
In turn, more focused and effective cavitation leads to more precise cavitation monitoring. A 
similar reason was attributed to the more effective ablation without off-target surface heating 
compared to microbubbles [163]. 
 The acoustic emission during BBB opening (Fig. 4, 5) reflected the behavior of droplet 
vaporization to cavitation associated with drug delivery and safety. A significant stable cavitation 
dose (either SCDh for volumetric oscillation or SCDu for surface oscillation) was detected in 
groups with successful delivery, meaning that cavitation was effective to achieve drug delivery 
due to highly localized and strong shear stress applied on the vessel wall after droplet vaporization. 
Harmonic emission was detected in the cases of the OFP droplets but not for DFB droplets possibly 
because the bubbles were rapidly disrupted after vaporization at high pressures (e.g. 900 kPa). 
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Nevertheless, ultraharmonics were detected for both OFP and DFB droplets since they were less 
affected by the nonlinear effect generating harmonics from the skull or tissue. Interestingly, 
stronger ultraharmonics were found in droplets with 100% successful delivery (OFP droplets at 
450 kPa and DFP droplets at 900 kPa) compared to microbubbles. This implied that irregular 
oscillation with bubbles after nanodroplet vaporization were effective in increasing BBB 
permeability, and may be due to the larger bubbles were more compliant and more prone to 
irregular oscillation than the small bubbles [100].   
Safety can be assessed by inertial cavitation with droplets, similar to what has been reported 
with microbubbles [76]. Significant inertial cavitation occurred at 900 kPa for DFB droplets 
demonstrated that the bubbles were disrupted right after droplet vaporization, and these strong 
shock waves and microjets may cause damage (Fig. 6). On the other hand, OFP droplets did not 
cause any damage since the bubbles were mainly undergoing stable cavitation at 300-450 kPa after 
vaporization, as demonstrated by insignificant broadband emission (ICD). Therefore, for 
delivering large molecules, OFP droplets were safer than DFB droplets due to the OFP 
vaporization threshold falling in the regime of stable cavitation. Nevertheless, the benefits of low 
vaporization threshold and high vaporization efficiency with lower dosage of OFP droplets 
demonstrated a safer, more effective, and more predictable drug delivery over microbubbles and 
DFB droplets. 
The restriction to use highly-efficient nanodroplets is the care of spontaneous vaporization 
due to the nature of highly volatile OFP. This spontaneous vaporization may occur at higher 
temperature (> 4 ⁰C) once been thawed, with a speedily temperature change such as been taken 
out from -80 ⁰C freezer to be thawed in the room temperature (as comparison to be thawed in the 
4⁰C fridge), or even during injection to the bloodstream. Therefore, low OFP droplet concentration 
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should be chosen in order to avoid embolism from spontaneous vaporization upon injection, and 
handled speedily with care because of their lower stability in room temperature (10 min. for OFP 
droplets vs. 1 h for DFB droplets [144]). Although the spontaneous vaporization was observed in 
the in vitro experiment, its effect on drug delivery in this study may be insignificant with the 
current dosage, as the SCDh is sensitive especially at lower pressures with microbubbles was 
insignificant with OFP droplets at 150 kPa and remained low at 300 kPa.  
Future applications for utilizing nanodroplets for drug delivery to the brain could be based 
on the characteristics of smaller size and the ability to encapsulate drugs. Owing to the small size, 
the nanodroplets could possibly enter the parenchyma after BBB opening or through intranasal 
delivery [147]. Their presence in the brain parenchyma could enhance drug delivery through 
sonoporation, or facilitate thermal ablation or occlusion therapy for droplets accumulated in tumors 
or other tissues in the brain. Moreover, nanodroplets could serve as drug carrier for targeted 




The entire sonication for BBB opening was monitored using passive acoustic cavitation detection 
(PCD) in order to shed light on the physical mechanisms behind cavitation with microbubbles and 
nanodroplets in mice. Modification of microbubble’s shell properties and droplet’s vaporization 
efficiency could significantly affect the outcomes of drug delivery. Furthermore, acoustic 
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cavitation detection showed a good correlation between the delivery efficiency and tissue damage 
using various acoustic agents in this chapter.  
First, the effects of the microbubble shell physicochemical properties on drug delivery 
efficiency using ultrasound have been characterized using microbubbles of three phospholipids 
with increasing hydrophobic chain lengths (C16, C18, C24) for drug delivery to the brain through 
BBB opening. The entire process was monitored using passive acoustic cavitation detection (PCD) 
in order to shed light on the physical mechanisms behind the shell effects. The dependence on both 
the molecular size and acoustic energy (by varying pressure and pulse length) were studied. We 
showed that relatively small changes in lipid hydrophobic chain length resulted in a significant 
increase for large (40 kDa) but not for small (3 kDa) dextran delivery, and the acoustic energy 
modulated the shell effects on the delivery efficiency. The C24 microbubble was deemed to be the 
most efficient for large-molecule delivery. Acoustic cavitation detection revealed possible 
mechanisms with different shells, and the findings showed a good correlation between the delivery 
efficiency and tissue damage for different shelled microbubbles.  
Second, in the initial feasibility study to explore the utilization of phase-shift nanodroplets 
for targeted drug delivery in the brain with FUS-induced BBB opening, significant dextran 
delivery was achieved in the mouse hippocampus using acoustically-activated nanodroplets at 
clinically relevant pressure amplitudes.  Passive cavitation detection was used in the attempt to 
establish a correlation between the amount of dextran delivered in the brain and the acoustic 
emission recorded during sonication.  Conventional microbubbles with the same lipid shell 
composition and perfluorobutane core as the nanodroplets were also used to compare the efficiency 
of FUS-induced dextran delivery.  It was found that nanodroplets had a higher BBB opening 
pressure threshold but a lower stable cavitation threshold than the microbubbles.  More 
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homogeneous dextran delivery within the targeted hippocampus was achieved using nanodroplets 
without inducing inertial cavitation or compromising safety.  Our results offered a new means of 
developing the FUS-induced BBB opening technology for potential extravascular targeted drug 
delivery in the brain. 
Nanodroplets can also be customized to enhance drug delivery to the brain for 
extravascular interrogation. The findings showed drug delivery outcomes were directly associated 
with the nanodroplet vaporization efficiency, i.e., the number of bubbles formed after vaporization. 
OFP nanodroplets after vaporization could deliver large molecules across the BBB with the 
outcomes comparable to microbubbles. Furthermore, the delivery with OFP nanodroplets was 
safer than with DFB droplets due to the lower vaporization threshold. While the restriction to use 
highly-volatile nanodroplets is the care of spontaneous vaporization, low concentration with slow 
injection could ensure safety. Our results provided information for customizing nanodroplets in 
delivering large molecules to the brain.  
 
3.6 SIGNIFICANCE & CONTRIBUTION 
Cavitation monitoring is the only way to study the physical mechanisms of BBB opening in vivo, 
and the feasibility using it as a tool to investigate the customization of various acoustic agents for 
BBB opening remained unknown. In this chapter, cavitation monitoring for assessing BBB 
opening has been studied with various acoustic agents from conventional microbubbles to phase-
shift nanodroplets in mice, and the customization of the agents includes shell and core modification. 
Our lab built the system to detect cavitation previously. Here, the quantification method for 
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different types of cavitation has been established and both the stable and inertial cavitation dose 
were found to be associated with BBB opening effectiveness and safety using modified 
microbubbles and nanodroplets. This study showed that cavitation monitoring could elicit the 
difference in physical response that affects the BBB opening outcomes in customized acoustic 
agents. Moreover, large molecules were difficult to be delivered were found been able to cross the 
BBB at ease for the first time using microbubbles of long acyl chain and nanodroplets of low 
boiling-point core, owing to the high stable cavitation dose imposing high shear stress on the vessel 
wall.  
The research contribution was shared with many colleagues and collaborators. Cherry 
Chen (PhD, Biomedical Engineering, Columbia University) and Yao-Sheng Tung, (PhD, 
Biomedical Engineering, Columbia University) assisted and mentored the microbubble shell study. 
Cherry Chen performed in part and mentored the nanodroplet study, and Paul Dayton (PhD, 
University of North Carolina) and his team provided the nanodroplets and assisted the in vitro 
experiments. Carlos Sierra Sanchez (PhD, Biomedical Engineering, Columbia University) 
performed the fluorescently-tagged microbubble study. Oluyemi Olumolade (B.A., Biomedical 




Chapter 4   
Acoustic Monitoring to Characterize BBB 
Opening & Drug Delivery in Primates 
 
4.1 INTRODUCTION 
As shown in Chapter 3, transcranial passive cavitation detection (PCD) provides methodology of 
monitoring the treatment. Acoustic cavitation monitoring could potentially serve as an on-line tool 
to assess and control the treatment. While it demonstrated a strong correlation in small animals, its 
translation to primates remains in question due to the thicker skull attenuating cavitation signal for 
monitoring, the anatomically different and highly heterogeneous brain structures with gray, white 
matter and dense vasculature. In this chapter, three objectives were achieved to address the above 
questions. All these new findings are critical in primates and provide essential information for 
clinical applications. 
1) The PCD performance through the primate skull was assessed both in vitro and in vivo. 
We investigated the sensitivity, reliability, and limitations of PCD through primate (macaque and 
human) skulls in vitro. The results were further correlated with the in vivo macaque studies 
including the transcranial PCD calibration. The stable cavitation doses using harmonics (SCDh) 
and ultraharmonics (SCDu), the inertial cavitation dose (ICD), and the cavitation signal-to-noise 
ratio (SNR) were quantified based on the PCD signals.  
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2) Real-time cavitation monitoring during BBB opening in primates was developed in order 
to determine how the cavitation activity was correlated with the BBB opening volume, the amount 
of model drug (gadolinium) delivered through the barrier and its delivery efficiency in NHP. All 
types of cavitation doses (SCDh, SCDu, and ICD) and the frequency spectra can be monitored in 
real time to ensure treatment effectiveness. They were used to investigate the inter- and intra-
animal variability in BBB opening. This study aimed at determining how cavitation activity can 
be reliably monitored through the primate skull, and how it is correlated with the amount and 
concentration of gadolinium delivered through the BBB and its associated delivery efficiency as 
well as the BBB opening volume in non-human primates. 
3) The heterogeneous brain effects on PCD monitoring were investigated, including gray 
and white matter and vasculature. The finding entails the effect of heterogeneous brain anatomy 
and vasculature of a primate brain, i.e., presence of large cerebral vessels, gray and white matter 
will also affect the cavitation activity associated with variation of BBB opening in different tissue 
types, which is not seen in small animals. 
  In achieving the first objective, both in vitro macaque and human skull experiments as well 
as in vivo skull effects and real-time monitoring in BBB opening of macaques were performed in 
this study. Three types of cavitation doses and the cavitation SNR were quantified and used to 
address the characteristics of cavitation, skull attenuation, and detection limit. The stable cavitation 
dose (SCD) representing the overall extent of stable cavitation is defined as the cumulative 
harmonic or ultraharmonic emission. The inertial cavitation dose (ICD) represents the overall extent 
of inertial cavitation, and is defined as the cumulative broadband acoustic emission [164]. The 
cavitation SNR is defined as the ratio of the post- to pre-microbubble administration cavitation 
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doses. The quantification of cavitation dose and SNR in this study is based on the detected signals, 
emitted by acoustic cavitation. 
For objective 2 and 3, real-time transcranial cavitation monitoring of the stable and inertial 
cavitation doses was performed in four macaque monkeys during BBB opening through 
stereotactic targeting. For the quantitative analysis of BBB opening volume and drug delivery 
efficiency, T1-weighted (T1w) imaging and variable flip-angle (VFA) T1 mapping in magnetic 
resonance imaging (MRI) were performed 1 h following BBB opening. These opening outcomes 
were then correlated with the acquired acoustic monitoring findings in order to assess the PCD 
predictability value among animals. The effect of gray and white matter on BBB opening and 
cavitation was analyzed after tissue segmentation. The vasculature effect on cavitation monitoring 
was evaluated by targeting a region proximal to the medial cerebral artery (MCA) with a 
monotonically increasing pressure for PCD calibration. The effect of the incidence angle with 
respect to the skull on cavitation monitoring was evaluated by varying the targeting angle with 
PCD calibration as well. 
 
4.2 METHODS 
4.2.1   Ultrasound System  
A single-element FUS transducer (H-107, Sonic Concepts, WA, USA) operated at 0.5 MHz with a 
-6-dB focal width by length equals to 5.85 mm by 34 mm and a geometric focal depth of 62.6 mm 
was used for sonication. A spherically focused, flat-band hydrophone made of polyvinylidene 
fluoride (PVDF) (Y-107, Sonic Concepts, WA, USA; sensitivity: 10 kHz to 15 MHz; mean absolute 
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characterization in 1.25 MHz to 5 MHz: 32.5 dB Volts/MPa) was coaxially and confocally aligned 
with the transducer and served as the passive cavitation detector. A PC work station (model T7600, 
Dell) with a customized program in MATLAB® (Mathworks, MA, USA) was developed to 
automatically control the sonication through a function generator (model 33220A, Agilent 
Technologies, CA, USA) followed by a 50-dB amplifier (A075, ENI, NY, USA). The PCD signal 
acquisition was performed at a 14-bit analog-to-digital converter (Gage Applied Technologies, QC, 
Canada) (sampling rate: 100 MHz and 50 MHz in vitro and in vivo, respectively). A 20-dB 
amplification was applied throughout the macaque experiments, while 10 dB was applied for the 
human skull due to large reflection. The electronic noise level and variance of the system in 1.25-
5.00 MHz was 1.20 µV and 0.66 µV, respectively. The PCD signals acquired in vivo including the 
frequency spectra and cavitation doses were monitored in real time.  
 
4.2.2 Quantification of Acoustic Cavitation Emission  
The PCD signals, frequency spectra, and spectrograms (8-cycle Chebyshev window, 98% overlap, 
4096-point Fast Fourier Transform) were used to monitor the cavitation using MATLAB®. In order 
to quantify the cavitation level−time derivative of the cavitation dose, the harmonic, ultraharmonic, 
and the broadband signals in the spectra for each pulse were separately filtered. The stable cavitation 
level based on harmonics only (dSCDh) was the root-mean squared amplitude of the harmonic 
signals in a single pulse, with the harmonic signals defined as the maxima in the 20-kHz (-6-dB 
width) range around the harmonic frequency (multiples of the excitation frequency) in the 
frequency spectrum. The stable cavitation level based on ultraharmonics only (dSCDu) was the root-
mean squared amplitude of the ultraharmonic signals in a single pulse, with the ultraharmonic 
signals defined as the maxima in 20 kHz around the ultraharmonic frequency (multiples plus a half 
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of the excitation frequency) in the frequency spectrum. The inertial cavitation level (dICD) was the 
root-mean squared amplitude of the frequency spectrum after excluding the harmonics (360 kHz 
around the harmonic frequency) and ultraharmonics (100 kHz around the ultraharmonic frequency).  
 The cavitation dose for each sonication was the cumulative sum of the cavitation level in 
1.25-5.00 MHz for every pulse. 
𝐶𝑎𝑣𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝑑𝑜𝑠𝑒 (𝐶𝐷) = ∑ 𝑑𝐶𝐷𝑡
𝑡=0−𝑇
= ∑ √𝑆2̅̅ ̅𝑡
𝑡=0−𝑇
 
𝐶𝑎𝑣𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝑆𝑁𝑅 =  20log (𝐶𝐷𝑝𝑜𝑠𝑡 𝐶𝐷𝑝𝑟𝑒⁄ ) 
where 𝑡 is the time for each pulse; 𝑇, the sonication duration; 𝐶𝐷, the cavitation dose (SCDh, SCDu, 
and ICD for harmonics, ultraharmonics, and broadband emissions, respectively); 𝑑𝐶𝐷𝑡 , the 
cavitation level for the pulse at time t (dSCDh, dSCDu, and dICD for harmonics, ultraharmonics, 
and broadband emissions, respectively); √𝑆2̅̅ ̅𝑡  the root-mean squared amplitude of the 
harmonic/ultraharmonic/broadband signals in the frequency spectrum for the pulse at time t; 𝐶𝐷𝑝𝑜𝑠𝑡, 
the post-microbubble administration cavitation dose; 𝐶𝐷𝑝𝑟𝑒, the pre-microbubble administration 
cavitation dose. 
  The frequency range used to quantify the cavitation level was 1.25-5.00 MHz in order to 
cover the strong harmonics, ultraharmonics, and broadband emission, while suppressing the linear 
and nonlinear scattering from the tissue and the skull. Moreover, the acoustic measurement in this 
frequency range is less dependent on the system or FUS frequency used in comparison to using a 
narrow frequency range. The quantification of the SCDh and the SCDu was based on the acoustic 
emissions generated by stable cavitation including harmonics and ultraharmonics, while the ICD 
was based on the broadband emission (after filtering the harmonics and ultraharmonics) emitted 
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from inertial cavitation. The harmonics and ultraharmonics were quantified separately due to the 
large difference of the spectral amplitudes. In addition, their physical mechanisms are assumed to 
be different: the harmonics is the result of volumetric oscillation, while the ultraharmonics and 
subharmonics may relate to the nonspherical bubble oscillation [18, 165]. For ICD quantification, 
the width of the spectral window for the broadband signals was chosen in order to minimize both 
the electronic noise and the increase due to the harmonic peaks (i.e., the window width is large 
enough to minimize the electronic noise by averaging and not to cover the broadening part of 
harmonic peaks). 
The SCD based on subharmonics (SCDs) was excluded in the present study due to the 
intrinsic low-frequency noise. In addition, since the excitation frequency used in this study was 
low, the subharmonics were overlapping with the linear scattering whose amplitude increased even 
more with the scattering of the skull.  
 
4.2.3 In vitro skull experiments 
The desiccated macaque skull was purchased from Skulls Unlimited (Macaca mulatta, OK, USA) 
and sectioned to keep the cranial part (including the frontal bone, the parietal bones, and the 
occipital bone) (Fig. 1). Its average thickness in the ultrasound beam path was 3.09 mm using a 
caliper at five points of the skull lined in a cross below the transducer, and was degassed for 24 h 
prior to the experiment. The desiccated human skull was purchased from The Bone Room (CA, 
USA), and sectioned to keep the frontal and the parietal bones (Fig. 1) with an averaged thickness 
of 4.65 mm using the same measuring method described above. It was degassed for 48 h prior to 
the experiment. The pressures at the focus of the FUS transducer with and without the skulls were 





Figure 4.1. In vitro experimental setup. A focused ultrasound (FUS) transducer was used for 
sonication, while a flat-band hydrophone at the center of the FUS transducer was used for passive 
cavitation detection (PCD). The cranial part of the macaque skull (including frontal bone, parietal 
bones, and occipital bone) was 3.09-mm thick in average of the beam-path region, and the human 
skull (including the frontal and the parietal bones) was 4.65-mm thick. 
 
Table 4.1. Number of in vitro sonications at each pressure. 









No skull 41 49 
Skull 33 46 
Human 
No skull 60 60 
Skull 70 81 
Pulse length effect 
(5000 cycles) 
No skull 20 20 
 
  
The experimental setup is shown in Fig. 4.1 and the number of sonications is summarized in 
Table 4.1. In-house, lipid-shell, monodisperse microbubbles [134] (median diameter: 4-5 µm) were 
diluted to 2×105 bubbles/mL and injected to the 4-mm-in-diameter channel in the acrylamide 
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phantom before and after placing the skull on the phantom. The channel was roughly 45 mm and 
25 mm below the macaque and human skulls, respectively. The PCD with the hydrophone and the 
diagnostic B-mode imaging system (Terason, MA, USA) were separately used to monitor the 
sonication (peak negative pressure (PNP): 50-450 kPa, pulse length: 100 cycles (0.2 ms) and 5000 
cycles (10 ms), pulse repetition frequency (PRF): 10 Hz, duration: 2 s) in order not to interfere the 
PCD. B-mode images of bubble disruption were acquired to ensure the FUS focusing at the channel, 
which was performed through a linear array transducer (10L5, Terason, MA, USA; center 
frequency: 5.1 MHz) placed transversely to the FUS beam. Before each sonication, the 
microbubbles were injected and the old microbubbles were flushed out, which ensured the 
independence between each sonication and experiment. During the experiments for PCD only, the 
microbubbles were constantly replenished at around 0.25 mL/s in order to mimic the replenishment 
of the microbubbles in the brain. 
The in vitro experimental setup was designed to mimic the in vivo conditions in terms of 
targeting through the skull. Specifically, FUS was applied through the parietal bone next to the 
sagittal suture, which corresponding to the position for targeting the thalamus, putamen, and 
caudate nucleus in the present and previous studies [65, 66]. The 4-mm channel was chosen to 
accommodate the area of bubble disruption at the highest pressure (450 kPa). The low microbubble 
concentration was chosen in order to minimize the bubble-bubble interaction (the mean distance 
between bubbles is 58.5 mm) while still capable of being captured for B-mode visualization. The 
sonication parameters (pulse length, PRF, duration) were set based on our previous mouse skull 
study [166], in which no changes in the detection threshold were found. Sonication using 5000-
cycle pulses without the skull in place was also performed in accordance to the in vivo BBB 




4.2.4 In vivo NHP experiments 
In accordance with the National Institutes of Health Guidelines for animal research, all procedures 
for the animal experiments were reviewed and approved by the Institutional Animal Care and Use 
Committee at Columbia University and the New York State Psychiatric Institute. Four male rhesus 
macaques (Macaca mulatta, weight: 7-10 kg, age: 8-20 yo) were used in this study. Each animal 
was sedated with ketamine (5-15 mg/kg in conjunction with 0.04 mg/kg of atropine through 
intramuscular injection) for placement of an endotracheal tube and an intravenous catheter in the 
saphenous vein, and was under anesthesia using 1-2% isoflurane-oxygen mixture with vital signs 
(electrocardiography, heart rate, blood pressure, SpO2, breathing rate, end-tidal CO2) monitored 
during the entire experiments. No animals were euthanized in this study. 
Three separate sets of experiments were performed in non-human primates, i.e., one set for 
the in vivo skull effect, one for the heterogeneous brain effects, and the other for BBB opening. 
The same type of in-house microbubbles was intravenously injected, and the total number of 
microbubbles administered was calculated based on the animal’s weight. For the purpose of BBB 
opening brain, a bolus of microbubbles (2.5×108 bubbles/kg) was injected and the sonication (PNP: 
200-600 kPa, pulse length: 10 ms, PRF: 2 Hz, duration: 2 min) started at the beginning of injection 
(N = 43). In order to study the in vivo skull effect, a bolus of microbubbles (1.25×108 bubbles/kg) 
was injected immediately after the BBB opening sonication (N = 22). 10 s after injection when the 
microbubbles perfused to the brain, a consecutive sonication at ramp-up pressures was started 
(PNP: 50-700 kPa, pulse length: 100 cycles (0.2 ms) or 5000 cycles (10 ms), PRF: 2 Hz, duration: 
10 s). This PCD calibration method was also used to investigate the effects of heterogeneous 
primate brain (N = 31) (a 5-s consecutive sonication at monotonically increasing pressures ranging 
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within 100-600 kPa starting at 10 s after re-injecting half the dose of microbubbles)[70] was 
performed after the regular sonication for BBB opening. The targeted regions were the caudate 
nucleus and putamen using the steretactic targeting technique shown in Fig. 4.2 [69]. 
After the FUS procedure, the animal was transferred to the MRI suite for assessing the 
BBB opening and safety within 1 h. 
 
Figure 4.2. In vivo NHP experimental setup. (A) A focused ultrasound (FUS) transducer was 
used for sonication and a hydrophone coaxially and confocally aligned with the FUS transducer 
served for passive cavitation detection (PCD). (B) Targeting was performed using stereotaxis with 
pre-planning for focusing at the caudate nucleus (left) or putamen (right) based on the preoperative 
MRI scan with a stereotax. 
 
4.2.5 MRI for validating BBB opening and safety 
A 3.0 T MRI system (Achieva, Philips Medical Systems, USA) with an eight-channel head coil 
was used for assessing safety and BBB opening. T1w imaging was used for BBB opening detection 
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and opening volume quantification because of its higher sensitivity, while T1 mapping was for 
quantifying the amount of delivered MR contrast agents and the delivery efficiency. For assessing 
BBB opening, both pre- and post- contrast agent T1-weighted (T1w) images and T1 maps using the 
variable flip-angle (VFA) SPGR method were acquired. The contrast agent used in this study was 
Gd-DTPA-BMA as the model drug (gadodiamide or Gd, molecular weight = 573.66 Da; 
Omniscan®, GE Healthcare, NJ, USA) with the same dosage suggested for patients (0.2 mL/kg or 
0.1 mmol/kg of body weight). Pre- and post-Gd (40 min after injection) T1w images using 3D 
spoiled gradient echo (SPGR) sequence (TR/TE = 8.5/4.8 ms, FA = 8º, SR = 0.97×0.97×1 mm3) 
were acquired for detecting the opening and analyzing the opening volume. For quantitative 
analysis of the Gd concentration and delivery efficiency, pre- and post-Gd (20 min after injection) 
T1 maps were acquired using a series of 3D SPGR sequence with five flip angles (TR/TE = 10/4 
ms, FAs = 5°/10°/15°/20°/35°, SR = 0.89×0.89 mm2, SL = 1 mm). For detecting edema, T2-
weighted (T2w) images were acquired using 3D Turbo Spin Echo sequence (TR/TE = 3000/80 ms, 
flip angle or FA = 90º, resolution = 0.42×0.42×2 mm3). For detecting hemorrhage, susceptibility-
weighted imaging (SWI) was performed (TR/TE = 19/27 ms, FA = 15º, resolution = 0.44×0.44×1 
mm3). Magnetic resonance angiography (MRA) was conducted in order to visualize the size and 
orientation of blood vessels using 3D time-of-flight SPGR sequence (TR/TE = 23/3.4 ms, FA = 
15°, resolution = 0.89×0.89×1 mm3) in a separate 3.0 T scanner (Signa, GE Healthcare, USA) with 
a customized two-channel head coil.   
 
4.2.6 Quantification for BBB Opening volume and delivery efficiency 
The BBB opening volume was quantified using pre- and post-Gd T1w images in Matlab with 
custom-built programs[70]. In brief, both pre- and post-Gd images were first registered to the 
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individual stereotactically-aligned images (IST) with FSL’s FLIRT toolbox[136], computing the 
ratio of post- to pre-Gd images as a measurement of contrast enhancement, which was normalized 
by linear scaling with reference to the unsonicated thalamus and the anterior cerebral artery (ACA) 
as shown in dashed and solid circle in the horizontal slice (Fig. 4.3A), respectively. In order to 
filter out the background contrast enhancement in the cerebral vessels and muscle tissue outside 
the brain for quantifying the BBB opening volume, the brain mask was applied (generated using 
pre-Gd T1w images from the no-FUS sham cohort with FSL’s Brain Extraction Toolbox[137]) and 
the enhancement images of the FUS-/MB- sham cohort for each individual was subtracted from 
the enhancement images (coronal slice in Fig. 4.3A), giving rise to Fig. Fig. 4.3B. Finally, the 
opening volume was calculated by applying a volume of interest (VOI, 10 × 10 × 32.5 mm3) on 
the targeted region (solid box) subtracting the VOI on the contralateral side (dashed box) as shown 
in Fig. 4.3C. The threshold of BBB opening (80 mm3) was defined by the average opening volume 
plus 3 times the standard deviation in the FUS+/MB- sham cohort.  
Similarly, the Gd concentration maps [167, 168] provide quantification of the Gd amount 
that crossed the BBB. The delivery efficiency was calculated using the pre- (Fig. 4.3D) and post-
Gd T1 maps (Fig. 4.3E)[168]. First, the standard line fit method of VFA SPGR[169] was used to 
calculate the pre- and post-T1 maps after registering the 3D SPGR images of various flip angles to 











) ,                                                     (1) 
where [𝐺𝑑]𝑐 is the Gd concentration, 𝑟1 is the relaxivity of the contrast agents (4 s
-1mM-1 for Gd-
DTPA-BMA[170]), 𝑇1 is the post-Gd T1 time, and 𝑇1,0 is the pre-Gd T1 time. Note that in the 
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[𝐺𝑑]𝑐 map (Fig. 2F), the concentrations in the unopened brain tissue (thalamus, dashed circle), 
temporalis muscle (black solid circle), and anterior cerebral vessels (ACA, white solid circle) were 
also calculated and compared with that of the BBB opening area. In order to filter out the [𝐺𝑑]𝑐 in 
the cerebral vessels and muscle tissue outside the brain for quantifying the delivered Gd due to 
BBB opening, the [𝐺𝑑]𝑐 maps (coronal slice in Fig. Fig. 4.3F) were thresholded by setting the 
concentration higher than that in ACA to zero and applying the brain mask, giving rise to Fig. 
4.3G. Finally, the amount of delivered Gd was calculated based on equation (2) by applying a 
volume of interest (VOI, 10 × 10 × 32.5 mm3) on the targeted region (𝑉𝑂𝐼𝑖𝑝𝑠𝑖 , solid box in Fig. 
4.3H) subtracting the VOI on the contralateral side (𝑉𝑂𝐼𝑐𝑜𝑛𝑡𝑟𝑎 , dashed box in Fig. 4.3H) for 
excluding the intrinsic Gd retention: 
[𝐺𝑑]𝐵𝐵𝐵 = (∑ [𝐺𝑑]𝑐𝑉𝑂𝐼𝑖𝑝𝑠𝑖 − ∑ [𝐺𝑑]𝑐𝑉𝑂𝐼𝑐𝑜𝑛𝑡𝑟𝑎 ) ∙ 𝑉,                              (2) 
where [𝐺𝑑]𝐵𝐵𝐵 is the amount of delivered Gd (mole) and 𝑉 is the voxel volume in the T1 map. 
The delivery efficiency was defined as the percentage of the amount of delivered Gd to the total 
amount of injected Gd (estimated to be 1 mmol). 
            The opening volume was separated by the tissue type (i.e., the gray matter, white matter, 
blood, cerebral spinal fluid) segmented based on the T1 time in the pre-Gd T1 map. The T1 time 
for blood is between 1 ms to 700 ms, 700 ms to 1170 ms for white matter, 1170 ms to 1800 ms for 
gray matter, and 1800 ms to 5000 ms for cerebral spinal fluid based on our measurement in the 




Figure 4.3. Pipeline for BBB opening volume quantification and drug delivery analysis based 
on MRI processing. (A) To quantify BBB opening volume, the contrast enhancement map (upper: 
horizontal slice, lower: coronal slice) were used after dividing the post-Gd T1 images by the pre-
Gd images. Then, after applying the brain mask and the vessel mask in order to filter out the 
contrast enhancement outside of the BBB opening area (B), the opening volume was calculated by 
subtracting the VOI in the contralateral area (dashed rectangle) from the targeted area (solid 
rectangle) (C). On the other hand, the pre- Gd T1,0  (D) and post-Gd T1 maps (E) were used to 
quantify the amount of Gd delivered and its delivery efficiency since the Gd shorted the T1 time 
after diffused the BBB opening region (arrowhead). The Gd concentration map (F)(upper: 
horizontal slice, lower: coronal slice) was acquired by calculating the change of T1 time between 
pre- and post-Gd T1 maps. After applying the brain mask and excluding the Gd retention in the 
vessels by thresholding (G), the amount of Gd delivered was calculated by subtracting the VOI in 
the contralateral area (dashed rectangle) from the targeting area (solid rectangle) (H). 
 
4.3 RESULTS 
4.3.1 Performance assessment of transcranial PCD 
4.3.1.1    In vitro skull effects  
Fig. 4.4 shows the PCD spectrograms before and after placing the skull. Before placing the skull, 
the amplitude of harmonics, ultraharmonics as well as the broadband signals increased significantly 
with pressure after microbubble administration (Fig. 4.4B) when compared to the control (Fig. 
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4.4A), in which the second harmonic became significant at and above 150 kPa. The broadband 
signals increased mostly within the range of 3-5 MHz according to the results at 150 kPa and 200 
kPa in Fig. 4.4B. In the case of the macaque skull (Fig. 4.4C), the high frequency components were 
attenuated, while the signals remained detectable at the lowest pressure (50 kPa). In the case of the 
human skull (Fig. 4.4D), the frequency components below 3 MHz were detected only at or above 
150 kPa. The cavitation emissions occurred at 0.05-0.10 ms (the echo arrival time to the focus (62.9 
mm)) after microbubble administration (Fig. 4.4 B-D). 
 
 
Fig. 4.4. In vitro cavitation monitoring: spectrograms. (A) Sonicating water without the skull 
in place. (B) Sonicating microbubbles without the skull in place. (C) Sonicating microbubbles with 
the macaque skull in place. (D) Sonicating microbubbles with the human skull in place. (i), (ii), 
(iii), and (iv) represents 50 kPa, 150 kPa, 200 kPa, and 450 kPa, respectively. The colorbar shows 
the intensity of the spectra, with a dynamic range of 25 dB and 15 dB for the macaque and human 




 B-mode cine-loops were also used to monitor the cavitation separately. Fig. 4.5 shows the 
images of the microbubbles in the channel phantom after sonication. The microbubbles were found 
to dissolve or fragment at or above 200 kPa as evidenced by the loss of echogenicity in the focal 
region in all experimental conditions, i.e., cases without (Fig. 4.5A), with the macaque (Fig. 4.5B) 
and the human (Fig. 4.5C) skull, and using longer pulses without the skull (5000 cycles in Fig. 
4.5D). The mean diameter of the hypoechogenic area at 200 kPa and 450 kPa was 1.3 mm and 4 
mm, respectively.  
 
Figure 4.5. In vitro cavitation monitoring: B-mode images in transverse plane after the 
sonication. (A) Without the skull in place using 100 cycles. (B) With the macaque skull in place 
using 100 cycles. (C) With the human skull in place using 100 cycles. (D) Without the skull in 
place using 5000 cycles. (i), (ii), (iii), and (iv) represents 50 kPa, 150 kPa, 200 kPa, and 450 kPa, 
respectively. The arrows indicate the spot losing echogenicity at the pressure threshold (200 kPa). 
The images showed good focal alignment to the channel and the bubbles lost the property of 
contrast enhancement at or above 200 kPa. The shape to the hypoechogenitic area was roughly a 
circle with an averaged diameter of 1.3 mm at 200 kPa and 4 mm at 450 kPa.  
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Fig. 4.6 shows cavitation doses with and without the skull in place using 100-cycle pulses. In 
the macaque skull experiments (Figs. 4.6A-C), the SCDh, the SCDu, and the ICD without placing 
the skull were significantly higher (p < 0.05) than the control at and above 50 kPa, which also 
increased monotonically with pressure. After placing the macaque skull, the SCDh was detectable 
(p < 0.05) at all pressures, whereas the detection pressure threshold for both the SCDu and the ICD 
increased to 150 kPa. In the human skull experiments (Figs. 4.6D-F), the SCDh was detectable at 
and above 100 kPa after placing the skull. For the SCDu, the detection pressure threshold increased 
to 250 kPa. For the ICD, it became 350 kPa. The SCDh at or above 400 kPa was undetected since 
the control signal with the human skull was strong. While the detection pressure threshold slightly 
changed after placing the macaque and the human skull, the sensitivity of cavitation doses to 
pressure changes remained the same. 
 The pulse length effect on the cavitation dose was also studied. Figs. 4.6G-I show the 
cavitation doses with 100-cycles and 5000-cycle pulse lengths. The SCDh using 100-cycle pulses 
increased monotonically with pressure increase, whereas the SCDh with 5000-cycle pulses reached 
a maximum at 300 kPa and started to decrease at pressures above 300 kPa. Similar to the SCDh, the 
SCDu using 100-cycle pulses increased monotonically with pressure, while the SCDu using 5000-
cycle pulses reached a plateau at 250 kPa and started to decrease at higher pressures. The ICD using 
100-cycle and 5000-cycle pulses both increased monotonically with pressure increase, and the latter 





Figure 4.6. In vitro cavitation doses. (A) SCDh, (B) SCDu, and (C) ICD for the macaque skull 
experiments using 100-cycle pulses. (D) SCDh, (E) SCDu, and (F) ICD for the human skull 
experiments using 100-cycle pulses. (G) SCDh, (H) SCDu, and (I) ICD without the skull in place 
using 100- and 5000-cycle pulses. The error bar shows the standard deviation. *: p<0.05. Green *: 
comparison made in the cases without the skull in place. Red *: comparison made in the cases with 
the skull in place. All of the comparisons in (G)-(I) showed statistical significance. All of the 
cavitation doses became detectable at 50 kPa, while this detectable pressure threshold may change 
after placing the skull. The nonlinear effect of the skull was seen after placing the human skull at 
high pressures as the SCDh increased significantly. Applying long pulses (5000 cycles) was 
effective in generating high cavitation doses at low pressures when compared with applying short 
pulses (100 cycles).  
 
 Fig. 4.7 shows the cavitation SNR, which was used to study the sensitivity of PCD using 
the pulse length, the detection limit, and skull attenuation. Before placing the skull, the cavitation 
SNR for the SCDh, SCDu, and ICD using 100-cycle pulses (Fig. 4.7A) ranged within 28.6-49.1 dB, 
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2.1-38.9 dB, and 3.1-37.0 dB, respectively. Followed by the SCDu and the ICD, the cavitation SNR 
for the SCDh was the highest. The cavitation SNR for the SCDh, SCDu, and ICD using 5000-cycle 
pulses (Fig. 4.7B) ranged within 24.8-54.6 dB, 2.2-54.8 dB, and 2.9-41.9 dB, respectively. Both the 
cavitation SNR for the SCDh, SCDu reached a plateau at 250 kPa, while it increased monotonically 
for the ICD.  
 
Figure 4.7. In vitro cavitation SNR (a) without the skull in place using 100-cycle pulses, (b) 
without the skull in place using 5000-cycle pulses, (c) with the macaque skull in place using 100 
cycles, and (d) with the human skull in place using 100 cycles. The error bar shows the standard 
deviation. The dash lines in (a) represent the SNR threshold for surpassing the skull attenuation 
(macaque: 15.2 dB, human: 34.1 dB). For SNR higher than 1 dB, the detected cavitation doses were 
significantly higher than that of control. This 1 dB was deemed as the detection threshold with and 
without the skull. 
 Figs. 4.7C-D show the cavitation SNR using 100-cycle pulses through the skull. The 
cavitation SNR through the macaque skull (Fig. 4.7C) ranged within 9.7-29.4 dB, 1.6-15.6 dB, and 
1.1-14.1 dB, respectively, corresponding to the statistically significant SCDh, SCDu, and ICD 
through the macaque skull compared to the control (Fig. 4.7A-C). The cavitation SNR through the 
human skull (Fig. 4.7D) ranged within 2.4-6.2 dB, 1.4-3.0 dB, and 1.2-1.9 dB, respectively, 
corresponding to the statistically significant SCDh, SCDu, and ICD through the human skull 
compared to the control (Fig. 4.7D-F). For the cavitation SNR with the skull lower than 1 dB, the 
corresponding cavitation doses failed to reach statistical significance (p < 0.05) compared to the 
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control. This 1 dB was deemed as the detection limit (or SNR limit), meaning that the PCD was 
reliable when the cavitation SNR exceeded 1 dB.  
 As described above, by correlating the cavitation SNR with the skull (Fig. 4.7C-D) to the 
cavitation doses with the skull (Fig. 4.6A-F), it was found that when the cavitation SNR exceeded 
1 dB−defined as the detection limit for PCD−the transcranially acquired cavitation doses were 
statistically significant compared to the control. In order to assess the skull attenuation, the 
cavitation SNR without the skull (Fig. 4.7A) was then compared against the cases with the skull 
surpassing the 1-dB SNR limit (Fig 4.7C-D). It was found that the SNR without the skull should be 
higher than 15.2 dB and 34.1 dB (Fig. 4.7A) in order to be detected through the macaque (Fig. 4.7C) 
and the human skull (Fig. 4.7D), respectively. In other words, for cavitation SNR higher than 15.2 
dB and 34.1 dB without the macaque and human skull, respectively (Fig. 4.7A), the cavitation SNR 
through the skull (Fig. 4.7C-D) would be higher than 1 dB and the corresponding cavitation doses 
with the skull would be significantly higher than those of the control (p < 0.05). The skull 
attenuation was then calculated by dividing by the measured skull thickness: 4.92 dB/mm and 7.33 
dB/mm for the macaque and human, respectively. 
 
Figure 4.8. In vivo cavitation doses using 100- and 5000-cycle pulses. (A) SCDh. (B) SCDu. (C) 
ICD. *: p<0.05. The error bar shows the standard deviation. When using 5000-cycle pulses, the 
SCDh became detectable transcranially at 100 kPa; for the ICD, 250 kPa; while the SCDu was 
unrealiable and could be detected at high pressures. When using 100-cycle pulses, the pressure 
threshold in detecion increased.  
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4.3.1.2    In vivo skull effects  
In vivo skull effects at different pressures and different pulse lengths were studied and compared 
with the in vitro findings. Fig. 4.8 shows the cavitation doses using 100- and 5000-cycle pulses. 
When applying 100-cycle pulses, the SCDh, SCDu, and ICD were significantly higher than the 
control at and/or above 300 kPa, 700 kPa, and 600 kPa, respectively. When applying 5000-cycle 
pulses, the SCDh, SCDu, and ICD were significant compared to the control at pressure lower than 
that for the 100-cycle pulses: at and above 100 kPa, at 200 kPa and 700 kPa, and at and above 250 
kPa, respectively. The cavitation dose when applying 5000-cycle pulses was higher than that with 
100-cycle pulses. In either case, the cavitation doses increased monotonically with pressure. 
Besides, the SCDh using 100-cycle pulses at 450 kPa, the SCDh using 5000-cycle pulses at 150 
kPa, and the ICD using 5000-cycle pulses at 300 kPa showed no significance compared to the 
control (0.05 < p < 0.06) due to their higher variability. 
 
 
Figure 4.9. In vivo cavitation SNR using (A) 100-cycle and (B) 5000-cycle pulses. The error 
bar shows the standard deviation. The cavitation SNR using 100-cycle pulses increased with 
pressure. When using 5000-cycle pulses, the SNR of the SCDu and ICD increased with pressure, 




Fig. 4.9 shows the cavitation SNR for the skull effect using 100- and 5000-cycle pulses. 
When applying 100-cycle pulses (Fig. 4.9A), the cavitation SNR for the statistically significant 
SCDh, SCDu, and ICD compared to the control ranged within 1.2-9.8 dB, 2.3 dB, and 0.7-2.1 dB, 
respectively. It increased monotonically for the SCDh and ICD, whereas it fluctuated for the SCDu. 
When applying 5000-cycle pulses (Fig. 4.9B), the cavitation SNR for the SCDh, SCDu, and ICD 
ranged within 3.8-13.3 dB, 1.4-3.5 dB, and 1.0-6.1 dB, respectively. It reached a plateau for the 
SCDh at 250 kPa and then started to decrease at 400 kPa. In the SCDh case, it fluctuated at low 
pressures and then increased monotonically at and above 400 kPa. In the ICD case, it increased 
monotonically without fluctuating or reaching a plateau. The cavitation SNR at pressures where 
significant cavitation signals were detected compared to the control was above the 1-dB SNR limit, 
with the exception for SCDu (57% of the measurements beyond the detection limit were 
statistically insignificant compared to the control). This result was remarkably consistent with our 
in vitro findings. 
 
4.3.2    Real-time PCD monitoring during BBB opening in NHP 
Real-time PCD monitoring during BBB opening was achieved. Fig. 4.10 shows four cases of PCD 
monitoring and the corresponding opening results in MRI at different pressures. The MRI showed 
BBB opening in two macaques in the thalamus and the putamen at pressures ranging from 250 kPa 
to 600 kPa, with the opening volume of 494.7, 230.9, 112.9, and 299.2 mm3, respectively. The 
volume increased with pressure in the same macaque (Fig. 4.10B-D) in general, and its range 
varied across animals. The dSCDh reached a plateau in 10-30 s after injecting microbubbles and 
was kept at the same level for the rest of sonication duration. The dSCDu remained mostly 
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undetected. The dICD increased by 3.18 dB at 350 kPa and 0.19 dB at 450 kPa as compared the 
end of the sonication to the beginning, while it remained unchanged at 275 kPa and 600 kPa.  
 
 
Figure 4.10. Real-time cavitation monitoring during in vivo BBB opening at (a) 275 kPa, (b) 
350 kPa, (c) 450 kPa, and (d) 600 kPa in the thalamus (orange arrow) or the putamen (green arrow). 
The upper and middle rows show the post-contrast T1 weighted images with calculated 
enhancement (with colorbar) in axial and coronal view, respectively. The opening volume of (a) 
to (d) was 494.7, 230.9, 112.9, and 299.2 mm3, respectively. The bottom row shows the real-time 
monitoring of the SCDh, SCDu, and ICD for sonicating the thalamus. Note that in (d) the 
microbubbles were injected before the sonication was started. Case (b)-(d) were performed in the 
same macaque.  
 
Finally, Fig. 4.11 shows the corresponded safety assessment using T2-weighted MRI and 
SWI corresponding to the four BBB opening cases in Figure 8. No edema or hemorrhage was 
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detected in any of the animals used, corresponded to the PCD monitoring results for which 
minimum or no ICD increase was recorded during sonication. 
 
 
Figure 4.11. Safety assessment using MRI at (a) 275 kPa, (b) 350 kPa, (c) 450 kPa, and (d) 600 
kPa. The upper row shows the T2-weighted images (coronal view) for detecting the edema, which 
is lighter if occurred. The lower row shows the SWI (coronal view) for detecting the hemorrhage, 
which is darker if occurred. In all cases, no hemorrhage and edema was detected. 
 
4.3.2.1    BBB opening reproducibility and variability 
The BBB opening in NHP was achieved with the opening volume and delivery efficiency 
quantified following the pipeline in Fig. 4.3 through pre- and post-contrast (Gd, gadolinium) T1w 
imaging and T1 mapping for Gd concentration ([𝐺𝑑]𝑐) as the Gd, a paramagnetic particle does not 
cross the BBB, perfused the BBB opening region and shortened the relaxation time of the tissue. 
Fig. 4.12 showed representative BBB opening findings in two NHPs with acoustic monitoring of 
the cavitation dose (SCDh: stable cavitation dose with harmonics, SCDu: stable cavitation dose 
with ultraharmonics, ICD: inertial cavitation dose with broadband emission). BBB opening was 
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revealed in both T1w imaging (Fig. 4.12A-B) and the [𝐺𝑑]𝑐 map (Fig. 4.12C-D) in both gray and 
white matter (Fig. 4.12E-F) after a significant increase of SCDh (Fig. 4.12G-H). In NHP 2 (300 
kPa on the right putamen), an opening volume of 298 mm3 was achieved with the highest [𝐺𝑑]𝑐 
in the opening area reached 0.07 mM, and the amount of Gd delivered was 10.7  nmol. The BBB 
opening volume was 393 mm3 in NHP 3 (600 kPa on the left putamen) with the highest [𝐺𝑑]𝑐 
reached 0.06 mM, and the amount of Gd delivered was 8.7 nmol. The [𝐺𝑑]𝑐 was higher in gray 
matter than that in white matter in the BBB opening area. While comparing to the Gd retention of 
the unsonicated tissue (Table 4.2), the [𝐺𝑑]𝑐 at the center of the opening was higher than that in 
the unopened brain parenchyma (0.01-0.02 mM), similar to that of the muscle (0.06-0.07 mM), 
and lower than that of the vessel (0.14-0.15 mM).  
 
 
Figure 4.12. BBB opening with real-time acoustic cavitation monitoring in two NHPs. FUS-
induced BBB opening in NHPs was visualized in T1w images after overlaying the contrast 
enhancement onto the post-Gd T1w image (A-B) (A: NHP 2 at 300 kPa; B: NHP 3 at 600 kPa). 
The corresponded Gd concentration map ([Gd]c) (C-D) showed the variation of Gd delivered in 
gray and white matter according to the tissue segmentation map based on the pre-Gd T1 map (E-
F)(dark gray: gray matter, light gray: white matter, black: blood, white: CSF). The acoustic 
cavitation emission were recorded and calculated in real time. (G-H). The BBB opening of NHP 




Table 4.2. Gd retention in different tissues after Gd injection (without applying FUS) 
 Thalamus (mM) Muscle (mM) ACA* (mM) 
NHP 2 0.017 ± 0.005 0.071 ± 0.008 0.153 ± 0.022 
NHP 3 0.012 ± 0.004 0.060 ± 0.009 0.142 ± 0.014 
 *anterior cerebral artery 
 
Both intra- and inter-animal variation in BBB opening were observed in the quantitative 
results (Fig. 4.13). In repeated sonication in NHP 1 (275 kPa at putamen, Fig. 4.13A) to estimate 
intra-animal variation, the coefficient of variation in the opening volume was 22% (ratio of the 
standard deviation to the mean). Inter-animal variation was observed in the pressure threshold for 
BBB opening after applying an estimate of 50% pressure increase to compensate the skull 
attenuation. As shown in Fig. 4.13B, the pressure threshold for NHP 1 and 2 was lower (250 kPa) 
than that in NHP 3 (350 kPa) with the same range of vital signs during sonication (Supplementary 
Table S1). This discrepancy was also observed in the [𝐺𝑑]𝑐 map analysis performed in NHP 2 and 
NHP 3 (Fig. 4.13C), showing that the amount of Gd delivered and the delivery efficiency in NHP 
2 was higher than that in NHP 3 using the same pressure. This inter-animal variation may be due 
to the difference in skull and tissue attenuation. Nevertheless, an opening volume of 400 mm3 and 




Figure 4.13. Cavitation monitoring in assessing the BBB opening and drug delivery. (A) In 
order to study the intra-animal variation, NHP 1 was sonicated with the same targeting (putamen) 
and acoustic parameters (275 kPa) in a bi-weekly basis five times. FUS-induced BBB opening was 
performed in three NHPs with the opening volume (B), and the drug delivery analysis was 
performed in two NHPs for the amount of Gd delivered and the delivery efficiency (C). NHP 1 to 
NHP 3 were sonicated 7, 12, and 24 times, respectively, and the error bar represents standard 
deviation. Both (B) and (C) showed an inter-animal variation as the BBB opening threshold for 
NHP 1 and 2 were lower than that for NHP 3. Quantified cavitation doses (SCDh: stable cavitation 
dose with harmonics, SCDu: stable cavitation dose with ultraharmonics, ICD: inertial cavitation 
dose) were correlated with the BBB opening outcomes. The SCDh can be used to detect the 
effectiveness of BBB opening (D). For a quantitative assessment, the opening volume (E), the 
amount of delivered Gd and delivery efficiency (F) was positively correlated with the total 
cavitation dose (SCDh + SCDu + ICD). (The R
2 of the linear fitting in (E) for NHP 1 to 3 and all 
experiments across animals was 0.81, 0.63, 0.50, and 0.47, respectively; that in (F) for NHP 2, 3, 
and all experiments across animals was 0.52, 0.71, and 0.61, respectively.)  
 
4.3.2.2    Cavitation monitoring characterizing BBB opening 
Cavitation monitoring characterized BBB opening without significant intra- and inter-animal 
variation, and could be used to predict BBB opening volume, amount of delivered Gd and its 
delivery efficiency. The cavitation monitoring was positively correlated with the BBB opening 
volume given the intra-animal variation (Fig. 4.13A), suggesting the possibility of using cavitation 
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monitoring as a feed-back loop to control the FUS treatment in NHPs. Moreover, the SCDh 
(sensitive to bubble activity at low pressures) was found to be an indicator of the effectiveness of 
the FUS procedure among animals (Fig. 4.13D, p < 0.01). The total cavitation doses (SCDh + SCDu 
+ ICD) was positively and linearly correlated with the opening volume (Fig. 4.13E, R2 = 0.47), 
amount of delivered Gd and delivery efficiency (Fig. 4.13F, R2 = 0.61), and could serve as a 
surrogate for MRI-based treatment evaluation. No significant difference was found among animals, 
while the R2 of each individual varied. The total cavitation doses was adopted since it best 
correlated with the opening outcomes as the SCDh and SCDu may reach a plateau at high pressures 
while the ICD was detected[70]. Transcranial cavitation monitoring showed insignificant intra-
animal variation may be because the recorded cavitation signal reflected the in situ pressure after 
attenuation. 
 
4.3.3    Effect of brain heterogeneity  
4.3.3.1    Gray and white matter 
The effect of brain heterogeneity on BBB opening, drug delivery, and cavitation monitoring was 
separated into two parts: the effect of gray and white matter, and the effect of large vessels. In 
studying the effect of gray and white matter (Fig. 4.14), three animals were sonicated at the caudate 
nucleus and putamen at pressures causing a BBB opening volume of 400 mm3 (300 kPa for NHP 
2, and 450 kPa for NHP 3 and 4 due to the inter-animal variation). The opening volume in the 
caudate nucleus was the same or slightly smaller than that in the putamen in the same animal 
without statistical significance (Fig. 4.14A), and the cavitation response revealed the same trend 
(Fig. 4.14B). Although the gray-and-white matter composition in the sonicated area was about 1:1 
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(Fig. 4.14C), the gray matter contributed 68.8% of the BBB opening in comparison to 21.4% for 
the white matter (Fig. 4.14D), meaning that the gray matter had the probability of BBB opening 
three times higher than that of the white matter. In order to investigate the capability of cavitation 
monitoring on the gray and white matter, their opening volume were delineated for correlating 
with the total cavitation dose. As shown in Fig. 4.14E, a better correlation of cavitation dose to the 
total opening volume was found (R2 = 0.51, p < 0.001) compared with the volume of gray matter 
only (R2 = 0.15, p = 0.05), suggesting that the cavitation was detected in both the gray and white 
matter and caused BBB opening in both. 
 
 
Figure 4.14. Effect of gray and white matter. FUS was applied in the caudate and putamen in 
three animals causing a BBB opening volume close to 400 mm3 (300 kPa for NHP 2, 450 kPa for 
NHP 3 and 4). The opening volume was shown in (A), and the total cavitation dose in (B). Based 
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on the tissue segmentation, the gray-and-white matter composition in the sonicated area (C) and 
in the BBB opening area (D) were calculated. The correlation of total cavitation dose to the BBB 
opening volume was calculated in (E), in which it was better correlated with the total opening 
volume than with the volume in gray matter. 
 
4.3.3.2    Vasculature 
The effect of the large vessel (diameter ≥ 1 mm) in the BBB opening and cavitation 
monitoring were investigated by targeting a region (putamen) close or including the middle 
cerebral artery (MCA) in NHP 4. As shown in the MRA (Fig. 4.15A-C), the NHP brain is rich in 
cerebral blood vessels of different sizes. When applying FUS at 450 kPa, the BBB opening was 
found to be successful regardless of the distance to MCA in the four cases in Fig. 5D (opening 
volume: 309, 469, 443, and 758 mm3 and angle of incidence to the skull: 24°, 18°, 35°, 41° for 
case i to iv, respectively). However, the cavitation response was significantly enhanced as the 
focus drew closer to the MCA. Interestingly, the spontaneous SCDu and ICD were found to be 
reliably detected when targeting a region including MCA, and a periodicity of the cavitation level 
was similar to the breathing rate in certain cases where large vessels were in the focus. This 
increased cavitation response was also observed in the PCD calibration assessing the cavitation 
level (the cavitation dose of one single pulse) at different pressures (Fig. 4.15E-G) after the BBB 
opening in Fig. 4.15D. The ICD increased monotonically with pressure (Fig. 4.15G) while the 
SCDh (Fig. 4.15E) and SCDu (Fig. 4.15F) increased until a plateau was reached at higher pressures. 
Furthermore, although the opening volume in cases ii and iii were similar, the cavitation level of 
SCDh, SCDu, and ICD in the PCD calibration followed a different variation. The SCDh was slightly 
lower at pressures above 300 kPa while the SCDu and ICD were higher in case iii (MCA in the 




Figure 4.15. Vasculature effect. MR angiography (MRA) in NHP in (A) coronal, (B) sagittal, 
and (C) horizontal view, and the middle cerebral artery (MCA) was indicated by an arrowhead. 
(D) Four BBB opening cases targeting regions proximal to the MCA (arrowhead) at 450 kPa in 
NHP 4, where the upper row showed the opening volume overlaying onto the post-Gd T1w images 
and the lower row was the cavitation response along the sonication time. PCD calibration (E-G) 
after BBB opening in cases i-iii was performed in order to assess the cavitation level at different 
pressures (10 pulses per pressure) with targeted regions near or include the MCA (E: SCDh, F: 
SCDu, G: ICD), and the errorbar represented the standard deviation of the 10 sonications. Note 
that the opening volume for case i to iv was 309, 469, 443, and 758 mm3 and angle of incidence to 
the skull: 24°, 18°, 35°, 41°, respectively. The cavitation level varied as the targeted region 
approached the MCA that was correlated with the opening volume but was found to be independent 




4.3.4    Safety for large BBB opening cases 
The safety of the FUS procedure was evaluated in all experiments using MRI in 1 h (edema in 
hyper-intensity of T2w imaging, and hemorrhage in hypo-intensity of SWI). No edema, hemorrhage, 
or any kind of macroscopic damage was detected in any of the animal in this study. Representative 
cases with large BBB openings in the four animals were shown in Fig. 4.16. For NHP 1, one 
sonication was performed at 275 kPa (putamen, opening volume: 397 mm3), two for NHP 2 at 400 
kPa (caudate and putamen, opening volume: 783 mm3 and 436 mm3, respectively), one for NHP 
3 at 450 kPa (putamen, opening volume: 845 mm3), and two for NHP 4 at 600 kPa (caudate and 
putamen, opening volume: 623 mm3 and 539 mm3, respectively). In addition, no damage was 
detected in the experiments for the vasculature effect (Fig. 4.15) despite the high cavitation 
response. The damage, if occurred, might be microscopic and insignificant in histological 





Figure 4.16. Safety assessments in the MRI. (A) NHP 1 targeting putamen at 275 kPa. (B) NHP 
2 targeting caudate nucleus and putamen at 400 kPa. (C) NHP 3 targeting putamen at 450 kPa. (D) 
NHP 4 targeting caudate nucleus and putamen at 600 kPa. No edema or hemorrhage was detected 
in any of the cases. 1st row: contrast enhancement of the BBB opening overlaying onto the post-
Gd T1w imaging; 2
nd row: T2w imaging for edema; 3




In this chapter, we have demonstrated the primate skull affecting the PCD performance using short 
and long pulses. Its sensitivity, reliability, and transcranial cavitation detection limit in macaques 
and humans were investigated, by performing in vitro macaque and human skull experiments as 
well as in vivo experiments in macaques with BBB opening. The in vitro study allows extensive 
investigation of the cavitation characteristics and the primate skull effects, while the in vivo study 
confirmed the in vitro findings using realtime PCD monitoring. The transcranial PCD was found 
sensitive to detect cavitation signals at pressures as low as 100 kPa in vivo. The transcranial 
detection limit (1-dB SNR limit) served as a criterion to guarantee reliable detection. Realtime 
PCD monitoring was performed during BBB opening, in which safe opening and reliable detection 
was achieved using long pulses. 
Moreover, our in vivo findings presented have provided a link in transcranial cavitation 
detection from small animals to primates through the use of both stable and inertial cavitation dose. 
We have demonstrated the primate skull effects in PCD both in vitro and in vivo, the detection 
threshold for harmonics, ultraharmonics, broadband emission to achieve reliable detection. The in 
vivo findings demonstrated a clear relationship between the cavitation measures and the BBB 
opening characteristics in non-human primates such as opening volume, the drug amount delivered 
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and the delivery efficiency. Cavitation was detected in both gray and white matter and was 
correlated with the BBB opening in both, while the cavitation response varied by the large cerebral 
vessels due to the change of cavitation threshold.  
 
4.4.1   B-mode imaging vs. PCD 
B-mode imaging was used to visualize the cavitation, ensuring the focal alignment to the channel 
and confirming the loss of echogenicity became detected at 200 kPa with and without the skull. It 
visualized cavitation by the maintenance or loss of echogenicity, representing stable or inertial 
cavitation, respectively. It also confirmed good focal alignment to the channel before and after 
placing the skull by detecting the bubble collapse at the center of the channel. In addition, it 
confirmed that the loss of echogenicity became detectable at 200 kPa in the presence of the skull.  
In contrast to the active visualization of B-mode imaging, the PCD served as an indirect 
monitoring tool. The PCD was shown to be more sensitive than B-mode imaging in this study 
since it detected inertial cavitation at 50 kPa, lower than the lowest pressure losing echogenicity 
(200 kPa). Detecting bubble destruction in B-mode imaging is limited by its spatial and contrast 
resolution, which failed to detect a smaller amount of bubble destruction at pressures lower than 
200 kPa. Therefore, B-mode imaging was used to supplement to the PCD results rather than to 
determine the inertial cavitation threshold. This result−PCD was more sensitive than B-mode 
imaging−was different from a previous study [171], which may due to the different excitation 
frequency and microbubbles used as well as different sensitivity of the imaging and PCD systems. 
On the other hand, the inertial cavitation occurred at 50 kPa in our study due to low excitation 
frequency, long pulse lengths [172], and low stiffness of the in-house microbubbles with a 4-5 µm 
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diameter [100]. This threshold is comparable to experimental results reported by other groups 
[172-174] as well as numerical simulation [175]. 
 
4.4.2 Cavitation doses without and with the skull 
There is a need to define a quantity that could be used to assess the FUS treatment outcome. Since 
both thermal and non-thermal based FUS treatment outcomes are closely related to the extent of 
cavitation [48, 176-178], which is typically reflected by the nonlinear emissions including 
harmonics, ultraharmonics, and broadband emissions, the quantity “cavitation dose” was 
employed here. The quantification of cavitation doses is based on the detected signals, emitted by 
acoustic cavitation and attenuated by the brain or skull. Therefore, the true cavitation dose (or 
cavitation dose in situ) should be estimated by accounting for the skull or tissue attenuation.  
The pulse length affected the characteristics of the cavitation dose (Fig. 4.6). Using 100-
cycle pulses, the cavitation doses increased monotonically with pressure increase as the magnitude 
of bubble oscillation increased. Furthermore, using long pulses (5000 cycles) was found to be more 
effective in generating higher cavitation dose. This was not only due to the integration over long 
pulse duration, as the cavitation doses did not linearly increase with the pulse length. In fact, the 
ICD still increased monotonically with pressure increase, while the SCDh and the SCDu reached a 
plateau at 250 kPa. It could therefore be explained that under a long-pulse excitation, a larger 
number of microbubbles underwent stable and inertial cavitation. When most microbubbles were 
undergoing inertial cavitation and collapse immediately without contributing to stable cavitation, 
stable cavitation reached a plateau and started to decrease. We also speculate that the microbubbles 
undergoing stable cavitation diffused faster using longer pulses and failed to enhance the SCDh. 
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Through the skull the trend of cavitation doses to pressure change remained the same, while 
the pressure threshold for the cavitation doses becoming detectable varied depending on the type 
of cavitation doses and the skull (Fig. 4.6). The monotonical increase of cavitation doses with 
pressure remained the same after placing the macaque and the human skull for signals surpassed 
the skull attenuation. On the other hand, the pressure threshold to detect the SCDh through the 
macaque skull remained unchanged, while it increased for the SCDh and ICD; for the human skull, 
the threshold increased for all three cavitation doses. In all types of cavitation doses, the pressure 
threshold for the SCDh was the lowest, followed by the SCDu and ICD. The SCDh remained 
detectable through the skull at 50 kPa and 100 kPa for macaques and humans, respectively. For 
the SCDu, the pressure threshold increased to 150 kPa and 250 kPa in the macaques and humans, 
respectively; for the ICD, 150 kPa and 350 kPa, respectively. This was due to the low signal 
intensity, even though the ultraharmonics and the broadband emissions occurred at 50 kPa. 
The in vivo skull effect (Fig. 4.8) was supported by the in vitro findings, except that the in 
vivo SCDu was unreliable. Using 100-cycle and 5000-cycle pulses, the SCDh as well as the ICD 
increased monotonically with pressure like the in vitro cases, with the exception that the SCDh for 
the 5000-cycle pulse did not reach a plateau. This could be due to the nonlinear scattering from 
the skull and possible air trapped between the transducer and the animal’s skin. On the other hand, 
unreliable SCDu was discerned due to the less frequent ultraharmonics as it was observed in real-
time monitoring of BBB opening (Fig 4.10). It could be attributed to microbubble dynamics in the 
biological environment such as blood, capillary, and blood vessel, as those were the main 
differences between the in vivo and the in vitro experiments. The biological environment could 
presumably affect cavitation for different types of microbubbles with varied extents. In addition, 
the varying blood pressure could contribute to the variation of the SCDu as well [179]. Finally, the 
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inertial cavitation was detected at and above 250 kPa, although it was possible that microbubble 
collapse could occur at lower pressures.  
The cavitation SNR was defined and used to investigate the sensitivity and reliability of 
PCD under different conditions such as varied pressures and pulse lengths, and the skull effects on 
them. It served as a quantitative way to find the transcranial detection limit (1-dB SNR limit), the 
skull attenuation, and ways to improve the detection. In order to achieve reliable PCD, one may 
increase the cavitation SNR in two ways: increasing the pressure or the pulse length. Using long 
pulse lengths was found effective in increasing the cavitation SNR at low pressures, while the 
cavitation SNR for the SCDh decreased at high pressures due to the cavitation characteristics and 
nonlinear skull scattering as described in the previous section for discussing the cavitation doses. 
Increasing the number of microbubbles injected could also improve the cavitation SNR since the 
inertial cavitation could be detected at low pressures (250 kPa) in the in vivo skull effect 
experiments after a second bolus injection of microbubbles, which was speculated that more 
microbubbles were circulating. Although safety could be a concern, no damages were reported in 
other studies using increased doses of microbubbles to induce BBB opening [160, 180]. 
The cavitation signals were reliable through the skull provided that the cavitation SNR was 
above 1 dB. This 1-dB SNR limit was acquired in the in vitro study and confirmed in the in vivo 
study. As in both studies, the cavitation doses showed statistical significance when satisfying this 
criterion with the only exception in SCDu. In future applications, this transcranial detection limit 
provides us indication of inertial cavitation detected for the macaque experiments. In the clinical 
studies, it could give us an indication of reliable PCD for all types of cavitation doses. 
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Skull attenuation for macaques (4.92 dB/mm) and humans (7.33 dB/mm) in this study are 
comparable to previous studies [130, 181]. The attenuation by the human skull is higher than that 
in the macaque, which might be due to high skull density [182], strong nonlinear ultrasound 
transmission [183], strong reflections and different extents of mode conversion [184]. The 
attenuation measured in this study was averaged over 1.25-5.00 MHz. The attenuation decreases 
when using lower frequencies. However, the broadband emission may be filtered out if signals 
within 3-5 MHz were excluded in the cases of low pressures (Fig. 4.4B). Besides, harmonics from 
the skull and tissue nonlinearity may hinder the detection at low frequencies as described in the 
following paragraph. The appropriate frequency range is therefore a compromise between skull 
attenuation, nonlinear effects, and frequency distribution of the cavitation signals. In the future, 
one could estimate the in situ cavitation strength by combining the transcranial PCD measurements 
(provided they pass the transcranial detection limit) with the skull attenuation acquiring from 
simulation or ex vivo measurement in order to assess the treatment outcome.  
In addition to the inherent skull attenuation, nonlinear ultrasound scattering due to the skull 
could further hinder the detection of harmonics. Nonlinear scattering from the human skull became 
apparent at and above 450 kPa (Fig. 4.7D), failing the detection of the harmonics (SCDh) generated 
by the microbubble cavitation. It could be due to the fact that higher pressure was applied in order 
to compensate for the 80% of pressure attenuation through the human skull, causing inevitable 
nonlinear scattering. Second, the FUS focus was 25 mm below the human skull, which could cause 
stronger nonlinear effects compared to a deeper focus [183]. Third, although precautions were 
taken, trapped air could still be present. This phenomenon was also revealed in the in vivo macaque 
results (Fig. 4.8A), in which nonlinear scattering was significant using a 5000-cycle pulse. This 
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nonlinear effect could cause serious problems as it fails the detection of the SCDh and may risk to 
overtreatment based on the monitoring. 
 
4.4.3   Real-time PCD monitoring in BBB Opening 
Real-time monitoring of the cavitation doses was performed during BBB opening using 5000-
cycle pulses (Fig. 4.10), providing the information of bubble perfusion and the cavitation level. 
Furthermore, the use of long pulses enables reliable PCD monitoring and facilitate opening at low 
pressures, and this lower pressure threshold was also found in the study done in mice [161]. By 
monitoring the SCDh, the time for microbubbles perfuse to the sonicated region as well as the 
microbubble persistence during the entire treatment could be monitored at and above 250 kPa. The 
lowest pressure for detecting the SCDh was 100 kPa as was found in the in vivo skull experiments 
(Fig. 4.8A).  
The SCDu was detected when the microbubbles first perfused the brain in two (Fig. 8b-c) 
out of the three cases (Fig 4.10A-C), although the variability was high. Our finding was consistent 
with the other group [67, 180], in which not all cases showed significant ultraharmonics. Low 
SCDu was affected by the noise from the system or the air trapped in the beam path. Therefore, in 
order to reliably detect the SCDu a pressure as high as 700 kPa should be applied (Fig. 4.10B), 
which increases the probability of damage. This finding was also consistent with the method of 
detection and real-time feedback control based on ultraharmonics in mice by O’Reilly et al. [79]. 
However, this feedback control method based on ultraharmonics may not be optimal for large 
animals due to unreliable SCDu and skull effects. 
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By monitoring the ICD, the safety of the treatment could be monitored in real time since 
low (SNR < 3dB) or no inertial cavitation was detected in the cases of safe BBB opening. Low or 
no ICD obtained during BBB opening experiments (Fig. 4.10) compared to the in vivo skull effect 
(Fig. 4.8) was most likely due to lower number of microbubbles circulating during FUS treatment, 
since significant increase of ICD was obtained in the same animal after a second bolus injection 
of microbubbles for in vivo skull effect.  
Safe BBB opening was achieved at low pressures (250-600 kPa) in both the putamen and 
the thalamus (Fig. 4.10). No differences were observed between the putamen and the thalamus in 
terms of cavitation doses in this study. The opening volume varied across animals, but it increased 
with pressure in the same macaque as compare the 350-kPa case (Fig. 4.10B) with the 600-kPa 
case (Fig. 4.10D). The 450-kPa case had smaller opening volume than the 350-kPa case was 
expected based on the slightly decreasing SCDh, which may due to the animal’s physiological 
effect to the circulating microbubbles. For the safety threshold of ICD, a 3.18-dB (1.44 times above 
the background signal) SNR of ICD was detected in the case without damage (Fig 4.10B). This 
indicated that the ICD safety threshold was higher than 3.18 dB for the system used. This result 
was consistent with the study done by Arvanitis et al. using a lower excitation frequency [180], in 
which 6.33 dB (4.3 times above the background power signal) was reported with hemorrhage. 
Studies correlating the cavitation dose to the opening volume based on single-element PCD 
should consider using the ICD instead of the SCDh at relatively high pressures due to three reasons. 
First, the positive correlation of the ICD to pressure is independent of the pulse length which 
affected the cavitation characteristics. Second, the ICD is not affected by the nonlinear ultrasound 
scattering due to the skull (e.g. the human skull results in Fig. 4.6D-F). Third, the ICD can also 
provide safety assessment [180, 185]. One major challenge here is to achieve reliable ICD 
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detection by increasing the cavitation SNR. On the other hand, passive cavitation mapping [186, 
187] including spatial information of cavitation could give us more precise estimation of opening 
volume and safety assessment using both the SCDh and ICD. Further studies regarding the effects 
of brain heterogeneity and individual differences in cavitation doses and treatment outcome in 
large animals are crucial before clinical applications. 
 
4.4.4   PCD to characterize BBB opening 
Several new findings have been shown in this study in comparison to previous NHP studies. First, 
the cavitation monitoring was shown to be highly correlated with clinically relevant measures in 
the deeply seated subcortical structures, an improvement compared with the previous study using 
relative MRI enhancement in the cerebral cortex [180]. Second, cavitation monitoring was capable 
of detecting the delivery in both gray and white matter, while large vessels (diameter > 1 mm) 
resulted in saturated stable cavitation response and significantly higher inertial cavitation response 
at high pressures without detectable damage in the MRI. Third, the cavitation quantification using 
harmonics, ultraharmonics, and broadband emission could improve the correlation to the BBB 
opening and drug delivery via compensation of the effect of brain heterogeneity and the nonlinear 
skull effect. Although harmonics can be more easily detected, they could be hindered by 
nonlinear skull or large vessel effects at higher pressures and deteriorate the correlation with drug 
delivery and BBB opening. The primate skull is reported to contribute to harmonic signals at higher 
pressures, which decreased the cavitation signal-to-noise ratio[70]. Furthermore, harmonics from 
bubbles in the large vessels could reach a plateau at higher pressures (Fig. 4.15). These could be 
the reasons why the use of harmonics has previously failed in predicting the BBB opening 
volume[69], and that harmonics were correlated well mostly in the cerebral cortex in a small 
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juvenile monkey with respectively fewer large vessels and thinner skull producing insignificant 
skull effects[180]. 
Inertial cavitation reported to be indicative of vascular damage [67] or using 
ultraharmonics to control the treatment [79] should be considered with caution in large animals, 
since the large vessels can result in high ultraharmonics and broadband emission without detected 
damage in radiologic examination implying no significant damage in the histological examination 
[67]. This vascular effects in humans could prove even more important due to the larger sizes of 
cerebral vessels compared to smaller animals (e.g. the cerebral artery diameter for mice, monkey, 
and human is 0.2 mm [188], 1.2 mm [189], and 2.0 mm [190], respectively). The reason behind 
variable cavitation monitoring may lie in the fact that the microbubbles circulating in large vessels 
responded differently to FUS. As has been reported previously, the threshold of inertial cavitation 
was lower in larger vessels [191, 192], so more bubbles may be disrupted in large vessels without 
stable cavitation, resulting in the decrease of SCDh and SCDu at higher pressures with a 
monotonically increase of the ICD. Since larger vessels allow microbubbles to nonlinearly 
oscillate, the energy of volumetric oscillation (SCDh) may convert to shell oscillation (SCDu) and 
violent bubble oscillation leading to bubble collapse (ICD)[19]. The high broadband emission in 
this case may not cause vascular damage as the microjets may exert negligible forces towards the 
vessel wall due to the larger lumen space. Furthermore, large vessels composed of thicker walls 
and muscles may not easily be disrupted. Therefore, large vessels should be excluded from the 
FUS focal region for reliable cavitation monitoring.  
For molecule delivery to the heterogeneous brain, the BBB opening results showed a 
localized delivery in both the contrast enhancement and the [𝐺𝑑]𝑐 map (Fig. 2). The highest [𝐺𝑑]𝑐 
after BBB opening was the same as that of the epicranial muscle (Table 1), since the highest tissue 
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permeability after BBB opening was comparable to that of tissue without BBB [193]. Moreover, 
the highest delivery ([𝐺𝑑]𝑐) occurred only at the center of the focus given a larger opening volume 
(298 or 393 mm3) with a shape similar to that of the transducer focus. This suggests that the 
technique is suitable for region- or point-specific delivery with the highest efficiency. If a higher 
amount of delivery is required, increasing the injection dosage of the drugs could enhance the 
amount of delivery [167]. If a larger opening volume is desired, sonication at multiple locations 
would be necessary. However, the BBB opening occurred with greater ease in the gray than in the 
white matter [67] was confirmed in this study. BBB opening occurred in both gray and white 
matter with the probability in the gray matter three times higher than that for the white matter (Fig. 
4.14), and the drug concentration (Gd) was significantly higher in the gray matter as well (Fig. 
4.12). This may be due to the lower vascularity or higher attenuation in the white matter than that 
in the gray matter [130]. Moreover, since cavitation could be monitored in both tissue types, this 
discrepancy may be associated with blood accompanied by microbubbles during sonication. For 
example, the blood volume (1.5-1.8 times [194, 195]) or blood flow (1.7 times [196]) in the gray 
matter was higher than that of the white matter. Future studies regarding this issue would be 
required in optimizing this technique for various tissue types.  
In addition, the BBB opening was achieved targeting a region including the large vessel 
MCA (Fig. 4.15). However, since microbubbles in circulation would attenuate ultrasound wave 
propagation at varying extents depending on the vessel distribution, size, and microbubble 
concentration [197], this microbubble shielding effect may impose potential difficulties in humans 
[41] as it was reported to hinder BBB opening in monkeys [66]. Therefore, large cerebral blood 
vessels should be avoided in the targeted region or acoustic path during FUS planning in order to 
avoid opening failure as well as monitoring discrepancies. MRA could be a useful tool for 
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visualizing the position and size of cerebral blood vessels during the pre-planning process. 
Furthermore, the use of nanodroplets to induce BBB opening could potentially minimize the 
shielding effect since nanodroplets vaporize into bubbles only in the focus and induce opening, 
which also strongly decreases variability in the relationship of cavitation dose to BBB opening 
[78].  
Modelling bubble dynamics could potentially provide a priori knowledge for the safety and 
efficacy of BBB opening and drug delivery in various tissue types, as the mechanical effects of 
cavitation have long thought to associate with vascular permeability enhancement. A proper model 
is thus required for these emerging therapeutic purposes. Currently, modified or lumped-parameter 
models based on the Rayleigh-Plesset equation (free gas bubble model) have enabled us to 
investigate the behavior of coated microbubbles [198, 199] and the bubble-microvessel wall effects 
[200], assuming symmetric bubble oscillating in free space. However, a finite-element modelling 
(FEM) approach provides flexibility for both symmetric and asymmetric bubble oscillation while 
considering a variety of bubble and in vivo environmental properties [201]. Despite the findings 
obtained with this modelling approach, many efforts are also required to build a linkage to the in 
vivo BBB opening and drug delivery. First, the mechanical effects directly associated with the 
therapeutic effects need to be identified. Second, the in vivo properties must be measured, 
including the size, shell, stiffness [100], and distribution of bubbles as well as the shape, size, and 
wall elasticity of the microvessels. Third, the bubble-to-bubble interaction and the bubble behavior 
after rupture [199]. Once the simulation method is established, magnetic resonance angiography 
(MRA) may be used to construct the simulation model in order to compensate for the cavitation 




4.5    CONCLUSION 
To achieve transcranial cavitation monitoring in primates, in vitro macaque and human skull 
experiments as well as in vivo macaque experiments to study the skull effect and BBB opening 
were performed. It was found that through the macaque skull the pressure threshold for detecting 
the SCDh remained the same, while it increased for SCDu and ICD; through the human skull, it 
increased for all types of cavitation dose. The pressure threshold for detection the SCDh was the 
lowest, followed by SCDu and ICD. The positive or negative trend of cavitation doses to pressure 
increase remained the same through the skull, provided that the signal intensity surpassed the skull 
attenuation (macaque: 4.92 dB/mm, human: 7.33 dB/mm). The SNR for reliable detection for the 
PCD system used in this study is 1 dB. Using long pulses enabled reliable PCD monitoring and 
facilitates BBB opening at low pressures. The in vivo results showed that the SCDh was detected 
at pressures as low as 100 kPa; the ICD, at 250 kPa and could occur at lower pressures; the SCDu, 
at 700 kPa and was less reliable at lower pressures. Real-time monitoring of PCD was performed 
in vivo in macaques during BBB opening, and safe opening has been achieved at 250-600 kPa in 
both the thalamus and the putamen, with minimum or no inertial cavitation detected. Our study 
showed that transcranial PCD in macaques in vitro and in vivo as well as humans in vitro is reliable 
by improving the cavitation SNR to surpass the 1-dB detection limit. 
The study presented in this chapter expanded the role of transcranial cavitation monitoring 
in NHPs in vivo and demonstrated a correlation with the BBB opening volume and the drug 
delivery efficiency with various the tissue types and targeting. The achieved BBB opening volume, 
amount of delivered molecules and delivery efficiency was as high as 800 mm3, 40 nmol, and 
0.004%, respectively, and could be predicted by the real-time cavitation monitoring. Quantitative 
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cavitation monitoring and drug delivery were achieved in both gray and white matter, with the 
probability of successful BBB opening three times higher in the gray matter than in the white 
matter. The targeting shift was 3.7 mm in the caudate and 7.5 mm in the putamen, and the incidence 
angle to the skull had negligible effects on the cavitation monitoring, showing the capability of 
cavitation monitoring for various targeting. The large cerebral vessels, however, may affect the 
cavitation monitoring, and should be excluded from the FUS path.  
 
4.6    SIGNIFICANCE & CONTRIBUTION 
In this chapter, a transcranial cavitation detection system for real-time calculating all types of 
cavitation dose during BBB opening has been established for the first time with performance 
assessed in monkeys in vitro and in vivo and humans in vitro. This monitoring technique was 
successfully used to assess the BBB opening volume and amount of gadolinium delivered in the 
heterogeneous monkey brain for the first time. The heterogeneous brain effects on BBB opening 
and monitoring including gray, white matter, and vasculature were extensively studied as well. In 
a nutshell, the results herein pave the way for clinical use of the monitoring system for BBB 
opening to ensure treatment effectiveness.  
The research contribution was shared with colleagues. Yao-Sheng Tung (PhD, Biomedical 
Engineering, Columbia University) and Fabrice Marquet (PhD, Biomedical Engineering, 
Columbia University) and mentored the study. They together with Tobias Teichert (PhD, 
Neuroscience, Columbia University), Carlos Sierra Sanchez (PhD, Biomedical Engineering, 
Columbia University), Amanda Buch (B.S., Biomedical Engineering, Columbia University), and 
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Matthew Downs (PhD, Biomedical Engineering, Columbia University) assisted the in vivo 
experiments. Vincent Ferrera (PhD, Neuroscience, Columbia University) facilitated the animal 
experiments.   
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Chapter 5   
Real-time Acoustic Mapping to Visualize 
Cavitation Events through Primate Skulls 
 
5.1 INTRODUCTION 
As shown in Chapter 4, passive cavitation detection (PCD) serves as the only online tool to real-
time monitor FUS-induced BBB opening in ensuring effectiveness and safety. For a single-element 
detector as described in Chapter 3 and 4, it provides overall intensity of the treatment without 
spatial information. While the spatial information of the treatment outcome is critical to precisely 
control the treatment in desired location to achieve treatment efficacy and safety, especially with 
the need of multiple sonication for larger BBB opening volume.  
With the passive beamforming algorithm based on time exposure acoustics (TEA) [82, 83], 
the spatial distribution of cavitation intensity could be reconstructed. This technique is known as 
cavitation mapping, using a conventional ultrasound imaging transducer as a PCD array to 
reconstruct the intensity and the spatial distribution of the cavitation. The concept behind TEA is 
from time-exposure photography in which the brightness of constant and low intensity light 
sources were enhanced by integration over time (long exposure time). For the adaptation to the 
applications of acoustics, a multi-dimensional array transducer with the passive beamforming 
technique is used by taking the time difference in the signals received by each element in the 
transducer into account regardless of the time origin. This technique is suitable for passive 
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cavitation mapping in therapeutic ultrasound including high-intensity focused ultrasound (HIFU) 
[83, 202, 203], BBB opening [187, 204], and drug delivery [205] owing to the use of long acoustic 
pulses and higher occurrence of cavitation emission relative to the background emission. This 
passive cavitation mapping in combining with a fast reconstruction algorithm called sparse matrix 
array beamforming [206] will be able to achieve real-time monitoring. 
The objective of this chapter was thus to develop a cavitation mapping technique to real-
time visualize the cavitation events in the primate brain during sonication. Real-time 
reconstruction of the cavitation maps was achieved by incorporating GPU computation to sparse 
matrix beamforming and time exposure acoustics – a breakthrough as conventional cavitation 
mapping takes hours to reconstruct. Its performance was assessed both in vitro through the primate 
skulls and in vivo during BBB opening in NHPs. In both experiments, cavitation mapping was 
achieved transcranially, granting a powerful FUS treatment monitoring tool for future applications. 
 
5.2 METHODS 
5.2.1   Experimental design 
Both phantom experiments with NHP and human skulls, and the in vivo NHP experiments for 
BBB opening were performed. The phantom experiments were performed to access the 
performance of cavitation mapping such as spatial and contrast resolution and the correlation to 
cavitation visualized in B-mode imaging, and the sensitivity of transcranial cavitation mapping 
through the NHP and human skull. The in vivo experiments were to show the feasibility of real-




5.2.2   Passive cavitation mapping algorithm and system 
The purpose of cavitation mapping was to provide both the intensity and the spatial distribution of 
cavitation associated with BBB opening using a conventional ultrasound imaging transducer. This 
spatial distribution of cavitation intensity could be reconstructed with the passive beamforming 
algorithm used in ultrasound imaging and time exposure acoustics (TEA) [82, 83]. The concept 
behind TEA is from time-exposure photography in which the brightness of constant and low 
intensity light sources were enhanced by integration over time (long exposure time). In our 
application, several passive frames were reconstructed in one single FUS pulse acquired from a 
PCD array (the same as an array transducer used for ultrasound imaging) and were summed 
together as integration over time to enhance the cavitation signals in a spatial domain, as described 
in Fig. 5.1.  
A programmable ultrasonic system (Vantage, Verasonics, WA) with a 128-channel linear 
array transducer (L7-4, Verasonics, WA) was used to passively detect cavitation signal (channel 
data) during sonication. The channel data were then reconstructed to the passive frames (cavitation 
maps in discrete time points) using dynamic receive beamforming ( ∑ 𝑆𝑛(𝑥𝑛, 𝑥, 𝜏)
𝑁




) over a period of time 𝑇: 







𝑆𝑛(𝑥𝑛, 𝑥, 𝜏) = 𝛼(𝑑(𝑥𝑛, 𝑥)) ∙ 𝑐𝑛(𝑡 + 𝑑(𝑥𝑛, 𝑥)/𝑐), 
where 𝑁 is the number of elements in the linar array, 𝑆𝑛 the channel data for the n-th element, 𝑥𝑛 
the location of the n-th transducer element, 𝑥 the location of the pixel to be reconstructed, 𝑡 the 
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delay of the emission, 𝑇  the duration of signal to be integrated (76 µs), 𝑆𝑛(𝑥𝑛, 𝑥, 𝑡)  the 
compensated channel data for the n-th channel, 𝛼(𝑑(𝑥𝑛, 𝑥)) the compensation term for the wave 
attenuation after transmission over the distance between 𝑥𝑛 and 𝑥 (𝑑(𝑥𝑛, 𝑥)), 𝑐𝑛(𝑡 + 𝑑(𝑥𝑛, 𝑥)/𝑐) 
the received cavitation signal for the n-th channel after adjusting for the time delay based on the 
distance between 𝑥𝑛 and 𝑥, and 𝑐 the speed of sound. Integration was applied to improve the SNR 
of cavitation intensity.  
 
 
Figure 5.1 Schematic of passive cavitation mapping algorithm based on time exposure 
acoustics. The passive cavitation signal was acquired in a PCD array, stored as channel data for 
each sonicated pulse. Several passive frames were reconstructed in one single FUS pulse with 
different time windows representing the cavitation map in each time segment. They were summed 





Figure 5.2. Matrix calculation for reconstructing a cavitation map. (A) Delay-and-sum (DAS) 
beamforming to reconstruct a series of radiofrequency (RF) frames using sparse matrix calculation. 
(B) The cavitation map of a single pulse is the sum of squared RF frames at each time window, 
i.e., the time integration of TEA. (C) The channel dataset in (A) is extracted from a series of time 




5.2.3   Sparse-matrix beamforming 
Beamforming has been widely used in ultrasound imaging both to transmit ultrasound beams and 
to reconstruct images after receiving scattered acoustic signals at the transducer. To reconstruct 
images efficiently, conventional delay-and-sum beamforming as a linear process can be 
programmed in a matrix format to perform fast sparse matrix computation in GPU [207]. It is a 
technique of software beamforming that could be implemented in Matlab with highly optimized 
sparse matrix multiplications. Briefly, the delay-and-sum calculation in receive beamforming 
could be transformed into a matrix multiplication 𝑦 = 𝐴𝑥 (Fig. 5.2A) with a linear operator 𝐴 
based on the delay time ( 𝑥  and 𝑦  are vectors for channel data and reconstructed image, 
respectively). 𝐴 is a sparse matrix since only a small number of data points are taken from each 
channel for summation, and the rest of the matrix element in 𝐴 are zeros.  This concept could then 
be applied to the cavitation mapping in order to achieve fast reconstruction by replacing 
∑ 𝑆𝑛(𝑥𝑛, 𝑥, 𝜏)
𝑁
𝑛=1  with a sparse matrix multiplication followed by summation of the squared RF 
frames (Fig. 5.2B) which were reconstructed frames based on channel data in a single pulse with 
a series of time window (Fig. 5.2C).  
 
5.2.4   In vitro skull experiments 
The experimental setup is shown in Fig. 5.3A. Similar to chapter 2, in-house, lipid-shell, 
monodisperse microbubbles (median diameter: 4-5 µm) were diluted to 2×105 bubbles/mL and 
injected to the 4-mm-in-diameter channel in the silicon phantom for sonication and cavitation 
detection. The PCD array and the diagnostic B-mode imaging system (Terason, MA, USA) were 
separately used to monitor the sonication (peak negative pressure (PNP): 100-600 kPa, pulse 
172 
 
length: 5000 cycles (10 ms), pulse repetition frequency (PRF): 10 Hz, duration: 2 s) in order not 
to interfere the PCD. B-mode images of bubble disruption were acquired to ensure the FUS 
focusing at the channel, which was performed through a linear array transducer (10L5, Terason, 
MA, USA; center frequency: 5.1 MHz) placed transversely to the FUS beam. Before each 
sonication, the microbubbles were injected and the old microbubbles were flushed out, which 
ensured the independence between each sonication and experiment. During the experiments for 
PCD only, the microbubbles were constantly replenished at around 0.25 mL/s in order to mimic 
the replenishment of the microbubbles in the brain. The PCD was performed either without or with 
the skull (NHP and human) in place between the channel phantom and the PCD array.  
 
5.2.5   In vivo NHP experiments  
The experimental setup is shown in Fig. 5.3B. Following the same animal procedure with the same 
FUS system in chapter 2 and 4, two male adult macaques (2 Macaca mulatta, weight: 9-11 kg, age: 
18-20 yo) were sonicated at 0.45, and 0.6 MPa (excitation frequency = 0.5 MHz, pulse length = 
10 ms, pulse repetition frequency = 2 Hz, duration = 2 min) with in-house microbubbles injected 
intravenously (lipid-shelled, 4-5 µm in diameter, 2.5×108 bubbles/kg), and targeted structures 
included the basal ganglia (caudate and putamen) and hippocampus. The PCD array was placed 
against temporal bone toward the FUS focus to acquire the cavitation signal for real-time 
monitoring of the cavitation maps during sonication. After the sonication, MRI was performed to 




Figure 5.3. Experimental setups for (A) the in vitro skull and phantom and (B) the in vivo 
BBB opening in NHP. In the in vitro experiment, the FUS transducer was place on top of the 
channel phantom orthogonal to the PCD array, and the skull was placed in between the phantom 
and the PCD array for assessing the skull effects on the cavitation mapping. In the in vivo 
experiment, the FUS transducer was targeted to the region of interest based on the stereotaxis while 
the PCD array was placed against the temporal bone toward the FUS focus. 
 
5.3 RESULTS 
5.3.1   Mapping quality vs. computational time 
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The concept behind TEA is to enhance the continuously scattered signal and eliminate noise by 
summation over the exposure time (defined as the time difference between 1st time window and 
the last time window for extracting the channel data in a single pulse as shown in Fig. 5.1C), which 
also determines the computational load as the more RF frames need to be reconstructed for longer 
exposure time. This therefore emphasizes the importance of investigating the effect of exposure 
time on the computational time and the mapping quality in order to achieve real-time cavitation 
mapping with optimized mapping quality. The phantom experiments without the skull were 
performed to acquire cavitation signals in the channel data, with the cavitation maps processed off 
line to calculate the computational time and the mapping characteristics with respect to different 
exposure time or number of RF frames used for a single cavitation map.  
  Both the computational time and mapping characteristics are shown in Fig. 5.4. The 
computational time was linearly correlated the exposure time (Fig. 5.4A). In order to achieve real-
time cavitation mapping, it requires a computational time lower than the pulse repetition time used 
in the FUS therapy, which is 0.5 s for BBB opening in NHP. Therefore, a maximum of 1.44 µs 
(30 RF frames reconstructed) is required to achieve real-time reconstruction and display of 
cavitation maps. For the mapping characteristics (Fig. 5.4B), the maximal intensity increased until 
reaching to a plateau at around 62.5 µs (1300 frames) due to the enhancement of the cavitation 
signal as more RF frames were included with a longer exposure time. The cavitation distribution 
started to form in the localized region even at a very short exposure time (1.44 µs for 30 frames). 
While the cavitation region (defined as -6 dB area from the maximal intensity) increased with 
exposure time at the beginning of 20 µs as more discrete spots were formed, it then started to 
decrease and reached a steady state at around 62.5 µs due to the enhancement of the cavitation 




Figure 5.4. The impact of exposure time on computational time and mapping characteristics. 
(A) The exposure time (Te) was linearly correlated with the computational time (Tc) since it 
determined the number of RF frames required to be reconstructed for one single cavitation map. 
(B) This exposure time also affected the mapping quality in terms of denoising and homogeneity 
of cavitation distribution. The maximal intensity of the map increased until reached to a plateau as 
more RF frames were added. This cavitation distribution also formed in a localized region at a 
very short exposure time (1.44 µs) as shown in the cavitation region (-6 dB area) until reaching a 
steady state at 62.5 µs. This representative case was performed at 450 kPa, while all other cases at 
various pressure showed the same trend. 
 
5.3.2   Acoustic mapping through the primate skull 
In the brain therapy such as BBB opening, the performance of transcranial detection is critical for 
clinical application. Therefore, detection threshold through the monkey and human skull were 
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investigated in the in vitro phantom experiments by placing the skull piece (parietal bone) in 
between the PCD array and the phantom from 150 to 600 kPa as shown in Fig. 5.5. Cavitation 
maps using 62.5-µs exposure time showed a localized cavitation distribution at all pressures 
applied (Fig. 5.5A), while successful transcranial detection was achieved at and above 300 kPa 
and 450 kPa for monkey skull (Fig. 5.5B) and human skull (Fig. 5.5C), respectively. This detection 
threshold lies in the range for successfully BBB opening, thus demonstrating its capability of 
monitoring the sonication transcranially.  
Although through the skull the cavitation distribution was more disperse, it still presented 
as a single event. The displacement of the cavitation event through the skull was around 1 cm, 
which may be due to the skull causing distortion of the cavitation signal or the slight movement of 
the PCD array or the phantom in order to fit the skull piece in limited space (the PCD array was 2 
cm away from the phantom where the channel was 1.5 cm deep).  
 
 
Figure 5.5. Detection threshold of cavitation mapping through the primate skulls. Cavitation 
maps at various pressures (A) without the skull in place, (B) with the NHP skull, (C) with the 
human skull in place were acquired. The cavitation distribution was successfully reconstructed at 
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all pressures from 150 kPa to 600 kPa. It can be detected at and above 300 kPa and 450 kPa through 
the monkey skull and human skull, respectively.   
 
5.3.3   Acoustic mapping during BBB opening in NHP 
After the in vitro assessment for the transcranial cavitation mapping, this technique was applied 
during BBB opening in NHP to show its in vivo feasibility of monitoring in large animals. The 
PCD array was placed against the temporal bone toward the FUS focus since it was the thinnest 
part of the skull close to the sonicated area, and the monitoring plane covered a lateral cross section 
of the ellipsoidal FUS focus (Fig. 5.3B). Two NHPs were sonicated at 450 kPa and 600 kPa to 
induce BBB opening, with the cavitation map, total intensity of the cavitation signal, and the 
spectrum monitored in real time (frame rate = PRF = 2 Hz).  
 A representative BBB opening and monitoring result at 450 kPa is shown in Fig. 5.6. Both 
a single-element PCD confocal to the FUS transducer and the PCD array were used to monitor the 
BBB opening (Fig. 5.6A). The single-element PCD showed a dramatic increase in both stable and 
inertial cavitation once microbubbles perfused the brain, which corresponded to the total intensity 
in the PCD array (summation of the squared channel data) over time (Fig. 5.6B). In the sequential 
cavitation maps, the cavitation distribution consistently demonstrated localized cavitation events 
in the same location (Fig. 5.6C). Cavitation mapping therefore provides both the spatial 
information and the intensity of cavitation.  
Another representative BBB opening and monitoring result at 450 kPa is shown in Fig. 5.7 
with only stable cavitation. Using a linearized intensity scale in the cavitation mapping allowed us 
to see both the spatial and the intensity of cavitation change over time (Fig. 5.7C). Interestingly, 
the cavitation events during the sonication seemed to occur at two locations. It may be due to the 
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cavitation occurred in the nearby vessel, sidelobe of the FUS transducer, or an artifact of the 
passive mapping. More information are required for investigation.  
 Moreover, in order to assess the treatment outcomes, the location of the PCD array relative 
to the brain is required to register the cavitation maps to the brain images. This can be achieved 
with a neuronavigation system, which will be described in Chapter 6.  
 
 
Figure 5.6. Cavitation mapping during BBB opening in NHP 1. (A) BBB opening (colored) 
revealed after post processing in the horizontal slice of the contrast-enhanced T1w MRI. BBB 
opening was induced at 450 kPa while the PCD array (placed against the temporal bone toward 
the FUS focus) acquired cavitation signals for reconstruction of cavitation maps. (B) Both the 
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single-element PCD and the PCD array acquired cavitation signal for real-time monitoring. The 
calculated cavitation doses from the single-element PCD is shown on the left, and the total intensity 
of cavitation signals (sum of the squared channel data) from the PCD array on the right. (C) The 
reconstructed cavitation maps at each time point revealed the location cavitation events in the brain 
(using the -6 dB scale relative to the maxima).    
 
 
Figure 5.7. Stable cavitation mapping during BBB opening in NHP 2. (A) BBB opening 
(colored) revealed after post processing in the horizontal slice of the contrast-enhanced T1w MRI. 
BBB opening was induced at 450 kPa while the PCD array (placed against the temporal bone 
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toward the FUS focus) acquired cavitation signals for reconstruction of cavitation maps. (B) Both 
the single-element PCD and the PCD array acquired cavitation signal for real-time monitoring. 
The calculated cavitation doses from the single-element PCD is shown on the left, and the total 
intensity of cavitation signals from the PCD array on the right. (C) The reconstructed cavitation 
maps at each time point revealed the location and intensity increase of cavitation events in the 
brain (using the intensity as the color scale).    
 
5.4 DISCUSSION 
In this chapter, real-time transcranial cavitation mapping using sparse matrix beamforming with 
GPU computation was developed and assessed in vitro through the monkey and human skull, as 
well as in vivo during BBB opening in monkeys. This cavitation mapping provides both the 
intensity and spatial distribution of cavitation that potentially enables the assessment and control 
of FUS treatment associated with cavitation more precisely. The transcranial detection through the 
primate skull also allows translational capability to the clinics.  
Passive cavitation mapping or passive acoustic imaging originally developed for seismic 
imaging to identify acoustic sources for military purposes [82] can monitor therapeutic ultrasound 
treatment associated with cavitation, since the cavitation events achieving the desired biological 
effects also serve as acoustic sources during sonication. It has been used in  high-intensity focused 
ultrasound (HIFU) [83, 202, 203], drug delivery [205] as well as BBB opening [187, 204] owing 
to the use of long acoustic treatment pulses resulting in higher occurrence of cavitation emission 
relative to the background emission, while the reconstruction often takes hours.  
 Its application in BBB opening holds great promise to replace costly and time-consuming 
MRI. Besides, real-time cavitation mapping may allow feedback control of the safety and 
effectiveness of FUS treatment in different location as what has been developed with single-
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element PCD [79]. Current challenges lie in the alignment of cavitation maps to the brain and the 
skull causing phase aberration and mapping distortion, and the use of neuronavigation and 
simulation could solve these problems.  
 
5.5 CONCLUSION 
Real-time transcranial cavitation mapping has been developed using sparse matrix beamforming 
with GPU computation in this study. It successfully demonstrated localized cavitation distribution 
at and above 150 kPa without the skull, 300 kPa through the monkey skull, and 450 kPa through 
the human skull, showing its capability of treatment monitoring. This real-time cavitation mapping 
was also applied in vivo during BBB opening in NHP, proving the monitoring feasibility in 
primates. Our technique is thus capable of translating to clinics.  
 
5.6 SIGNIFICANCE & CONTRIBUTION 
This chapter fulfilled the specific aim 2 to develop an online treatment monitoring tool together 
with Chapter 3 and 4. In the last two chapters, cavitation monitoring using single-element PCD 
was implemented in mice and NHP. It provided the measure of an overall cavitation dose without 
spatial information. In this chapter, passive cavitation mapping utilizing a PCD array and an 
imaging technique with GPU computing, the spatial distribution of cavitation could be constructed 
in real time for the first time, which shed lights on the location of BBB opening. The performance 
was assessed in monkeys in vitro and in vivo, and humans in vitro, which guaranteed the feasibility 
182 
 
of this technique in clinical use. Its use with BBB opening could potentially control the BBB 
opening in real time to ensure safety and effectiveness, and eventually replace the MRI as a post-
treatment assessment tool.  
The research contribution was shared with colleagues and interns in the lab. Julien Grondin 
(PhD, Biomedical Engineering, Columbia University) assisted in the development of sparse matrix 
reconstruction with GPU computing. Wenlan Zheng (B.S., Biomedical Engineering, Columbia 
University) and Marc Heidmann (M.S., Biomedical Engineering, Columbia University) assisted 
the in vitro experiments. Carlos Sierra Sanchez (PhD, Biomedical Engineering, Columbia 
University) and Amanda Buch (B.S., Biomedical Engineering, Columbia University) assisted the 
in vivo experiments. Yao-Sheng Tung (PhD, Verasonics Inc.) assisted the Verasonics system 




Chapter 6   
Neuronavigation-Guided Focused 
Ultrasound and Acoustic Mapping for BBB 
Opening in Non-human Primates 
 
6.1 INTRODUCTION 
Both simulation (Chapter 2) and real-time cavitation monitoring during BBB opening (Chapter 3-
5) have been developed to personalize the treatment planning and to ensure treatment safety and 
effectiveness. Since drug delivery often requires multiple applications, the treatment duration is 
especially critical in order to serve a large patient population. Currently, the bottleneck is the 
targeting procedure, which takes more than two hours using MRgFUS [12], while the process can 
be fairly efficient using frameless stereotaxic method, called neuronavigation. The objective of 
this chapter was to develop a seamless neuronavigation-guided transcranial ultrasound system with 
targeted sonication and acoustic mapping for clinical use, and the protocol demonstrated from in 
silico preplanning, online treatment and monitoring, to post-treatment assessment. The system and 
protocol were tested in both sedate and awake non-human primates (NHP) with BBB opening to 
evaluate the performance of simulation, targeting accuracy, and monitoring. The system for FUS 
sonication and acoustic mapping was assessed in both a sedate setting, where the animal was lying 
prone on the operating table under anesthesia, and an awake setting, while the animal was trained 
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to sit in a customized chair. The accuracy of targeting as well as the cavitation mapping was 
evaluated comparing to the BBB opening based on contrast enhanced MRI. 
 
6.2 METHODS 
6.2.1   Neuronavigation-guided ultrasound system  
An armless neuronavigation system (Brainsight Vet System, Rogue Research Inc., Canada) 
designed for primates (both monkeys and humans) was customized to be used in conjunction with 
an ultrasound system. This neuronavigation system was based on paired-point registration with an 
optical tracking device and reflective spheres (Northern Digital Inc.), and the fiducial bite bar 
system (bite bars bearing six fiducials; Rogue Research Inc., Canada) were constructed for each 
individual with their unique tooth imprints in the sedate animal experiments (Fig. 6.1). For the 
awake animal experiments, in-house fiducial bearing pieces were designed attachable to the head 
post implantation of the animal. Two unique tool trackers with three reflective spheres were 
mounted separately on the therapy transducer and the monitoring transducer (Fig. 6.2A) and 
calibrated for the neuronavigation system in order to recognize them in the operating space. 
 
Figure 6.1. Acquiring preoperative 
anatomical images with fiducials for 
registration. (A) A NHP skull with a bite bar 
connecting unique teeth impression to the 
fiducial plates. (C) NHP brain images with 
donut-shape fiducials (D) in T1w MRI. The 
fiducial landmarks (center of the fiducials) were 





Figure 6.2. Experimental setup with neuronavigation for (A) the sedate and (B) the awake 
animal. Infrared (IR) camera was the position tracking device connected to the computer to 
process image registration in real time in the neuronavigation system. The trackers bared three 
reflective spheres for the IR camera to detect transducers (tool trackers) relative to the animal 
subject in the physical space (subject tracker). At the beginning of the treatment session, the 
fiducials were attached to the invariant traits (bite bars or head post) of the animal for registering 
the animal subject to the neuronavigation system. After the registration, the fiducials were removed 
and the FUS transducer was aligned to the preplanned targeting and secured with the free-guide 
arm or stereotactic arm for sonication. 
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The ultrasound system consisted of a focused ultrasound treatment unit controlled by a 
customized program in Matlab with a single-element, 0.5-MHz FUS transducer (diameter: 64 mm, 
focal depth: 62.6 mm; H-107, Sonic Concepts, WA, USA) triggered by a function generator 
(model 33220A, Agilent Technologies, CA, USA) after 50-dB amplification (A075, ENI, NY, 
USA), and an acoustic monitoring unit with a programmable acoustic signal acquisition system 
(Vantage 256, Verasonics, WA, USA) and an array of acoustic detectors (Philips ATL L7-4 linear 
array, bandwidth = 2 to 8 MHz, 38 mm wide with 128 elements) synchronized with the FUS system 
for real-time passive cavitation mapping and storage of the entire acoustic signals. Both the FUS 
and cavitation mapping were guided with the neuronavigation system during the FUS procedure. 
 
6.2.2   Experimental design 
All procedures were reviewed and approved by the Institutional Animal Care and Use Committees 
at Columbia University and the New York State Psychiatric Institute. Three male adult macaques 
(2 Macaca mulatta and 1 Macaca fascicularis, weight: 6-11 kg, age: 8-20 yo) sonicated at 0.3, 0.45, 
and 0.6 MPa (excitation frequency = 0.5 MHz, pulse length = 10 ms, pulse repetition frequency = 
2 Hz, duration = 2 min) with in-house microbubbles injected intravenously (lipid-shelled, 4-5 µm 
in diameter, 2.5×108 bubbles/kg), and targeted structures included the basal ganglia (caudate and 
putamen) associated with neurodegenerative diseases such as Parkinson’s and Huntington’s 
disease as well as the primary motor cortex in the central sulcus and precentral gyrus. Three 
experimental groups (cohorts) were designed. First, neuronavigation + stereotaxic sonication 
(NHP 1, 2) to investigate the targeting and monitoring accuracy by locating the acoustic focus with 
neuronavigation intraoperatively with stereotaxic preplanning (Fig. 6.2A). Second, 
neuronavigation-guided sonication (NHP 1, 2) with preplanning on the neuronavigation system 
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was implemented with a free-guide surgical arm (Rogue Research Inc., Canada) coupling the FUS 
transducer to investigate the targeting and monitoring accuracy through neuronavigation guidance. 
The animals were under anesthesia in cohorts 1-2. Finally, neuronavigation-guided sonication was 
translated to an awake animal trained to sit on a customized chair (NHP 3) to mimic the clinical 
settings with its head fixated to the chair (Fig. 6.2B). 
 
6.2.3   Preoperative image acquisition 
Both CT and MRI were acquired preoperatively for personalized pre-planning and 
neuronavigation guidance. CT (helical scan, resolution = 0.2 × 0.2 × 0.6 mm; Siemens) was used 
to extract skull properties such as density and thickness in order to estimate the acoustic energy 
loss in simulation, and T1-weighted MRI (3D turbo field echo sequence, TR/TE = 11.1/5.1 ms, 
FA=8⁰, resolution = 0.7 × 0.7 × 0.7 mm; Philips 3T) for the anatomical scan of the brain 
surrounded by 6 contrast-enhanced fiducials used for registration of the neuronavigation system.  
 
6.2.4   Reconstruction of acoustic maps 
Time-exposure acoustics [82] in combination of dynamic receive beamforming using sparse 
matrix calculation in the graphic processing unit [207] (GPU; Tesla K40, NVIDIA) were 
developed for the reconstruction of passive acoustic maps in real time during the sonication (frame 
rate = pulse repetition rate = 2 Hz). In a single pulse, 30 passive image frames (root-mean-square 
of the RF frame) were reconstructed and summed as an integration over an exposure time of 1.44 
µs to enhance the cavitation signal and eliminate the background noise, and an exposure time of 
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62.5 µs (1300 passive image frames) was used for off-line processing in order to acquire the 
optimal acoustic mapping quality for post-comparison to the BBB opening.  
 
6.2.5   Experimental procedure 
The experimental setup is shown in Fig. 6.2. For animal anesthesia in experimental cohort 1-2, the 
animal was sedated with ketamine (10 mg/kg in conjunction with 0.04 mg/kg of atropine through 
intramuscular injection) for placement of an endotracheal tube and an intravenous catheter in the 
saphenous vein, and then transported to a dedicated suite for the anesthesia procedure (1-2% 
isoflurane-oxygen mixture) with vital signs monitored during the entire experiment9, 10. While 
for the awake animal experiments, the animal was lightly sedated with ketamine (5 mg/kg) for 
placement of an intravenous catheter in the saphenous vein prepared for injection of microbubbles, 
and then was placed into the chair with head fixed while awake30. During the treatment session, 
the animal subject in the physical space (represented by the subject tracker) was first registered to 
the virtual image space on the neuronavigation system. Specifically, the pointer tool recognized 
by the system was used to select the fiducials one-by-one, which were bared on the bite bar secured 
by the upper jaw of the animal after been fixed on the stereotaxic frame (sedate animals) or bared 
on the head post (awake animals). Once registered, the orientation of the tools (represented by the 
tool trackers) relative to the brain including the FUS transducer and the imaging probe could be 
displayed on the real-time reconstructed 2D and 3D images on the neuronavigation monitor. In 
cohort 1 (neuronavigation + stereotaxic sonication)(Fig. 6.2A), the stereotaxic targeting9 was 
visualized and recorded on the neuronavigation system. In cohort 2 (neuronavigation-guided 
sonication), the mechanical robotic arm was utilized to align the FUS transducer to the pre-planned 
targeting in terms of the focus and orientation. Lastly in cohort 3 for the awake animal setting (Fig. 
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6.2B), the animal was secured in the customized chair for neuronavigation-guided sonication. In 
all cohorts, the imaging probe for cavitation mapping was aligned to the FUS focus against the 
temporal bone, the thinnest part of the skull with less acoustic signal attenuation. 
At the beginning of the sonication, the microbubbles were injected in a bolus intravenously 
(saphenous vein) followed by saline flush within 30 s, and the cavitation maps were displayed in 
real time during the entire sonication. In order to confirm the BBB opening and safety, MRI was 
performed 1 h after the sonication. T1-weighted images (3D spoiled gradient echo sequence, 
TR/TE = 8.5/4.8 ms, FA = 8º, resolution = 1×1×1 mm) before and after gadolinium injection (Gd-
DTPA-BMA, Omniscan®, GE Healthcare, NJ, USA; 0.2 mL/kg) for confirming BBB opening, 
T2-weighted images (TR/TE = 3000/80 ms, flip angle or FA = 90º, resolution = 0.4×0.4×2 mm) 
for assessing potential edema, and susceptibility-weighted images (TR/TE = 19/27 ms, FA = 15º, 
resolution = 0.4×0.4×1 mm) for assessing potential hemorrhage.  
 
6.2.6   Accuracy analysis of targeting and acoustic mapping 
In analyzing the targeting accuracy for the BBB opening, the contrast enhancement from the 
sonicated region was first identified by taking a division of post to the pre-contrast T1w images 
and filtering the vessel signal with the control scan (pre- and post-contrast T1w images without 
sonication) as described previously [71]. The center and the trajectory of the BBB opening was 
defined as the center of mass in 3D and the linear fit of the center of mass in each 2D slices in the 
volume of interest (10 × 10 × 32.5 mm3), which was compared with the location and trajectory of 
the ultrasound focus recorded by the neuronavigation system in order to assess the target shift.  
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For analyzing the monitoring accuracy, the enhancement image corresponded to the 
imaging plane of the monitoring probe was interpolated based on the pixel position in the brain 
images, which was calculated based on the transformation matrix provided by the neuronavigation 
system. The center of the cavitation maps was then calculated and compared with the center of the 
BBB opening in the enhancement image in order to estimate the distance shift. 
 
6.3 RESULTS 
6.3.1 Feasibility with targeted BBB opening 
6.3.1.1   Neuronavigation procedure 
After acquiring the MRI and CT scan of the subject, three experimental groups were designed to 
compare the targeting accuracy with frame-based stereotaxis (Cohort 1), to implement 
neuronavigation-guided sonication in the sedate animal setting (Cohort 2), and to translate to an 
awake animal setting (Cohort 3) using the setup shown in Fig. 6.2B. Experimental cohort 1 (N=7) 
was planned with the stereotactic calculation while during the FUS session the location of the 
focus was visualized and recorded in the neuronavigation system. Experimental cohort 2 (N=6) 
was planned on the neuronavigation software before sonication, and the targeting was 
implemented with the free-guide mechanical arm through the guidance of the neuronavigation 
system during the sonication session. This cohort showed the feasibility of incorporating the 
neuronavigation system for sonication and BBB opening. Finally, experimental cohort 3 (N = 5) 
was to perform the sonication in the awake animal with planning and guidance through the 
neuronavigation system. The neuronavigation-guided cavitation mapping was performed in all 
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four cohorts. All the BBB opening results were used to quantify the targeting accuracy of 
neuronavigation-guided sonication as well as the cavitation mapping. 
 
 
Figure 6.3. Preplanning procedure for FUS targeting. (A) Flowchart for preplanning and FUS 
treatment procedure of neuronavigation-guided ultrasound. (B) Screenshots of the preplanning on 
the neuronavigation system. Preplanning for the FUS target and trajectory through the 3D 
segmented and reconstructed skull (1), basal ganglia (2), and the scalp with the donut-shaped 




In the preplanning process on the neuronavigation system after acquiring the preoperative 
radiological images (Fig. 6.3), the 3D skull, subcortical structure, the scalp were segmented and 
visualized together with the MRI slices in order to assist the selection of the focal location and the 
trajectory by covering the region of interest and avoiding pre-existing lesions, large vessels, 
ventricles inside the brain, as well as physical hindrance such as implants, thicker part of the skull, 
or thick epicranial muscle in the beam path outside the brain.  
During the sonication session, both the FUS beam and the monitoring probe were guided 
and aligned with neuronavigation system following the procedure described in Fig. 6.4A, and the 
screenshot of the neuronavigation system is shown in Fig. 6.4B. The subject was first registered 
to the pre-scanned anatomical images based on the donut-shaped fiducials in order to create a 
linkage between the operational space to the virtual image space shown on the screen, and the error 
for each fiducial was kept below 1.5 mm after registration. Followed by the installation of the 
transducer with the mechanical arm, the trajectory of the FUS beam and the focus were visualized 
in the virtual image space in real time with feedbacks of the targeting implementation accuracy as 
shown in the step 4 in Fig. 6.4B. Specifically, the distance and angle deviation was reflected by 
the distance of the red dot to the center of the green circle and to the red circle, respectively, which 
gave two concentric circles for a perfect implementation. This implementation accuracy, i.e., the 
deviation of the FUS beam to the pre-planned targeting in session was displayed and kept below 
1 mm in distance and 5⁰ in angle. After the FUS transducer was set to the preplanned targeting 
orientation, the monitoring probe was placed against the temporal bone toward the FUS focus with 
the imaging plane covering the focus through the neuronavigation guidance as shown in the step 
5 in Fig. 6.4B. The entire procedure from registration of the subject (5 to 10 min), neuronavigation 
of the FUS beam and the monitoring probe (10 to 20 min), to the sonication (2 min) took around 
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30 min. Therefore, the room time was within 1 h including 2 min of the treatment time for single 
sonication.  
 
Figure 6.4. Neuronavigation-guided FUS treatment procedure. (A) Flowchart for 
implementing FUS targeting to the preplanning. (B) Screenshots of the online session showing the 
FUS trajectory in the reconstructed 3D brain (1) targeted the putamen in two orthogonal MRI slices, 
in which the vertical arrows represent the FUS trajectory pointing at the focus (2-3). (4) The 
implementation accuracy of the FUS transducer to the preplanning was displayed as a feedback 
for the distance (visualized as the distance between the red dot and the center of the larger circle) 
and the angle deviation (visualized as the distance between the red dot and the center of the smaller 
circle) during the guiding process. (5) The PCD array for cavitation mapping was aligned to the 
FUS focus before the sonication with neuronavigation guidance. 
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6.3.1.2   Sedate vs. awake animal setting 
Both the basal ganglia and the cerebral cortex were targeted with successful BBB opening through 
neuronavigation guidance. The following shows the representative BBB opening results in both 
the sedate (Fig. 6.5) and the awake (Fig. 6.6) animal setup with the quantitative targeting accuracy 
summarized in Fig. 6.7. The average accuracy of neuronavigation was 3.1 mm, which was better 
than stereotaxis (4.3 mm) without statistical significance (Fig. 6.7A). Nevertheless, the lateral shift 
was found to be significantly improved from 3.2 mm to 1.8 mm after using neuronavigation while 
the axial shift and angle shift remained in the same range (2.6-3.2 mm and 8⁰-9⁰)(Fig. 6.7B). By 
comparing the targeting accuracy in the sedate and awake animal setting, the accuracy in the awake 
animal setting (3.0 mm) was comparable to the sedate animal setting (3.2 mm). Overall, the 
accuracy of the neuronavigation-guided FUS was consistent to what has been reported in 
neuronavigation-guided surgery (1.6-3.0 mm)[72].  
In all the experiments performed, no acute damage such as hemorrhage (SWI) or edema 





Figure 6.5. Neuronavigation-guided FUS for BBB opening in the sedate animal.  Accurate 
BBB disruption were achieved with neuronavigation in the caudate nucleus (NHP 2 at 450 kPa) 
and in the putamen (NHP 3 at 600 kPa). The coronal slices in (A) and (E), the sagittal slices in (B) 
and (F), the horizontal slices in (C) and (G), and the stacked horizontal slices with the BBB opening 
trajectory (red line) and the planned trajectory (blue line) in (D) and (H). The cross represents the 
centroid of BBB opening and the circle the FUS focus in the neuronavigation system. 
 
 
Figure 6.6. Neuronavigation-guided FUS for BBB opening in the awake animal trained to sit 
in the customized chair.  Accurate BBB disruption were achieved with neuronavigation in the 
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central sulcus and in caudate nucleus (NHP 4 at 300 kPa). The coronal slices in (A) and (E), the 
sagittal slices in (B) and (F), the horizontal slices in (C) and (G), and the stacked horizontal slices 
with the BBB opening trajectory (red line) and the planned trajectory (blue line) in (D) and (H). 




Figure 6.7. Accuracy for the neuronavigation-guided ultrasound system compared with 
frame-based method. (A) The total focal shift with the neuronavigation was slightly smaller than 
with the stereotaxis although it showed no statistical significance. (B) After breaking into the 
lateral (lat), the axial (ax) direction and the angle, the neuronavigation showed a significant 
improvement on the lateral direction.  
 
6.3.2   Feasibility with acoustic mapping 
Real-time cavitation mapping was performed with neuronavigation guidance during the sonication, 
and the monitoring results, the reconstructed maps with the corresponded BBB opening were 
shown in Fig. 6.8. The averaged frequency spectra in a single pulse of the acquired channel data 
showed a dramatic increase of cavitation signal (harmonics and ultraharmonics) after injecting 
microbubbles (Fig. 6.8A), and the total acoustic signal intensity (sum of the channel data in each 
single pulse) reflected the viability of microbubbles over the entire 2-min sonication duration in 
the brain (Fig. 6.8B). Both the post-reconstructed and the real-time cavitation maps revealed the 
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location of the cavitation event during sonication which overlapped with the BBB opening region 
in the caudate (Fig. 6.8C) and putamen (Fig. 6.8D). The overall quantitative results (Fig. 6.8E) 
showed an averaged distance between the centroids of BBB opening and the cavitation events of 
2.5 mm (0.7 mm laterally and 2.2 mm axially), with no significant difference between animals or 
targeted regions.  
 
Figure 6.8. Neuronavigation-guided cavitation mapping during sonication for BBB opening. 
(A) The averaged frequency spectra in the channel data of the PCD array. (B) The total intensity 
of the channel data during the 2-min sonication showed significant cavitation response after 
microbubbles perfused the brain. The reconstructed cavitation maps showed the exact location of 
the BBB opening in the caudate at 450 kPa (C) and the putamen at 450 kPa (D).  (E) The cavitation 




In this study, a novel protocol for the transcranial neuronavigation-guided ultrasound system has 
been demonstrated to disrupt the BBB in a precise location in both sedate and awake non-human 
primates from initial preplanning to on-line FUS procedure and acoustic monitoring. The fast 
procedure (30 min) with flexible targeting will benefit a broad patient population especially with 
diseases requiring repetitive treatment such as chemotherapy for brain tumors or 
neurodegenerative diseases. It will also facilitate the neuromodulation research using FUS in 
primates. Furthermore, real-time monitoring for the energy distribution of the acoustic cavitation 
in combination with the neuronavigation technology holds great potential to assess and control the 
treatment in the desired targeted regions.  
The neuronavigation-guided ultrasound system tested in non-human primates both on the 
surgical table and in the chair maintains translational capability to a clinical setting. The proposed 
protocol covers from in silico preplanning, FUS treatment procedure, real-time monitoring, to 
post-treatment assessment. First, in the initial preplanning after acquiring the MRI with fiducials 
and CT, the region of interest and trajectory for the acoustic beam could be selected in the 
neuronavigation pre-planning panel assisted by the 3D reconstructed brain structure and scalp. 
Second, when an optimal targeting was decided, it is then implemented by the neuronavigation 
system for an online operation for sonication and cavitation mapping. Finally, the treatment 
outcome is evaluated. For BBB opening and drug delivery, the animal is currently evaluate with 
contrast-enhanced MRI using gadodiamide. This can potentially be replaced by acoustic 
monitoring technique as the cavitation mapping is now under development to control the safety 
and efficacy based on the distribution of cavitation occurred in situ.  
199 
 
 Neuronavigation-guided ultrasound system holds several advantages compared with the 
currently available systems including MRgFUS[15] and the implantable ultrasound device[41] 
available for clinical trials. Different from MRgFUS, the mobility and fast treatment of our system 
could benefit a significantly larger crowd with seamless procedure, and cavitation associated with 
BBB opening could be monitored at ease without MRI interference. On the other hand, compared 
with the implantable ultrasound device our noninvasive technique with flexible targeting ensure 
adjustable treatment if different targeting or larger BBB opening region (e.g. tumor progression) 
is desired. Our system is thus suitable for applications based on mechanical effect such as BBB 
opening, drug delivery, and neuromodulation. However, it could potentially assists targeting for 
FUS surgery using MRgFUS system. 
This technology also advanced upon our previous stereotactic method with single-element 
cavitation monitoring in several folds. First, the online visualization and guidance allowed an 
interactive adjustment for accurate targeting due to online visualization and feedback (Fig. 6.4). 
Whereas the stereotactic method is blinded during the sonication, and any slight misplacement of 
the animal or transducer in the stereotactic frame introduces error. Second, its flexibility in 
preplanning and implementation through the free-guide mechanical arm grants a higher degree of 
freedom to place the transducer, and enables the transducer orientation to align with the orientation 
of the brain structure[124] which is not application through the stereotaxic arm. Third, the 
cavitation mapping combined with neuronavigation technology envisions the spatial distribution 
of cavitation events associated with the treatment outcome. It could serve as an online tool to 
monitor and control the treatment like single-element passive cavitation monitoring, with a plus of 
the spatial information.  
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The targeting accuracy was determined by small errors in the neuronavigation system, the 
skull distorting the acoustic wave propagation, and the BBB opening results. While the monitoring 
accuracy was affected by both the neuronavigation system and the cavitation mapping acquired 
through the skull and its resolution. With the neuronavigation system, the targeting accuracy in the 
lateral direction was significantly improved compared with using stereotaxis. This improvement 
could be due to the variation in placing the animal to the stereotaxic frame with the ear bars. On 
the other hand, the axial shift and the angle shift remained in the same range and may be due to 
the skull based on the simulation results in Chapter 2 or the characteristics of BBB opening as the 
gray matter had higher probability of BBB opening than the white matter [71]. As shown in 
Chapter 2, an averaged focal shift of 1.8 mm was estimated in the acoustic pressure distribution in 
silico, which was close to the axial shift of 2.4 mm with neuronavigation (Fig. 6.7B). Although 
the skull could also affect cavitation mapping in terms of location and focal quality of the cavitation 
events due to phase aberration [208], the effect was minimal through the thin temporal bone in 
NHPs in this study. A more accurate monitoring assessment in the lateral direction in comparison 
to the axial direction could result from a better mapping resolution in the lateral direction. 
  There are, however, limitations of the proposed system, especially in targeting and 
monitoring technique. Sources of error in targeting are caused by registration errors with the 
neuronavigation system, the focal shift due to the skull, and the error in post-processing of the 
MRI, etc. To minimize the registration error, the location of the fiducials during the treatment 
session should be invariant to the pre-operative MRI with fiducials. In addition, since the 
neuronavigation system localized the tools relative to the subject tracker, maintaining a distance 
between the subject tracker and target as small as possible (< 10 cm) could improve the accuracy. 
To reduce the acoustic focal shift due to the skull, simulation of the acoustic pressure field and the 
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use of phased array focused ultrasound transducer with phase aberration correction could 
potentially compensate this type of error. On the other hand, in order to evaluate or control the 
treatment safety and efficacy, a robust acoustic monitoring technique such as cavitation mapping 
is required to minimize the need for an MRI. 
 
6.5 CONCLUSION 
This neuronavigation-guided transcranial ultrasound system and treatment protocol has 
successfully, efficiently, and accurately opened the BBB in non-human primates with both the 
animal lying on the surgical table and sitting on the customized chair. It holds great potential to 
facilitate both research and treatment for both drug delivery and neuromodulation in a clinical 
setting. 
 
6.6 SIGNIFICANCE & CONTRIBUTION 
This chapter fulfilled the specific aim 3 to develop a neuronavigation-guided ultrasound procedure 
in order to achieve an efficient and precise FUS treatment for future clinical applications. As 
current systems have several limitations such as lengthy procedure and limited targeting region 
(MRgFUS) or invasiveness (implantable ultrasound device), and the frame-based stereotactic 
method previously developed in our lab lacks of targeting flexibility and varying accuracy. Here, 
the neuronavigation was customized to guide both targeting and monitoring in primates for the 
first time. It time efficiency and targeting flexibility allows easy re-application and personalized 
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treatment that will not only benefit the brain research but also clinical trials for a broad patient 
population in the future.  
The research contribution was shared with colleagues and collaborators. Christian Aurup 
(M.S., Biomedical Engineering, Columbia University) and Carlos Sierra Sanchez (PhD, 
Biomedical Engineering, Columbia University) assisted the study design and in vivo experiments. 




Chapter 7  
Conclusion & Future Works 
 
7.1 CONCLUSION 
The conclusion from each chapter is summarized as follows:  
Acoustic wave simulation predicts BBB opening characteristics. 
- Chapter 2: The developed simulation method for in situ acoustic pressure predicted the 
BBB opening characteristics such as the location and volume. It has been tested for pulse 
design to improve localization quality in mice by eliminating standing waves in mice. In 
the NHP study, it has been used to estimate the focal shift and the in situ pressure, both 
corresponded well with in vivo BBB opening results. The pressure after skull attenuation 
was found to be associated with the density and thickness of the skull in the acoustic beam 
path.  The skull distortion of the acoustic focus also resulted in a 2 mm shift in monkeys. 
It is thus of vital importance to assess the pressure distribution of the acoustic focus through 
the skull before the FUS treatment to ensure a safe pressure distribution is applied in the 
brain. Lastly, the simulation method was used to evaluate the targeting effect through 
human skulls. Both the incidence angle and the focal depth below the skull affected the 




Cavitation monitoring reveals physical mechanism, and could assess and visualize BBB 
opening. 
- Chapter 3: Passive cavitation detection (PCD) revealed the physical mechanisms with 
customized acoustic agents (microbubbles, nanodroplets) during BBB opening in mice in 
vivo. It demonstrated the usefulness of assessing the BBB opening with various agents. 
Furthermore, three acoustic agent design schemes were evaluated to improve drug delivery 
efficiency. First, lipid-shelled microbubble with long hydrophobic chain lengths could 
enhance the delivery of large molecules (> 40 kDa). Second, drug-loaded microbubbles 
required bubble disruption to enhance delivery.  Third, acoustically-activated nanodroplets 
could achieve high amount of large molecule delivery (> 40 kDa) with a highly-volatile 
liquid core used.  
 
- Chapter 4: PCD could be achieved through the monkey and human skull in vitro, and the 
monitored cavitation dose was positively correlated with BBB opening volume, amount of 
contrast agent delivered and the delivery efficiency in NHP in vivo. Results showed that 
through the macaque skull the pressure threshold for detecting the SCDh remained the same 
as without the skull in place, while it increased for the SCDu and ICD; through the human 
skull, it increased for all cavitation doses. In addition, using long pulses enabled reliable 
PCD monitoring and facilitate BBB opening at low pressures. The in vivo results showed 
that the SCDh became detectable at pressures as low as 100 kPa; the ICD, at 250 kPa while 
it could occur at lower pressures; the SCDu, at 700 kPa and was less reliable at lower 
pressures. Real-time monitoring of PCD was further implemented during BBB opening, 
with successful and safe opening achieved at 250-600 kPa in both the thalamus and the 
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putamen. Cavitation activity was correlated with the amount and concentration of 
gadolinium delivered through the BBB and its associated delivery efficiency as well as the 
BBB opening volume in non-human primates. Another important finding entails the effect 
of heterogeneous brain anatomy and vasculature of a primate brain, i.e., presence of large 
cerebral vessels, gray and white matter will also affect the cavitation activity associated 
with variation of BBB opening in different tissue types, which is not seen in small animals. 
 
- Chapter 5: Passive cavitation mapping visualized the spatial distribution of cavitation at 
a pressure range feasible for BBB opening (150-600 kPa), and could be achieved through 
the monkey (at and above 300 kPa) and human skull (at and above 450 kPa) and during 
the in vivo BBB opening in NHPs. The computational time increased with the exposure 
time, while the mapping quality reach a plateau at the exposure time of 62.5 µs. To achieve 
real-time mapping, a short exposure time (1.44 µs) can be chosen for reconstruction with 
sparse matrix calculation in the GPU. This real-time mapping was successfully applied in 
vivo during BBB opening in two NHPs, demonstrating both the intensity and location of 
cavitation events during sonication. 
 
Neuronavigation guidance provides streamlined targeting with real-time feedbacks. 
- Chapter 6: Neuronavigation system was customized for FUS procedure, with protocol 
established from in silico planning, on-line navigation for sonication and acoustic mapping, 
to post-treatment assessment and offline analysis. This system and protocol was tested both 
in the sedate NHP in the surgical unit and in the awake NHP sitting on the customized 
chair. It provided fast (30 min) and precise (3 mm) FUS treatment. Its flexibility allowed 
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personalized targeting and monitoring independent of the MRI, and can be translated for 
human applications. 
 
Figure 7.1. Flowcharts for the (A) in silico preplanning and (B) online FUS treatment 
procedure. 
 
In a nutshell, a transcranial ultrasound system and protocol (Fig. 7.1) suitable for BBB 
opening in both clinical and preclinical studies was developed, covering from simulation of 
acoustic wave propagation for in silico preplanning, online targeting guidance with 
neuronavigation, real-time acoustic monitoring to uncover the physical mechanism and assess the 
treatment outcomes, to post-treatment assessment in sedate and awake non-human primates. To 
ensure a safe and effective BBB opening, the acoustic pressure distribution in the brain could be 
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simulated before the treatment to compensate for the skull distortion. After personalized 
preplanning of the FUS treatment, the targeting could be accurately and efficiently aligned with 
neuronavigation for sonication. During the sonication, the cavitation could be monitored in real 
time to assess the location and size of BBB opening. A clinical procedure for neuronavigation-
guided FUS has been proposed in Fig. 7.1.  
 
7.2 FUTURE WORKS 
A novel FUS system and protocol from in silico planning and simulation to real-time targeting and 
monitoring has been developed and tested for BBB opening in primates. In order to facilitate its 
usage in clinical application, clinical trials in collaboration with medical doctors are required. 
There are thus several steps recommended to proceed. First, the system and protocol have been 
established and tested in monkeys in this thesis. It is required to get US Food and Drug 
Administration (FDA) approval of this system and microbubbles to be used in humans, and an 
Institutional Review Boards (IRB) approval for protocol of clinical trials for BBB opening. Second, 
simulation in this thesis has shown feasibility in predicting the characteristics of BBB opening in 
mice and monkeys. A simulation study should be continued in humans with various targeting for 
future treatment optimization. Third, several drug delivery studies have been performed in the lab 
previously such as neurotrophic factors (BDNF, Neurturin) and gene-carrying virus in wild-type 
or disease-model mice. In order to ease the transition to human applications, studies for delivery 
of pharmacological compounds should be performed in monkeys such as MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) monkeys as a Parkinson’s disease model to show FUS 
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treatment safety and efficacy. All these work will facilitate neuronavigation-guided FUS treatment 
in humans in the future. 
On the other hand, there are also work to improve the system and protocol. First, the 
transducer through neuronavigation guidance is currently placed manually to the head. This 
procedure could be optimized with an implementation of a robotic arm as a way to reduce human 
error and streamline the navigating procedure. Second, MRI as it is currently used as a post-
treatment assessment tool. In order to completely replace it to save time, the cavitation mapping 
in NHP should be continued to correlate with the size of BBB opening. Third, both CT and MRI 
are required for current preplanning. A new pulse sequence technique called ultrashort echo-time 
MRI may be developed for simulation instead of CT to improve the workflow. Lastly, 
nanodroplets have been shown feasible in mice and the cavitation monitoring correlated with the 
BBB opening outcomes. Its feasibility in large animals needs to be investigated in order to improve 
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